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2 Abbreviations and Acronyms 
AAA Amino acid analysis 
AED Atomic emission detector 
AQC 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate 
BSTFA N,O-bis-(trimethylsilyl)-trifluoroacetamide  
CE Collision energy 
CE Capillary electrophoresis 
CoA Coenzyme A 
CUR Curtain gas 
CXP Collision cell exit potential 
đ Mean difference 
DABS-Cl Dimethylamino-azobenzenesulfonyl chloride 
DC Direct current 
DP Declustering potential 
FID Flame ionization detector 
ECD Electron capture detector 
EI Electron impact ionization 
EIC Extracted ion chromatogram 
ELCD Electrolytic hall conductivity detector 
EOF Electroosmotic flow 
EP Entrance potential 
ESI Electrospray ionization 
FDA Food and drug administration 
FITC Fluorescein isothiocyanate 
FPD Flame photometric detector 
FMOC-Cl 9-fluorenylmethylchloroformate 
GC Gas chromatography 
HFB 2,2,3,3,4,4,4-heptafluorobutanol 
HILIC Hydrophilic interaction liquid chromatography 
HPLC High-performance liquid chromatography 
 V
HSQC Heteronuclear single-quantum correlation 
INTERMAP INTERnational collaborative of Macronutrients and blood 
Pressure 
IP Ion pair 
IS Internal standard 
IT Ion trap 
LC Liquid chromatography 
LLOQ Lower limit of quantification 
LOD Limit of detection 
LOQ Limit of quantification 
MCF Methyl chloroformate 
MRM Multiple reaction monitoring 
MS Mass spectrometry / mass spectrometer 
MS/MS Tandem mass spectrometry 
MPS Multipurpose Sampler 
MSTFA N-methyl-trimethylsilyltrifluoroacetamide 
MSUD Maple syrup urine disease 
MT Migration time 
NEFA Non-esterified fatty acid 
NMR Nuclear magnetic resonance 
NPD Nitrogen phosphorus detector 
NPD-F 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole 
OPA o-phthalaldehyde 
PCF Propyl chloroformate 
PID Photoionisation detector 
PITC Phenylisothiocyanate 
PKU Phenylketonuria 
PTV Programmed-temperature vaporization 
QC Quality control 
QTRAP Triple quadrupole – linear ion trap hybrid mass spectrometer 
R Correlation coefficient 
 VI
RF Radio-frequency 
RP Reversed phase 
RSD Relative standard deviation 
RSQ Square of the correlation coefficient R 
RT Retention time 
SD Standard deviation 
SIM Selected ion monitoring 
SPE Solid-phase extraction 
SRM Single reaction monitoring 
TCD Thermal conductivity detector 
TE Technical error 
TEM Auxilary gas temperature 
TLC Thin layer chromatography 
TOF Time-of-flight 
TQ Triple quadrupole 
ULOQ Upper limit of quantification 
UPLC Ultra-performance liquid chromatography 
UV Ultraviolet 
 
 
 
The abbreviation for the amino acids are listed in chapter11, Table 11.
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3 Motivation 
Amino acids are important targets for metabolic profiling and their quantitative 
analysis is essential in many areas including clinical diagnostics of inborn errors 
of metabolism, biomedical research, bio-engineering and food sciences. 1, 2 
There is an increasing need for fast and robust methods for the quantitative 
analysis of amino acids in large clinical and epidemiological studies.3 The 
prevailing method for amino acid analysis has been cation exchange 
chromatography followed by post-column derivatization with ninhydrin and UV 
detection. But due to the low throughput and the low specificity of detection it is 
not suitable for the analysis of large sample batches of complex biological fluids 
such as urine and blood serum. There are several other methodologies available 
to analyze amino acids, which are based on chromatography, capillary 
electrophoresis, direct infusion coupled to different mass analyzers, as well as 
nuclear magnetic resonance (NMR). Protein precipitation is required for all LC 
and CE methods independent of the detection method used, which renders 
complete automation difficult. Shortcomings of NMR are relatively high limits of 
detection and large sample volumes required. Therefore there is still need for a 
method that allows the completely automated analysis of amino acids in 
biological fluids that can meet the demand for high sample throughput in large 
metabolomic studies.  
Aim #1: Development of a fully automated method for the direct 
quantitative analysis of amino acids in various biological matrices 
The aim was to develop a robust, accurate, fast and precise method for the 
analysis of urinary amino acids and its application to urine specimens from the 
INTERMAP study that examines the correlation between diet and 
ethnogeographic patterns of blood pressure, where urinary amino acids serve as 
surrogate markers of dietary protein sources. GC-MS was chosen because of its 
high separation efficiency and wide dynamic range. In order to obtain volatile 
analytes usually derivatization of metabolites is performed for GC analysis. GC-
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MS based metabolomics studies commonly use silylation, which however causes 
degradation of some amino acids. The GC-MS method of choice builds on the 
direct derivatization of amino acids in diluted urine with propyl chloroformate, GC 
separation and mass spectrometric quantitation of derivatives using stable 
isotope labeled standards. Since derivatization with propyl chloroformate can be 
carried out directly in the aqueous biological sample without prior protein 
precipitation or solid-phase extraction of the amino acids, the entire analytical 
process, starting from the addition of reagents, over extraction, derivatization to 
injection into the GC-MS can be automated. Method parameters such as limit of 
detection (LOD), lower limit of quantification (LLOQ), linear range, 
reproducibilities and evaluation of matrixe spikes were to be determined to show 
to the method`s applicability to analyze amino acids in several biological 
samples. Propyl chlorofromate can react with all compounds containing amino 
and/or a carboxy function therefore there is space to include other metabolites 
e.g. fatty acids. The integration of fatty acids was to be determined, additionally. 
Specific Aim #2: Urinary Amino Acid Analysis: A Comparison of iTRAQ®-
LC-MS/MS, GC-MS and Amino Acid Analyzer 
Another goal was the comparison of the performance of classical ion-exchange 
chromatography with postcolumn ninhydrin detection and the GC-MS method 
developed under aim #1 and a novel LC- MS/MS method based on the 
derivatization of amino acids with iTRAQ®. In this process, the performance of 
the iTRAQ® -LC-MS/MS method was to be evaluated. 
Using two blinded sets of urine samples containing replicates and a certified 
amino acid standard, the precision and accuracy of the GC-MS method could be 
tested and the results compared with iTRAQ® derivatization LC-MS/MS and 
postcolumn ninhydrin detection of amino acids. The performance of the three 
methods was to be compared using various statistics, including technical error of 
mearuement, regression analysis and Bland-Altman plotting.  
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Specific Aim #3: Quantitative analysis of amino acids and related 
compounds by LC-MS/MS 
Some important amino acids are thermally instable and cannot be quantified by 
GC-MS, such as arginine, citruline as well as 1- and 3- methyl histidines. Amino 
acids are highly polar analytes and, therefore, not suitable for conventional 
reversed-phase high-performance liquid chromatography (RP-HPLC). Thus, a 
derivatization is needed. The potential of derivatization with propyl 
chloroformates, follow by LC-MS/MS analysis for amino acid determination was 
to be tested and expanded to tryptophan metabolites and polyamines that are of 
great interest in several biological projects. Due to their amino function they can 
be derivatized with propyl chloroformate and analyzed by LC-MS/MS. For 
quantification aims it is important to use internal standards. However, isotope- 
labeled standards are not available commercially for all metabolites of interest. 
Instead of synthesizing individual standards for each metabolite, we wanted to 
exploite the derivatization of amino and carboxy functions with propyl 
chloroformate employing d3-labeled propanol as a mean of generating an internal 
standard for each analyte. 
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 4 Background 
An abbreviated version of this chapter was published in Analytical Bioanalytical 
Chemistry.4  
4.1 Metabolomics 
The complete set of small molecules in an organism is termed metabolome. 5  
Nucleus
DNA (Genome)
mRNA
t
mRNA (Transcriptome)
(Proteome)
(Metabolome)
Proteins 
Metabolites
 
Figure 1: Information flow in a cell. 
 
Metabolomics is the last step in the “omics” cascade (Figure 1). Metabolites are 
the end products of cellulary processes. Therefore, their concentration can be 
regarded as the response of biological systems to genetic and/or environmental 
changes. Metabolomics aims at the quantitative analysis of all metabolites in a 
given biological system.6 In the absence of a single analytical technique that can 
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cover the entire metabolome, analysis is typically limited to the quantitative 
profiling of selected pathways or building blocks of the metabolome. 7 
There are different approaches in the field of metabolomics: 
Metabolic profiling is the quantitative analysis of sets of metabolites in a 
selected biochemical pathway or a specific class of compounds. Important 
targets for metabolic profiling are e.g. amino acids, intermediates of the central 
carbon metabolism, nucleotides and polyamines, just to name a few. For this 
approach, it is necessary to develop accurate and robust methods to quantify 
those compounds. 
Target analysis is more focused than metabolic profiling and only very few 
analytes are measured. They are often directly related to a genetic perturbation, 
such as substrates or products of enzymatic reactions, or they serve as 
biomarkers for a certain disease. 7 
Metabolic fingerprinting aims at the detection of as many analytes as possible. 
Metabolic fingerprinting is a global screening approach to classify samples based 
on metabolite patterns or “fingerprints. 
Metabolic footprinting uses the same methods as fingerprinting but is limited to 
the analysis of metabolites in cell culture media. The reasoning is that 
compounds excreted by a cell or taken up from the medium will also give 
valuable insights into a cell’s phenotype and physiological state. 8 
4.2 Amino acids  
Twenty standard amino acids are used by organisms in protein biosynthesis. The 
structures of the proteinogenic amino acids are shown in Figure 2.  
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Figure 2: Molecular structure, formula weight and empirical formula for all 20 proteinogenic 
amino acids. Molecular structures are illustrated as they are at pH of 7; depending on their side 
chain, they are divided in a) unpolar side chain, b) polar uncharched side chain, c) aromatic side 
chain, d) negative charged side chain, e) positive charged side chain.  
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 At pH 7 the α-amino group is protonated and the α-carboxy group is 
deprotonated. The positive and negative charges are equal, resulting in a neutral 
charge; therefore, they are called zwitterions. Depending on the chemical 
behavior of the side chains at pH 7 amino acids can be grouped as follows. 
Neutral amino acids have a non-charged (Figure 2a-c), acidic amino acids a 
negatively (Figure 2d) and basic amino acids a positively charged side chain 
(Figure 2e). Neutral amino acids can be subdived into neutral amino acids with 
unpolar side chain (Figure 2a), polar side chain (Figure 2b) and aromatic side 
chain (Figure 2c). Mammals including humans, can synthesize only 11 of the 
proteinogenic amino acids: tyrosine, aspartic acid, asparagine, alanine, serine, 
glycine, cysteine, glutamic acid, glutamine, proline and arginine. They are known 
as the non-essential amino acids. Tyrosine for example can be synthesized out 
of phenylalanine catalyzed by the enzyme phenylalanine monooxygenase 
(Figure 3) 
 
NH3
O
O
NH3
O
O
HO
Phenylylanine
monooxygenase
Phenylalanine Tyrosine  
 
Figure 3: Biosynthesis of the non-essential amino acid tyrosine. PKU patients have a deficiency 
in the enzyme phenylalanine hydroxylase (PAH), also named Phenylalanine monooxygenase. 
 
If the enzyme or its cofactors are defect, phenylylalanine is accumulating.9 
Phenylalanine accumulates and is converted into phenylketones, which can be 
detected in the urine and cause problems with brain development, leading to 
progressive mental retardation and seizures. This disease is called 
Phenylketonuria (PKU).2, 9 Aminotransferase enzymes can catalyze the reaction 
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from α-keto acids to the corresponding amino acid. Transamination of pyruvate, 
oxaloacetate, and α-ketoglutarate, yields alanine, aspartic acid, and glutamic 
acid, respectively. From glutamic acid the amino acids glutamine, proline and 
arginine can be formed and asparagine can be synthesized out of aspartic acid. 
Serine, glycine and cysteine are made from the intermediate 3-phosphoglyceric 
acid, formed by glycosis.10 The other nine amino acids-phenylalanine, threonine, 
methionine, lysine, tryptophan, leucine, isoleucine, valine and histidine cannot be 
synthesized in mammals and must be provided in the diet.  They are called 
essential amino acids. 
4.3 Gas chromatography (GC)  
4.3.1 Principles of GC 
Gas chromatography is a separation technique that employs a gas as mobile 
phase and either a solid (gas solid chromatography) or a liquid (gas liquid 
chromatography) as stationary phase. Nowadays, most GC applications use 
capillary columns, with the stationary phase coated on the inner wall of the 
capillary. In case of a solid stationary phase these are called PLOT (porous layer 
open tubular) columns and if a liquid stationary phase is used they are called 
WCOT (wall coated open tubular) columns. This type of separation is suited for 
compounds, which can be vaporized wihout decomposition. The retention time of 
the analytes depends on the type of analyte and the interaction with the 
stationary phase. This is expressed by the partioning coefficient K, which is 
temperature dependend (lnK~1/T) and, therefore, the retention time can be 
controlled by column temperature. The temperature is either kept constant 
(isothermal) for analytes in a narrow boiling point range or is ramped for analytes 
in a wide boiling point range. The carrier gas that transports the sample through 
the column. Typical carrier gases are helium, argon, nitrogen or hydrogen.  
For the quantitative analysis it is very important to have baseline resolved peaks. 
Chromatographic resolution is calculated as follows: 
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Where RS is the resolution, tR1 and tR2 are the respective retention times of peak 
1 and 2, and wb1 and wb2 are the respective base peak witdths of peak 1 and 2. 
For quantitative analysis the value for RS should be higher then 1.5.11 
4.3.2 Injector types 
The sample is transfered onto the column by means of the injector. Commonly 
employed injectors are hot split/splitless and programmed-temperature 
vaporization (PTV) injection. Split and splitless injection are both performed using 
the same inlet, which is often termed a split/splitless inlet. For both applications 
the sample is introduced into a heated small chamber via a syringe through a 
septum. Split injection is used for concentrated samples, where only a small 
portion of the sample is transfered on the column and the major part is emerged 
through the split outlet. The amount of sample is controlled by the splt ratio. The 
whole sample amount is introduced onto the column using splitless injection. A 
programmed-temperature vaporization (PTV) inlet is a hybrid of the techniques 
described above. It is a split/splitless inlet that has been modified to allow cold 
injection and rapid temperature programming. This is a rather gentle injection 
technique, which is favorable for thermally labile compounds. A critical 
component of the injector is the liner. It is the chamber into which the sample is 
injected. The sample is vaporized and throughly mixed with the carrier gas. The 
liner shape must ensure complete sample vaporization, provide sufficient volume 
to accommodate the resulting vapor and must be inert to avoid analyte 
adsorption. Glass liners are used commonly and exist in wide range, differing in 
volume, special form or design, fillings (e.g. quarz or glas wool packed) or 
treatment for deactivation of the surface.  
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4.3.3 Gas chromatographic columns and stationary phases 
There are two main groups of columns, namely packed columns and capillary 
open tubular columns. For most applications capillary columns are used. 
Capillary columns are made of fused-silica with a polyimide outer coating and the 
stationary phase coated onto the inner surface. Presently, fused-silica capillary 
columns having a length of 10–100 m and an inner diameter of 0.10–0.53 mm 
are in widespread use. The most common stationary phases in gas-
chromatography columns are polysiloxanes, which contain various substituent 
groups to change the polarity of the phase. The commercial nonpolar end of the 
spectrum is polydimethyl siloxane, which can be made more polar by increasing 
the percentage of phenyl- and/or cyanopropyl groups on the polymer. Wide 
spread stationary phases in metabolomics are 100% polydimethyl siloxane, 5% 
polydiphenyl- 95%- polydimethyl siloxane or with 14% polycyanopropylphenyl- 
86%- polydimethyl siloxane. For very polar analytes, polyethylene glycol 
(carbowax) is commonly used as stationary phase. The chemical structures of 
the four mentioned stationary phases are shown in Figure 4. 
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Figure 4: Chemical structur of popular stationary phases in GC. 
 
The stationary phase can varry in the film thickness from 0.1 to 5 µm. The 
thickness of the film has an effect on the retentive character of the column. Thick 
films are used for the analysis of highly volatile analytes and thin films are used 
for the analysis of less volatile compounds.11 
4.3.4 Detectors 
A large number of GC detectors are available. The most popular detector is the 
flame ionizations detector (FID). A hydrogen/air flame is used to decompose the 
carbon containing analytes from the GC into ions by burning them and the 
changes in the current are measured afterwards. The FID detects most organic 
compounds when they are ionized and cause a voltage drop across the collector 
electrodes. The measured change is proportional to mass, and therefore number 
of carbon atoms, of the organic compound. One important benefit of a FID is that 
it is insensitive to H2O, CO2, CS2, SO2, CO, NOx, and noble gases because they 
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are not able to be oxidized/ionized by the flame. There are still a lot of 
applications using flame ionization detector (FID) as detector. However it is a 
non-specific detector and coeluting compounds cannot be separated.  
Some gas chromatographs are connected to a mass spectrometer (MS) which 
acts as the detector. Suitable mass analyzers for GC are quadrupole/triple 
quadrupole, ion trap (IT), time of flight (TOF). The most common type of MS 
coupled to a GC is the quadrupole mass spectrometer. A quadrupole ion filter 
consists in four parallel rods. The rods have fixed DC (direct current) and 
alternating RF (radio-frequency) voltages applied to them. Depending on the 
electric field, only ions of a particular m/z will be allowed to pass, all the other 
ions will be deflected into the rods. Quadrupole ion filters are used in routine 
analysis due to their good reproducibility and excellent stability. 
In conventional GC-MS electron impact (EI) ionization technique is employed. EI 
is an ionization method whereby energetic electrons interact with gas phase 
atoms or molecules to produce ions. This is a hard ionization technique and 
therefore the molecular ions break up into smaller fragments. The resulting mass 
spectrum is complex and provides important information about the structure of 
the molecule. Another possibilty to ionize compounds is the chemical ionization 
that begins with the ionization of methane, creating radicals which in turn impact 
the samples molecules rendering them postively charged as [MH]+ molecular 
ions.  
Other detectors for GC include nitrogen phosphorus detector (NPD), electron 
capture detector (ECD), photoionisation detector (PID), flame photometric 
detector (FPD), thermal conductivity detector (TCD), and atomic emission 
detector (AED). 
4.3.5 Sample preparation 
Sample preparation in biomedical analysis is mainly performed by liquid-liquid 
extraction and solid-phase extraction (SPE). In liquid-liquid extraction, dissolved 
components are transferred form one liquid phase to another. The most common 
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application is the transfer of analytes from aqueous solution to an organic solvent 
that is more suitable for GC. 11 With the SPE technique the analytes are trapped 
on solid sorbent for concentration or cleanup. Another technique is the 
headspace technique used for the determination of cancerogen or toxic 
substances in urine or blood.12, 13 It is most suited for the analysis of the highly 
volatile analytes in samples that can be efficiently partitioned into the headspace 
gas volume from the liquid or solid matrix sample. Higher boiling compounds and 
semi-volatiles are not detectable with this technique due to their low partition in 
the gas headspace volume. However, many biological analytes including amino 
acids have to be derivatized prior to GC to render them volatile. Several 
derivatization methods are available to obtain volatile derivatives suitable for GC. 
Derivatisations for GC analysis will be discussed in chapter 4.4.6.  
4.4 Amino acid analysis for metabolomics 
Amino acids are important targets for metabolic profiling. Besides being the basic 
structural units of proteins, amino acids have several non-protein functions. They 
are a source of energy either through formation of keto acids from the ketogenic 
amino acids or through gluconeogenesis from glucogenic amino acids. Glutamic 
acid and γ-aminobutyric acid are neurotransmitters,14 while tryptophan and 
tyrosine are precursors of serotonin and catecholamines, respectively.15 Glycine 
is a precursor of porphyrins, whereas ornithine is a precursor of polyamines16 
and arginine can be metabolized to form nitric oxide.17 Elevated amino acid 
levels in blood plasma and urine are well-known markers for inborn errors of 
metabolism, such as phenylalanine in phenylketonuria or maple syrup urine 
disease.1, 2 Amino acids also serve as markers for nutritional influences, e.g., 
urinary taurine levels serve as an indicator for fish intake,18 while the 1-
methylhistidine level in urine correlates with meat protein intake.19 
Due to the important biological functions of amino acids, their quantitative 
analysis is required in several fields, including clinical diagnostics of inborn errors 
of metabolism, biomedical research, bio-engineering and food sciences. 
Consequently, different analytical methods have been developed and 
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commercialized over the past few decades for amino acid analysis. Nevertheless, 
efforts to improve existing methodology with regards to speed of analysis, 
robustness, reproducibility and sensitivity are ongoing and have been driven by a 
shift in application away from the analysis of protein hydrolysates to the analysis 
of free amino acids in various biological matrices. To that end, mass 
spectrometry coupled to chromatography has become a major means of amino 
acid analysis because of its selectivity and sensitivity. 
4.4.1 Sample preparation 
Analysis of free amino acids in biological samples often requires protein 
precipitation prior to analysis. Methods described for deproteinization include 
precipitation with acid or organic solvent, and ultrafiltration. The most common 
method to remove proteins is precipitation with sulphosalicylic acid.20 Amino 
acids are highly polar analytes and, therefore, not suitable for conventional 
reversed-phase high-performance liquid chromatographic (RP-HPLC)21 or gas 
chromatographic (GC) analysis. Capillary electrophoresis (CE) does not require 
derivatization, but sensitivity for CE-UV analysis can be increased by introduction 
of a UV active label. Therefore, a derivatization step is often employed. Most 
reagents used react with the amino group. Some derivatizing reagents react only 
with primary amines, but ideally secondary amines, such as proline and 
hydroxyproline, are also covered. Another option is to derivatize the carboxy 
function of the amino acids. The most common derivatization reagents are listed 
in Table 1 and their use will be discussed in the following chapters. 
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4.4.2 Liquid chromatographic methods coupled with optical 
detection 
There are several LC methods coupled with UV absorbance detection available 
for the quantification of amino acids. The two general approaches are either ion-
exchange chromatography followed by post-column derivatization or pre-column 
derivatization preceding Reversed-phase (RP) HPLC. The gold standard method 
is cation-exchange chromatography using a lithium buffer system followed by 
post-column derivatization with ninhydrin and UV detection. The separation of the 
amino acids is achieved through changes in the pH and cationic strength of the 
mobile phase. Through the reaction of ninhydrin with amino acids containing a 
primary amine Ruhemann’s purple (Figure 5) is generated, which is UV active 
(λmax 570 nm). Secondary amines, such as proline, produce a yellow product 
(λmax 440 nm).  
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Figure 5: Reaction of amino acids with ninhydrin to Ruhemann`s Purple. 
 
The eluate is monitored at 440 and 570 nm, respectively. Linearity ranges 
typically from 5 - 2500 µmol/L. Routinely, 38 amino acids are separated with a 
conventional amino acid analyzer in 115 min, but the method can be expanded to 
more than 140 min to resolve more analytes. A typical elution profile of urinary 
amino acids monitored at both 440 nm and 570 nm is shown in Figure 6.  
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Figure 6: Typical elution profiles of urinary amino acids obtained on a Biochrom 30 amino acid 
analyzer with continuous UV absorbance monitoring at 440 and 570 nm, respectively. 
 
Shortcomings of the method are the long runtime, the instability of ninhydrin, the 
necessity of protein precipitation, which impedes complete automation, and 
crosstalk by analytes other than amino acids and related compounds that may 
react with ninhydrin in complex biological samples and prevent accurate 
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quantitation.22 For example, methionine (Met) and homocitrulline (Hcit), 
phenylalanine (Phe) and aminoglycoside antibiotics, as well as histidine (His) and 
the anticonvulsant gabapentin, commonly have overlapping retention times. 
Derivatization with o-phthalaldehyde23 (OPA) has been used both post-column 
after cation-exchange chromatography and pre-column coupled with RP-HPLC. 
OPA reacts with amino compounds in the presence of a thiol such as 
mercaptoethanol to form a fluorescent derivative. RP-HPLC provides good 
selectivity for separating the OPA derivatives. The OPA derivatives of amino 
acids can be detected by UV absorbance at 340 nm, fluorimetry at excitation and 
emission wavelengths of 340 nm and 450 nm, respectively, amperometry for 
those OPA-derivatives that show little or no fluorescent activity, or a combination 
of the aforementioned detection methods. Alternative reagents for precolumn 
derivatization of free amino groups are phenylisothiocyanate (PITC), 
dimethylamino-azobenzenesulfonyl chloride (DABS-Cl), 9-fluorenylmethylchloro-
formate (FMOC-Cl) and 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole (NBD-F).24 The 
derivatization time can vary between 1 min for OPA and 20 min for PITC. 
Depending on the number of the analytes, chromatographic run time varies 
between 13 min for 23 compounds and 95 min for 38 compounds.24 
Based on the coupling reaction of the well-known Edman degradation, the 
reaction of phenylisothiocyanate (PITC) with both primary and secondary amino 
acids produces phenylthiocarbamyl derivatives, which are also separated by RP-
HPLC and detected at 254 nm. This reaction served as the basis for the 
PICO•Tag method commercialized by Waters Inc. (Milford, MA, USA). More 
recently, Waters Inc. introduced a new kit (AccQ•Tag) based on the precolumn 
derivation of amino acids with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate 
(AQC). AQC converts both primary and secondary amino acids into exceptionally 
stable, fluorescent derivatives that are amenable to UV-absorbance, 
fluorescence, electrochemical, and MS detection.25 
To achieve faster analysis and improved resolution, the AccQ•Tag Ultra UPLC 
method has been introduced that employs columns packed with uniform 1.7-µm 
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particles. The UPLC method is 3-5 times faster than conventional HPLC analysis, 
and baseline separation of all proteinogenic amino acids is achieved in less than 
10 min. Boogers et al.26 published a comparison between Pico•Tag HPLC and 
AccQ•Tag ultra UPLC analysis. They separated 16 amino acids in 23 min and 8 
min, respectively, using the Pico•Tag HPLC and the AccQ•Tagultra UPLC 
method. For the Pico•Tag HPLC method lower limits of quantification (LLOQ) 
were in the range of 4.3-8.4 µM and for the AccQ•Tag ultra UPLC method in the 
range of 1.3-5.3 µM. 
A drawback of the aforementioned methods is the lack of analyte specificity of 
optical detection. Therefore, uncertainties arise in the analysis of complex 
biological samples that may contain other non-protein amino acids or compounds 
with an amino function that display similar or identical retention behavior. This 
may be avoided by the use of mass spectrometry that allows the identification of 
co-eluting compounds unless they are isobaric and/or display identical 
fragmentation patterns. Optical detection systems are also not suited to 
distinguish between isotopes and, therefore, cannot be used for flux analysis in 
organisms fed with stable isotope labeled substrates. The major advantages of 
LC coupled to optical detection are good reproducibility, the comparatively 
inexpensive equipment and the high sensitivity in the low pmol range.  
4.4.3 Ion pair reversed-phase liquid chromatography – tandem 
mass spectrometry (IP-LC-MS/MS) 
It is feasible to analyze underivatized amino acids by ion pair IP-LC-MS/MS. 
Elimination of derivatization reduces sample preparation and minimizes the 
errors introduced by reagent and derivative instability, side reactions, and 
reagent interferences. Usually, charged hydrophobic species are used as IP 
reagents in combination with RP-C18-HPLC columns. There are two 
mechanisms discussed as basis for IP separation. The IP-reagent can be 
adsorbed at the interface between the stationary and mobile phase, creating a 
charged surface with the inorganic counterions forming a corresponding diffuse 
layer. Hence, the IP-reagent creates an electrostatic surface potential, and the 
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magnitude of this potential is primarily determined by the surface concentration of 
the IP-reagent. Another hypothesis is the generation of uncharged complexes 
between the IP-reagent and the analyte that are less polar and will thus be 
retained on a C18 column.27 The use of volatile IP reagents, such as 
perfluorocarboxylic acids, allows the hyphenation of LC to electrospray ionization 
mass spectrometry (ESI-MS). Piraud et al.28 utilized HPLC separation on a C18 
column with tridecafluoroheptanoic acid (TDFHA) as IP reagent coupled to 
tandem mass spectrometry for amino acid analysis. To quantify the amino acids, 
multiple reaction monitoring (MRM) was used. A total of 76 amino acids were 
quantified in less than 20 min and the quantification of 16 amino acids was 
validated using their stable isotope-labeled analogs as internal standards. 
De Person et al.29 studied the effect of five perfluorinated carboxylic acids (C3-
TFA, C4-HFBA, C5-NFPA, C7-TDFHA and C8-PDFOA) on MS response. Signal 
intensity depended on type and concentration of IP reagent, as well as MS 
interface geometry. Limits of detection ranged 0.0003 – 9 µM depending on 
amino acid, type of mass spectrometer and IP reagent. Armstrong et al. 21 
coupled IP-RP-HPLC using TDFHA as IP reagent to time-of-flight mass 
spectrometry. Twenty-five amino acids were quantified in human plasma and the 
calibration curves were linear over a range of 1.56 to 400 µM. 
4.4.4 HILIC (Hydrophilic Interaction LIquid Chromatography) 
Another approach to separate polar compounds is hydrophilic interaction liquid 
chromatography. Separation is achieved using a polar stationary phase, such as 
bare silica, amide-, hydroxyl-, cyano-, amino-, and ion-exchange columns, in 
combination with RP-type solvent systems. Gradient elution is started with a high 
percentage of organic solvent, typically acetonitrile, and the retained compounds 
are eluted by increasing the water-content in the mobile phase. Langrock et al.30 
demonstrated the separation of 16 proteinogenic amino acids in 25 min using an 
amide-column coupled to ESI-MS/MS. Detection was carried out using a neutral 
loss scan of formic acid. In a neutral-loss scan, all precursors that undergo loss 
of a specified common neutral, formic acd in this case, are monitored. Further, 
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separation of all hydroxyproline isomers (trans-4-Hyp, trans-3-Hyp, and cis-4-
Hyp) present in collagen hydrolysates was achieved. Detection limits were below 
50 pmol for the Hyp-isomers 
4.4.5 Capillary electrophoresis mass spectrometry (CE-MS) 
Amino acids are chargeable analytes and, therefore, amenable to capillary 
electrophoresis (CE) separation without prior derivatization. However, if optical 
detection is employed, derivatization is needed to improve sensitivity. Labeling 
can be carried out with FMOC, NDA, OPA, or FITC.31 Capillary electrophoresis 
with laser-induced fluorescence detection (CE-LIF) was used to analyze free 
amino acids in cerebrospinal fluid.32 The amino acids were derivatized with FITC 
prior to analysis and the separation was completed within 22 min. Detection limits 
were in the low nanomolar range. Light-emitting diodes (LED) are replacing 
conventional gas lasers for CE-LIF. LEDs are very stable and provide high 
intensity at low cost. 33 Soga et al.34 analyzed urinary amino acids without 
derivatization by bare fused-silica capillary electrophoresis-electrospray 
ionization-triple-quadrupole mass spectrometry. The method was validated for 32 
amino acids with LODs between 0.1 and 14 µM and a linear dynamic range of 
approximately 10 – 200 μM. The relatively high LODs are due to the low injection 
volumes applied in CE.  
4.4.6 Gas chromatography for amino acid analysis 
The derivatization procedure most commonly employed in GC-MS is silylation, 
which replaces acetic hydrogen in functional groups by an alkylsilyl group, 
primarily trimethylsilyl, using reagents such as N,O-bis-(trimethylsilyl)-
trifluoroacetamide (BSTFA) or N-methyl-trimethylsilyltrifluoroacetamide (MSTFA). 
A reaction scheme for the derivatization with MSTFA is shown in Figure 7. GC 
analysis of silylated amino acids is feasible, but not all derivatives are stable; for 
example, arginine decomposes to ornithine, and glutamic acid rearranges to form 
pyro-glutamic acid. Another drawback is the sensitivity of the reagents and 
derivatives to moisture.35 
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Figure 7: Silylation of functional groups with MSTFA. 
 
Other derivatization procedures for GC analysis include acylation/esterification 
using various anhydride/alcohol combinations, such as pentafluorpropyl 
anhydride / isopropanol or trifluoroacetic anhydride / isopropanol.36 An alternative 
is the derivatization of amino acids with alkyl chloroformates and alcohol. 
Carboxylic groups are converted directly to esters and amino groups to 
carbamates. This reaction can be catalyzed by pyridine or picoline. Using the 
alkyl chloroformate reaction, amino acids can be derivatized directly in aqueous 
solution without prior removal of proteins. The amino acids react very quickly, for 
instance, with propyl chloroformate and the derivates can be extracted with an 
organic solvent. From the organic phase an aliquot can be injected directly into 
the GC-MS.37, 38 Fluorinated alcohols yield even more volatile compounds and 
have been applied to the separation of amino acid enantiomers.39 Recently, 
fluoroalkyl chloroformates were used for the analysis of amino acids on 5% 
phenylmethylsilicone phase by GC with MS or FID.40 Linearity was observed in 
the range of 0.1 - 100 nmol and LODs, defined as amount on column, ranged 
from 0.03 pmol for proline to 19.38 pmol for glutamic acid. More than 30 amino 
acids were separated in less than 10 min, including 1- and 3-methylhistidines, 
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which were previously not described as amendable to GC analysis using alkyl 
chloroformate derivatization. 
4.4.7 iTRAQ®-LC-MS/MS 
In 2007, Applied Biosystems (Foster City, CA, USA) introduced a kit for the 
quantification of 42 physiological amino acids and related compounds based on 
the iTRAQ® chemistry originally developed for the quantification of peptides41 by 
LC-MS/MS. Each reagent consists of a reporter group (with the masses m/z 114, 
115, 116 and 117), a neutral balance linker (masses 24-32) and an amino 
reactive group (N-hydroxy-succinimide) (Figure 8).  
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Figure 8: Structure and isotope patterns of iTRAQ® reagents. 
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The amino acids are derivatized with a reactive ester to introduce an isobaric tag. 
The N-hydroxy succinimide ester reacts with the amino group to give an amide 
(Figure 9) 
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Figure 9: Reaction of iTRAQ® labeling reagent with amino acids. 
 
All derivates of one amino acid are isobaric and cannot be separated by RP-
HPLC. The tag contains a cleavable reporter ion, which can be detected upon 
collision-induced dissociation in MS/MS mode (Figure 10). These reporter ions 
differ by one mass unit and can be used to quantify multiplexed biological 
samples. For the analysis of free amino acids, the biological sample is labeled 
with the tag containing the reporter ion m/z 115. Before analysis, the sample is 
mixed with an amino acid standard solution labeled with the reagent containing 
the reporter ion m/z 114. Because the two derivatives of one amino acid have the 
same mass, they elute at the same retention time and experience the same 
matrix effects during ESI. Consequently, each amino acid is quantified based on 
the ratio of the m/z 115-ion over the m/z 114-reporter ion. The main advantage of 
iTRAQ®-LC-MS/MS is the availability of 42 internal standards for all physiological 
amino acids and related compounds, such as taurine, ethanolamine or 
phosphoethanolamine. Disadvantages are the insufficient recovery of amino 
acids with sulfur containing groups, such methionine and cysteine, and the 
somewhat imprecise quantification due to the large number of transitions and the 
resultant insufficient acquisition of data points per peak in a single LC-MS/MS 
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run. The latter may be alleviated by the use of time scheduled multiple reaction 
monitoring (sMRM). 
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Figure 10: Amino acid analysis by iTRAQ®-LC-MS/MS: Separation of derivatives by HPLC and 
detection by MS/MS in multiple reaction monitoring (MRM), Each amino acid has its own internal 
standard correcting for matrix effects. 
 
4.4.8 Direct infusion tandem mass spectrometry 
Analysis of blood and urinary amino acids are used routinely in newborn screens 
for inherited metabolic disorders, such as phenylketonuria and maple syrup urine 
disease. Blood and urine samples are typically collected on filter paper, from 
which disks of defined size are punched out. Amino acids are then extracted with 
methanol containing stable isotope labeled amino acids. Extracted amino acids 
are converted into the corresponding butyl esters using hydrochloric acid in n-
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butanol.2 The screening for inborn errors of metabolism is performed using direct 
infusion MS/MS, which allows the very fast analysis of large number of samples. 
Additionally fatty acid and organic acid disorders can be detected in one brief 
analysis. However, isobaric amino acids, such as leucine, isoleucine and allo-
isoleucine or alanine and sarcosine cannot be distinguished. For direct infusion, 
mass analyzers that provide high mass resolution, such as electrospray 
ionization time-of-flight mass spectrometry (ESI-TOF-MS) and fourier transform 
ion cyclotron resonance mass spectrometry (FTICR-MS) are employed. This 
allows the identification of metabolites using accurate mass measurement. Dunn 
et al. showed the identification of amino acids and other metabolites in fruit 
extracts matching experimental accurate masses to the theoretical masses, for 
example glutamine and lysine are isobaric but can be distinguished by their 
accurate mass.42 
4.4.9 Nuclear magnetic resonance (NMR) 
The main advantage of NMR is its ability to detect all proton-containing 
metabolites in a sample simultaneously. Its sensitivity does not depend on 
chemical properties of the analytes such as pKa or hydrophobicity. Physiological 
fluids such as urine can be directly analyzed with only limited preparation. NMR 
is a very reproducible method and signals scale linearly with metabolite 
concentrations, which allows for reliable quantification. The main drawback of the 
method is its limited sensitivity compared to mass spectrometry. However, with 
the use of the newly developed cryo-probes limits of detection in the low µM 
range are obtained. Due to the high number of metabolites typically present in 
biological samples, however, significant overlap of amino acid signals with other 
signals is commonly observed in 1D 1H NMR spectra as seen in Figure 11A. A 
mathematical solution to this problem is to fit overlapped signals with modelled 
peaks.43 Alternatively, multidimensional NMR such as 2D 1H-13C heteronuclear 
single-quantum correlation (HSQC) spectra may be used to separate the 
overlapping metabolite signals in a second heteronuclear dimension.44 A typical 
example obtained for human urine can be seen in Figure 11B 
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Figure 11: A) 1D 1H spectrum of human urine measured at 600 MHz on a Bruker Avance III 
spectrometer equipped with a cryo-probe. B) The corresponding 1H-13C HSQC spectrum 
measured at natural abundance. As an example for amino acid metabolites in both spectra the 
signals corresponding to the alanine methyl groups are marked. 
 
The availability of the newly developed cryo-probes allows partial compensation 
for the low natural abundance (≈1.1%) and low gyromagnetic ratio of the 13C 
nuclei. In many instances it is advantageous to combine the results obtained by 
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different methods such as NMR and mass spectrometry. As mentioned above 
some intensity loss is observed by going from 1D 1H spectra to 2D 1H-13C HSQC 
spectra. One way of regaining this intensity loss due to the low natural 
abundance of 13C is to chemically N-acetylate the amino-acid metabolites with 
13C-labeled acetic anhydride.45 Using this approach, it is possible to obtain, on 
the one hand, highly sensitive 1H-13C HSQC spectra for amino acids and, on the 
other hand, background related to metabolites not modified by the derivatization 
procedure is drastically reduced, thus enabling lower limits of detection in the 
upper nanomolar range. 
4.4.10 Comparison of methods for amino acid analysis 
A comparison of the methods available for the analysis of amino acids is given in 
Table 2. The major advantage of NMR is that physiological fluids may be 
analyzed directly, albeit at the expense of sensitivity. Gains in sensitivity are 
feasible, but require N-acetylation of the amino acids with 13C-labeled acetic 
anhydride. Another disadvantage is the large sample volume required, albeit due 
to the non-destructive nature of NMR, samples may be retrieved and subjected to 
further testing. The need for the acquisition of 2D-spectra limits throughput, but 
this is balanced by the ability of NMR to detect proton and carbon containing 
metabolites other than amino acids. Protein precipitation is required for all LC 
and CE methods independent of the detection method used, which renders 
complete automation difficult. Liquid chromatographic methods coupled with 
optical detection are well established and highly reproducible. However, classical 
pre- and post-column derivatization protocols employing OPA or ninhydrin suffer 
from long chromatographic runtimes, which render them poorly suited for large 
clinical and epidemiological studies. Another drawback shared by all methods 
based on optical detection is their lack of analyte specificity compared to mass 
spectrometry. The latter, however, is subjected to matrix and ion suppression 
effects that impair quantitative accuracy and necessitate the use of stable-isotope 
labeled internal standards. Nevertheless, MS based methods will prevail in the 
future. HILIC-MS and CE-MS allow the direct analysis of amino acids without 
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prior derivatization, but they suffer from low throughput and comparatively poor 
reliability. Ion-pair LC-MS has been applied to the analysis of both native and 
iTRAQ®-labeled amino acids. The most important benefit of iTRAQ®-LC-MS/MS 
compared to other MS-based methods is the availability of internal standards not 
only for the 20 proteinogenic amino acids, but also for non-protein amino acids. 
But iTRAQ®-LC-MS/MS has a number of disadvantages including somewhat 
poor reproducibility due to the large number of transitions that have to be 
acquired, which may be alleviated in the future by scheduled multiple reaction 
monitoring (sMRM), the inability to accurately measure sulfur-containing amino 
acids, the difficulty of automating sample preparation, and the higher reagent 
costs.  
GC-MS is a very robust method with excellent reproducibility of retention times. 
Especially with alkyl chloroformate derivatization excellent reproducibility of 
quantitative data has been observed and the method can be automated easily, 
thus, allowing high sample throughput. However, thermo-labile derivatives cannot 
be measured.  
Finally, direct flow injection analysis with ESI-MS/MS offers high throughput and 
is now widely used in newborn screening for inborn errors of metabolism. The 
one major limitation is the inability to resolve isobaric amino acids. To date 
various methods exist for the quantification of amino acids in protein hydrolysates 
and physiological fluids. The great importance of amino acid analysis is reflected 
in a number of commercialized solutions ranging from kits to dedicated 
instruments. The development of new methods or the improvement of existing 
methods is still ongoing. Expansion of the analyte spectrum covered, reduction of 
sample preparation and analysis time, improved sensitivity, good robustness and 
reproducibility are the focus of research. An important aspect is method 
automation and high sample throughput, which is essential in studies with large 
sample numbers. There is room for new or improved methodology for amino acid 
analysis, including expansion of the analyte spectrum covered, reduction of 
sample preparation and analysis time, improved sensitivity, good robustness and 
reproducibility. Due to high selectivity and sensitivity, MS is expected to play a 
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key role provided that stable isotope labelled standards, which are a prerequisite 
for robust quantification, become readily and cheaply available. Reduced sample 
pre-treatment is another important aspect for facilitating automation and 
improving robustness and sample throughput, which are essential in 
epidemiological studies with large sample numbers. 
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Table 2: Comparison of selected approaches for the metabolic analysis of amino acids 
Method Advantages Disadvantages LOD Ref. 
LC-methods coupled 
with optical detection 
• Highly reproducible 
• Inexpensive equipment  
• Good linearity over a broad range 
• Protein precipitation and derivatization 
necessary 
• Lack of analyte specificity 
• Co-eluting substances cannot be 
distinguished 
• Not applicable to flux analysis 
 
UV: 5 µM 
(LOQ) 
22-25 
UPLC-MS • Fast separation • Good resolution 
 
• Protein precipitation necessary 
• High pressure requires special 
equipment  
• Limited number of amino acids covered 
• Ion suppression 
 
1.3 - 5.3 µM 
(LOQ) 
26 
IP-LC-MS/MS • Derivatization not necessary • High number of analytes covered 
• Good resolution for polar amino acids 
• Protein precipitation  necessary 
• Ion suppression 
• Contamination of analytical system with 
IP reagent 
 
0.0003 - 9 µM 
(LOD) 
21, 28, 29 
HILIC • Derivatization not necessary • Compatible with MS 
• Well-suited for polar compounds 
• Protein precipitation necessary 
• Poor reproducibility 
• Ion suppression in case of MS detection 
 
5 µM (LOD)  
10 µM (LOQ) 
30 
CE-MS • Derivatization not  necessary • Low sample consumption 
• Protein precipitation necessary 
• Only low injection volume possible 
 
0.1 - 14 µM 
(LOD) 
34 
GC-MS • Robust method • Highly reproducible 
• Good resolution 
• Fast separation 
• Derivatization necessary  
• Not suited for thermolabile amino acid 
derivatives 
0.03 - 19.98 
pmol on 
column (LOD) 
 
40 
iTRAQ® 
• Fast separation 
• Availability of internal standards for each 
analyte 
• Protein precipitation necessary 
• Insufficient recovery of sulfur containing 
amino acids 
2-10 µM (LOQ) Unpub-lished 
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• Difficult to automate own data 
Direct infusion MS/MS, 
TOF 
• No separation needed 
• High throughput 
• Extraction and derivatization required 
• Isobaric amino acids cannot be 
resolved 
 
  
NMR • No separation and derivatization needed • Robust quantification 
• Minimal sample preparation 
• Insufficient sensitivity, albeit LOD can 
be lowered by derivatization 
• Long analysis time  
 
2D: 20 – 312 
µM (LOD) 
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 5 High-throughput analysis of free amino acids in 
biological fluids by GC-MS 
5.1 Introduction 
Our aim was to develop a robust, accurate, fast and precise method for urinary 
amino acid analysis. Amino acids can be derivatized directly in aqueous solution 
using alkyl chloroformate. The amino acids react very quickly, for instance, with 
propyl chloroformate and the derivates can be extracted with an organic solvent. 
From the organic phase an aliquot can be injected directly into the GC-MS.37, 38 
Applying this approach, a fast and fully automated quantitative method for the 
analysis of amino acids in physiological fluids by GC-MS was developed. The 
analysis was performed using a modified protocol based on the EZ: faast kit from 
Phenomenex (Phenomenex Inc, Torrence, CA, USA), whereby the cation-
exchange cleanup step was omitted and the amino acids were derivatized 
directly in the aqueous biological sample. This simplified protocol allowed for the 
full automation of the procedure with an MPS-2 sample robot from Gerstel 
(Gerstel, Muehlheim, Germany), with reliable quantification of amino acids in 
various biological matrices having been accomplished over a wide dynamic 
range using stable isotope labeled standards. A shortened version of this chapter 
was published in the Journal of Chromatography B. 47 
5.2 Materials and methods 
5.2.1 Chemicals 
A standard solution of 17 amino acids at 1mM each in 0.1 M HCl, phenol, 
isooctane, methyl chloroformate, n-propanol, hippuric acid and thiodiglycol were 
purchased from Sigma (Sigma-Aldrich, Taufkirchen, Germany). The certified 
amino acid solution was purchased from NIST (National Institute of Standards 
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and Technology, Gaithersburg, MD, USA). Methanol (LC-MS grade) and 
chloroform (HPLC grade) were from Fisher (Fisher Scientific GmbH, Ulm, 
Germany). The [U-13C, U-15N] cell free amino acid mix was from Euriso-top 
(Saint-Aubin Cedex, France) and α-aminoadipic acid [2, 5, 5-2H3] and [2,3,4,5,6-
2H5] hippuric acid were purchased from C/D/N Isotopes Inc. (Quebec, Canada). 
N-Methyl-N-trifluoroacetamide (MSTFA) was obtained from Macherey-Nagel 
(Dueren, Germany), and the Phenomenex EZ:faast GC kit (Phenomenex Inc. 
Torrence, CA, USA) was used for the derivatization of amino acids with propyl 
chloroformate. 
5.2.2 Biological samples 
Human urine was collected from healthy volunteers. Mice urine was obtained 
from collaborators at the University of Regensburg, while urine and serum 
samples from patients with inborn errors of amino acid metabolism were provided 
by the Zentrum für Stoffwechseldiagnostik Reutlingen GmbH. The lyophilized 
human plasma control was purchased from Recipe (Munich, Germany) and 
reconstituted in HPLC water. The cell culture medium was RPMI 1640 (PAA 
Laboratories GmbH, Cölbe, Germany) with phenol red, to 500 mL of which 
penicillin (30 mg/L) and streptomycin (10.4 g/L) (Invitrogen, Karlsruhe, Germany) 
had been added, as well as 25 mL of fetal calf serum (PAA Laboratories GmbH), 
153 mg glutamine and 115 mg sodium pyruvate (Sigma-Aldrich). To stabilize the 
amino acids in the biological sample, 20 µL of an aqueous solution containing 
10% n-propanol, 0.1% phenol and 2% thiodiglycol, were added to 20-50 µL 
biological sample. 
5.2.3 Instrumentation 
An Agilent model 6890 GC (Agilent, Palo Alto, USA) equipped with a MSD model 
5975 Inert XL, PTV injector) and a MPS-2 Prepstation sample robot was used 
(Gerstel, Muehlheim, Germany. The robot has two autosamplers equipped with 
one syringe each of different volume. A 10-µL syringe is used for addition of the 
internal standards and for sample injection, while a 250-µL syringe is used for 
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adding reagents. Between the adding steps, the syringes were washed at least 3 
times with chloroform and/or propanol. The syringes were washed with propanol 
after adding aqueous solutions and with chloroform and propanol after adding 
organic solutions. Biological samples were kept in a cooled tray (5°C). The MPS-
2 Prepstation is shown in Figure 12. 
 
Figure 12: GC-MS with MPS-2 Prepstation 
 
The GC-column was a ZB-AAA (Phenomenex Inc.), 15 m x 0.25 mm ID, 0.1 µm 
film thickness. In addition, a RTX-35 Amine column and a RXI-5 MS column from 
Restek (GmbH, Bad Homburg, Germany) were tested. The oven temperature 
was initially held at 70°C for 1 min, raised at 30°C/min to 300°C, and held here 
for 3 min. The column flow was 1.1 mL He/min. The injection volume was 2.5 µL 
and the split ratio was 1:15. The temperature of the PTV Injector was set at 50°C 
for 0.5 min and ramped at 12°C/sec to 320°C (5 min). 
The following liners from Gerstel were tested: Deactivated baffled glass liner, 
glass wool packed liner, quartz wool packed liner and the chemically inert 
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SILTEC liner. The transfer line to the mass spectrometer was kept at 310°C. The 
MS was operated in scan (50-420 m/z) and SIM (selected ion monitoring) mode. 
For SIM, appropriate ion sets were selected and two characteristic mass 
fragments of the derivatized amino acids were used for almost all amino acids, 
except for the labeled amino acids. The ion traces are listed in Table 3. 
 
Table 3: Ion traces selected for the SIM analysis of 33 physiological amino acids, dipeptides and 
norvaline. Amino acids printed in bold were quantified via stable isotope dilution using the internal 
standard quantification trace of the corresponding stable-isotope labeled amino acid. 
Amino acid Quantification trace 
Secondary Ion 
trace 
Internal standard 
quantification trace 
Alanine 130 88 133 
Sarcosine 130 217  
Glycine 102  105 
α-Aminobutyric acid 144 102  
Valine 158 116 163 
ß-Aminoisobutyric acid 116   
Norvaline 158 72  
Leucine 172 130 178 
allo-Isoleucine 172 130  
Isoleucine 172  178 
Threonine 101 203 104 
Serine 146 203 149 
Proline 156  161 
Asparagine 155 69 160 
Thiaproline 174 147  
Aspartic acid 216 130 220 
Methionine 203 277 206 
Hippuric acid 134 105 139 
Hydroxyproline 172 86  
Glutamic acid 230  235 
Phenylalanine 190 206 199 
α-Aminoadipic acid 244  247 
α -Aminopimelic acid 258 84  
Glutamine 84 187 89 
Ornithine 156 70  
Glycyl-Proline 70 156  
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Lysine 170 128 176 
Histidine 282 168 290 
Hydroxylysine 129 169  
Tyrosine 107 206 114 
Proline-Hydroxyproline 156   
Tryptophan 130  140 
Cystathionine 203 272  
Cystine 248 216  
 
5.2.4 Derivatization 
In contrast to the original Phenomenex protocol, the cation exchange clean-up 
step was omitted. Amino acids were directly derivatized in the aqueous biological 
sample, 20-50 µL of which were transferred manually together with 20 µL of the 
stabilization reagent, described in chapter 5.2.2, to a 2-mL autosampler vial 
(Gerstel). The vial was closed with a magnetic crimp cap to allow automated 
handling by the robot. The first step performed by the robot is the dilution of the 
sample with water up to 225 µL, followed by addition of 10 µL of a norvaline 
solution (200 µM) and 10 µL internal standard mix. A mixture of uniformly 13C, 
15N labeled alanine, glycine, valine, leucine, isoleucine, threonine, serine, proline, 
asparagine, aspartate, methionine, glutamate, phenylalanine, glutamine, lysine, 
histidine, tyrosine and tryptophan, as well as [2,5,5-2H3] α-aminoadipic acid and 
[2,3,4,5,6-2H5] hippuric acid were used as internal standards with a concentration 
range from 0.0438 to 1.4175 mM. To increase the pH of the solution, 120 µL of 
0.33 M sodium hydroxide solution were added, followed by 50 µL of picoline in 
propanol, which acts as a catalyst for the derivatization reaction (solution 
provided by Phenomenex). The vial was moved to an agitator and the solution 
was mixed at 750 rpm for 0.2 min at 35°C. 50 µL of propyl chloroformate in 
chloroform were added to the sample, the solution was mixed for 0.2 min (750 
rpm, 35°C), equilibrated for 1 min and again mixed again for 0.2 min. To extract 
the derivatives, 250 µL of isooctane were added and the vial was vortexed for 0.2 
min (750 rpm, 35°C). For analysis, an aliquot (2.5 µL) was taken from the upper 
organic phase and injected directly into the PTV. All steps were automated and 
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done by the MPS-2 Prepstation from Gerstel. The different features of the MPS-2 
Prepstation are shown in Figure 13. 
Two Autosamplers
10 µL Syringe 
Standard spike
Injection
250 µL Syringe 
Sample Preparation
Two Agitators
(left and right):
Vortex sample,
Incubate at given 
temperature
Cooled sample 
tray
Sample tray
Syringe wash 
stion
Syringe wash 
station
Reagent 
reservoirs
Two injection ports
Front: hot split/ 
splitless
Back: PTV 
Automated 
Liner 
Exchange 
(ALEX)
 
 
Figure 13: MPS Prepstation features. 
 
5.2.5 Quantification 
Absolute quantification of 33 compounds (alanine, sarcosine, glycine, α-
aminobutyric acid, valine, ß-aminoisobutyric acid, leucine, allo-isoleucine, 
isoleucine, threonine, serine, proline, asparagine, thiaproline, aspartic acid, 
methionine, hippuric acid, hydroxyproline, glutamic acid, phenylalanine, α-
aminoadipic acid, α-aminopimelic acid, glutamine, ornithine, glycyl-proline, lysine, 
histidine, hydroxylysine, tyrosine, proline-hydroxyproline, tryptophan, 
cystathionine and cystine) was performed by analyzing standard solutions 
containing equimolar amounts of all amino acids. The Phenomenex kit contains 3 
different standard amino acids mixtures at 200 µM each. The first mixture 
consists of 23 amino acids. The second mixture contains amino acids not stable 
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in acidic solution (asparagine, glutamine and tryptophan), while the third mixture 
includes complementary amino acids and dipeptides occurring in urine (α-
aminoadipic acid, cystathionine, glycyl-proline, hydroxylysine, proline-
hydroxyproline and thiaproline). For calibration, the three different mixtures were 
mixed in equal amounts and hippuric acid was added separately to yield a final 
concentration of 60 µM for each compound. The mix was further diluted to final 
concentrations of 6 µM and 0.6 µM, respectively. For calibration, increasing 
volumes of the diluted and non-diluted standards were pipetted automatically by 
the autosampler into empty vials and then derivatized as described above. A 1-
mM amino acid standard solution from Sigma was used to extend the calibration 
curve to higher concentrations. The amino acids were normalized by the area of 
the labeled amino acid for the generation of calibration curves in the range of 0.3-
2,000 µM or normalized by the area of the closest eluting internal standard 
compound. 
5.2.6 NMR 
For NMR structural analysis, the propylformate derivative of asparagine was 
dissolved in 99.99% CDCl3 that was also used as internal standard at 7.26 and 
77.00 ppm for 1H and 13C, respectively. 
NMR experiments were recorded at 300 K on a Bruker Avance III spectrometer 
equipped with two channels and a cryo-cooled pulse field gradient triple 
resonance probe with z-gradients. The conformation of the molecule was 
confirmed by 1D 1H, 2D 1H-13C HSQC and 2D 1H-13C HMBC experiments. 
NMR assignments: C2 155.6 ppm; C4 67.2 ppm; H4A/H4B 3.98 ppm; C5 22.0 
ppm; H5A/H5B 1.59 ppm; C6 10.0 ppm; H6A/H6B/H6C 0.89 ppm; C8 50.5 ppm; 
H8 4.47 ppm; C9 21.6 ppm; H9A 2.96 ppm; H9B 2.87 ppm; C10 115.8 ppm; C12 
168.5 ppm; C15 68.2 ppm; H15A/H15B 4.12 ppm; C16 21.6 ppm; H16A/H16B 
1.65 ppm; C17 10.0 ppm; H17A/H17B/H17C 0.89 ppm (numbering is shown in 
Figure 24, chapter  5.3.9). 
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5.3 Results and Discussion 
5.3.1 Derivatization and column selection 
Both the amino and the carboxyl group of amino acids react readily with alkyl 
chloroformates as shown in Figure 14 to yield volatile derivatives for GC-
analysis.37 
R
HH2N
OHO
Cl O
O
+
cat.
solvent:
OH
- 2 HCl
- CO2
H
N
R
H
OO
O
O  
Figure 14: Reaction scheme for the derivatization of amino acids with propyl chloroformate. 
  
Hydroxyl groups as found in serine and threonine have a very low reactivity and 
amide groups are not derivatized. Zampolli et al.39 showed that methyl 
chloroformate (MCF) and 2,2,3,3,4,4,4-heptafluorobutanol (HFB) produce mono- 
and bis-acylated derivatives for serine, while no acylation of the hydroxyl group in 
threonine was observed. For amino acids without any additional functional 
groups two equivalents of alkyl chloroformate are needed. The acid function is 
converted to the ester, under loss of CO2, and the amino group reacts to the 
corresponding amide. Using U-13C, U-15N labeled amino acids it was shown that 
the CO2 loss originated from the derivatization reagent (data not shown).  
For derivatization of the amino acids with propyl chloroformate prior to GC-MS 
analysis the Phenomenex EZ:faast GC kit was employed. To allow for complete 
automation of sample pretreatment and injection, we explored whether the 
cation-exchange solid-phase extraction step recommended by Phenomenex prior 
to derivatization could be omitted given the high selectivity of a quadrupole mass 
spectrometer operated in SIM mode. Indeed, no significant differences in 
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retention times and number of amino acids detected were observed between 
urine and plasma samples subjected to either solid-phase extraction or 
derivatized directly (data not shown). 
Initially, propyl chloroformate derivates were analyzed on a Phenomenex ZB-
AAA column, 10 m x 0.25 mm ID, which was provided with the Phenomenex 
EZ:faast GC kit. The separation of the analytes was completed in less then 7 
minutes (Figure 15). 
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Figure 15: Typical GC-MS chromatogram for the analysis of an amino acid standard on a 10 m x 
0.25 mm ID ZB-AAA column after derivatization with propyl chloroformate.  
 
However, for some amino acids either peak tailing (e.g., tryptophan and tyrosine) 
or non-linear calibration curves (e.g., glutamine and tryptophan) were observed.  
Further, not all amino acids, including the isobaric leucines, were baseline 
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separated. Therefore, other stationary phases were evaluated.  The first column 
tested was a RTX-35 Amine column (30 m x 0.25 mm ID, 0.5 µm film thickness), 
which is specifically designed for the separation of amines. (Figure 16a) 
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Figure 16: GC-MS chromatograms of an amino acid standard separated on a 30-m RTX-35 
column after derivatization with (a) propyl and (b) methyl chloroformate, respectively. 
 
Peak tailing was significantly reduced. However ornithine, histidine, glutamine, 
glycyl-proline, lysine, hydroxylysine, proline-hydrxyproline, cystathionine and 
cystine were not detected due to either the significant column bleeding occurring 
at high temperatures, which might mask late eluting analytes, or the fairly high 
film thickness (0.5 µm) of the RTX-35 Amine column, which might retain amino 
acid derivates indefinitely. The column is not commercially available with a 
thinner film. To obtain more volatile derivates the reaction with methyl 
chloroformate was tested.38 But even then, many amino acids, including 
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asparagine, serine, glutamine, glycyl-proline, lysine, histidine, hydroxylysine, 
tyrosine, proline-hydroxyproline, tryptophan, cystathionine and cystine, were not 
detected on the RTX-35 Amine column (Figure 16b). In addition to the polar 
column, a low bleeding non-polar RXI-5 MS column was tested (30 m x 0.25 mm 
ID, 0.25 µm film thickness). Using the propyl chloroformate reaction, five amino 
acids were not detected (threonine, serine, glutamine, cystathionine and cystine) 
(Figure 17a), while with the methyl chloroformate reaction aspargine, serine, 
threonine, ornithine, hydroxyproline, proline-hydroxyproline, cystathionine and 
cystine could not be detected (Figure 17b). 
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Figure 17: GC-MS chromatograms of an amino acid standard separated on a 30-m RXI-5MS 
column after derivatization with (a) propyl and (b) methyl chloroformate, respectively. 
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We also compared the separation of the propyl chloroformate derivatives on a 
15-m ZB-AAA column versus the original 10-m column. Employing the same 
temperature program, better resolution was obtained on the longer column for 
asparagine and methionine as well as glutamic acid and phenylalanine, which 
facilitates a more robust selection of SIM windows. For both amino acid pairs the 
resolution (defined in chapter 4.3.1) was 1.7 with the 10-m column and it 
improved to > 2.5 using the 15-m column. Figure 18 represents a typical 
chromatogram of the 34 compounds including norvaline, which is a non-
endogenous compound and used as an internal standard. Less than ten minutes 
were required to resolve all compounds. 
Figure 18: Typical GC-MS chromatogram for the analysis of an amino acid standard on a 15 m x 0.25 mm ID ZB-AAA column after derivatization 
with propyl chloroformate. Amino acids printed in red were quantified using the corresponding stable-isotope-labeled amino acid as internal 
standards for quantification. 
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 5.3.2 Injection and liner selection 
Sample injection was done using programmed-temperature vaporization. The 
sample was introduced into the cold insert (50°C), which was then rapidly 
heated to vaporize and transfer the analytes into the GC column. This is a 
rather gentle injection technique, which is favorable for thermally labile 
compounds. Since the amino acid derivatives are still rather polar analytes, 
adsorption to the insert surface can occur, reducing the reproducibility of the 
analysis. Proper selection of the insert type is important. Therefore, different 
liners were tested with regard to the reproducibility of urine analysis: 
Deactivated baffled glass liner, glass wool packed liner, quartz wool packed 
liner and the chemically inert SILTEC liner (Figure 19.). Using the glass or 
quartz wool packed liner increases the liner surface to retain the liquid sample 
injected, which can then evaporate from the glass or quartz wool surface. 
However, there is the risk of increased analyte adsorption to the active sites on 
the surface.  
Carrier
gas inlet Septum purge
Split outlet
Septum
Column
Vaporization
chamber
LinerHeated metal 
block
Test of four different liners:
SilTEC deactivated
baffled liner
Deactivated
baffled liner
Glass wool
packed liner
Quartz wool
packed liner
 
Figure 19: Injector scheme and four different liners tested for reproducibility 
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 A urine sample was analyzed five times using each liner and the relative 
standard deviation (RSD) was calculated (Figure 20).  
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Figure 20: Comparison of the relative standard deviation values obtained for the repeated 
analysis (n=5) of urinary amino acids using different injector inserts. 
 
The glass wool packed liner showed the worst reproducibility, in particular for 
amino acids with polar functional groups such as aspartic acid, glutamic acid 
and asparagine. Additionally, it was not possible to detect glutamine, 
cystathionine and cystine. Reproducibility was better for the quartz wool packed 
liner, but still inferior to the SILTEC liner. With the baffled liner, there were more 
amino acids with an RSD > 10%, and for thiaproline the RSD exceeded 20 %. 
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Only with the SILTEC liner, the RSDs were < 10%, except for sarcosine with 
10.6 %, and all amino acids were detected successfully. Therefore, the SILTEC 
liner was used for all further analyses following its prior conditioning by the 
consecutive injection of the silylation reagent MSTFA, a 1 mM amino acid 
standard solution, and blanks to deactivate any active sites on the glass 
surface. 
5.3.3 Internal standard selection 
For the generation of reliable quantitative data, internal standards are required 
to correct for chemical and analytical losses during derivatization and analysis. 
We observed that norvaline corrected quite well for such losses for amino acids 
similar structure and retention to norvaline, e.g. leucine and glycine. But for 
amino acids with a more complex structure and more functional groups, e.g. 
glutamine, histidine and tyrosine, the linearity was lost over a wider 
concentration range, as shown in Table 4. Additionally, the reproducibility 
decreased. This led to the conclusion that more internal standards structurally 
similar to as many analytes as possible were needed. This is best realized by 
stable-isotope labeled amino acids. It is important that the mass difference 
between analyte and internal standard is more than one unit to avoid the 
overlap with the content of the natural isotope 13C.  A standard mix of 18 
uniformly 13C and 15N labeled amino acids was chosen. The labeled amino 
acids are extracted from algae. Consequently, their individual concentrations, 
as analyzed by HPLC, differ and range from 0.043 - 1.417 mM. Additionally 
[2,5,5-2H3] α-aminoadipic acid and [2,3,4,5,6-2H5] hippuric acid were used as 
internal standard. To compare the difference with and without using the internal 
standard mixture, the R square-values of the calibrations of all amino acids are 
shown in Table 4. The R square-values are at least 0.99 using the labeled 
amino acids as internal standards except for hydroxyproline and glycyl-proline. 
In comparison, the R square-values of the calibration curves using norvaline as 
the only internal standard were mostly < 0.99. In summary, the R square-values 
improved for all amino acids except sarcosine, α-aminobutyric acid, α-
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aminopimelic acid and cystathionine, for which no stable-isotope labeled amino 
acids were available. 
 
Table 4: Comparison of the R-square values obtained for the calibration curves of selected 
amino acids using either norvaline (Nval) or stable-isotope labeled amino acids as internal 
standards. The RSD values represent the inter-day reproducibility of urinary amino acid levels 
for 11 repeated injections using either quantification method.  
Amino acida R2 R2 RSD (%) RSD (%) 
 Nval Stable isotopes Nval Stable isotopes 
Alanine 0.9732 0.9997 7.04 1.5 
Sarcosine 0.9974 0.9969 10.91 5.7 
Glycine 0.9893 0.9998 9.06 2.2 
α-Aminobutyric acid 0.9984 0.9984 4.07 4.2 
Valine 0.8904 0.9996 1.96 2.1 
ß-Aminoisobutyric acid 0.9977 0.9970 4.92 5.6 
Leucine 0.9988 0.9992 2.64 2.8 
allo-Isoleucine 0.9953 0.9985 2.86 2.5 
Isoleucine 0.9061 0.9996 2.96 2.7 
Threonine 0.9191 0.9988 n.d. n.d. 
Serine 0.8637 0.9975 n.d. n.d. 
Proline 0.9955 0.9960 6.90 3 
Asparagine 0.9754 0.9986 13.70 2.2 
Thiaproline 0.9858 0.9900 n.d. n.d. 
Aspartic acid 0.9939 0.9997 15.49 14.1 
Methionine 0.9915 0.9958 7.36 11.8 
Hippuric acid 0.9921 0.99 18.60 16.7 
Hydroxyproline 0.9725 0.9758 n.d. n.d. 
Glutamic acid 0.9993 0.9999 8.13 3.3 
Phenylalanine 0.9972 0.9997 5.34 3.4 
α-Aminoadipic acid 0.9908 0.9982 6.81 2.5 
α -Aminopimelic acid 0.9956 0.9925 n.d. n.d. 
Glutamine 0.9523 0.994 15.66 4.2 
Ornithine 0.9909 0.9971 9.07 4.8 
Glycyl-Proline 0.9659 0.984 n.d. n.d. 
Lysine 0.975 0.996 7.79 3.9 
Histidine 0.8937 0.9987 12.28 2.2 
Hydroxylysine 0.985 0.9976 n.d n.d. 
Tyrosine 0.9688 0.9984 5.99 2.5 
Proline-Hydroxyproline 0.9807 0.9906 n.d. n.d. 
Tryptophan 0.9802 0.9987 4.02 2.8 
Cystathionine 0.9959 0.993 5.42 2.5 
Cystine 0.9861 0.995 9.56 11.3 
a Amino acids printed in bold were quantified with a corresponding stable isotope. 
n.d.-not detected above the LLOQ 
 
In addition, we compared the inter-day reproducibility of 11 biological replicates 
of a urine sample. This biological sample was measured 11 times during a 
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batch of 351 biological samples. The RSDs using norvaline as the sole internal 
standard ranged from 1.98% to 18.6%. But they improved significantly (1.5% to 
5.7%) for most amino acids, except for aspartic acid, methionine,hippuric acid 
and cystathionine, when stable-isotope labeled amino acid standards were 
employed. For the latter no stable isotope labeled standards had been 
available.  
5.3.4 Method characterization  
For absolute quantification, calibration curves were generated. Calibration 
curve parameters, retention time, range of quantification, R square-values and 
limits of detection are presented in Table 5. The quantification range is 
determined by the lower (LLOQ) and the upper limit of quantification (ULOQ), 
which are defined as the lowest, respectively highest point of the calibration 
curve with an accuracy between 80-120%, in agreement with the FDA Guide 
for Bioanalytical Method Validation.48 The R square-value or coefficient of 
determination was calculated as the square of the correlation coefficient r of the 
regression analysis over the quantification range. The limit of detection (LOD) is 
defined as the concentration producing a signal to noise (S/N) ratio of at least 
3:1. Concentrations reported in Table 5 were calculated from the analysis of 50-
µL aliquots of human urine. The lowest LOD was 0.03 µM, corresponding to an 
absolute injected amount of 15 fmol.  
The LOD of 0.03 µM was determined for alanine, glycine and tryptophan. The 
LODs for most other amino acids were below 1 µM except for serine, 
asparagine, histidine, hydroxylysine, cystathionine and cystine, which yielded 
an LOD of 3 µM. The highest LODs with 12 µM were obtained for proline-
hydroxyproline and glutamine. For glutamine, this was due to partial 
decomposition of the propylformate derivative through elimination of water, as 
evidenced by two peaks in the chromatogram. For asparagine, elimination of 
water was complete. Nevertheless, both glutamine and asparagine could be 
determined by derivatization with propyl chloroformate, thereby not confirming 
the observation by Casal et al.49, that glutamine and asparagine are converted 
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to aspartate and glutamate during derivatization with ethyl chloroformate and 
2,2,3,3,4,4,4-heptafluoro-1-butanol. The LOD for all amino acids might be 
improved by using less organic solvent for extraction or injecting more sample 
using large volume technique.  
 
Table 5: Calibration curve parameters. Limits of detection and ranges of quantification were 
defined by the lower and upper limits of quantification. Amino acids printed in bold were 
quantified using the corresponding stable isotope-labeled amino acid. 
Amino acid R-squarea LODb 
(μM) 
Range of 
quantification 
[µM] c 
Regression line Retention 
time (min) 
Alanine 0.9997 0.03 0.3-2000 1.507 * x + 0.011940 4.35 
Sarcosine 0.9969 0.3 0.9-270 1.611 * x + -0.008277 4.43 
Glycine 0.9998 0.03 3-2000 1.238 * x + 0.068277 4.49 
α-Aminobutyric acid 0.9984 0.12 0.3-270 2.521 * x + 0.001067 4.62 
Valine 0.9996 0.18 0.3-2000 1.174 * x + 0.001163 4.73 
ß-Aminoisobutyric acid 0.9970 0.27 0.9-270 0.613 * x + -0.003078 4.83 
Leucine 0.9992 0.06 0.3-2000 1.102 * x + 0.005131 4.98 
allo-Isoleucine 0.9985 0.3 0.9-270 1.252 * x + -0.005865 5.02 
Isoleucine 0.9996 0.12 0.9-2000 1.122 * x + -0.002333 5.05 
Threonine 0.9988 0.18 0.3-2000 1.03* x + -0.001590 5.29 
Serine 0.9975 3.0 12-2000 1.22 * x + 0.443377 5.34 
Proline 0.9960 0.27 0.3-2000 0.623 * x + -0.010681 5.43 
Asparagine 0.9986 3.0 12-270 1.125 * x + -0.036928 5.53 
Thiaproline 0.9900 0.3 0.9-270 4.349 * x + -0.006387 5.93 
Aspartic acid 0.9997 0.3 3-2000 1.251 * x + -0.018064 6.11 
Methionine 0.9958 0.9 3-1000 1.177 * x + -0.028463 6.16 
Hippuric acid 0.99 3 12-2000 0.062 * x + -0.003033 6.28 
Hydroxyproline 0.9758 0.9 3-270 0.334 * x + -0.004975 6.30 
Glutamic acid 0.9999 0.9 3-2000 1.249 * x + -0.023798 6.49 
Phenylalanine 0.9997 0.3 0.9-2000 1.191 * x + -0.005860 6.55 
α-Aminoadipic acid 0.9982 0.9 3-270 1.089 * x + -0.033340 6.81 
α-Aminopimelic acid 0.9925 0.9 3-270 2.351 * x + -0.131996 7.09 
Glutamine 0.9940 12.0 30-270 1.197 * x + -0.012232 7.58 
Ornithine 0.9971 0.3 0.9-270 1.526 * x + -0.018075 7.18 
Glycyl-proline 0.9840 0.9 3-270 0.161 * x + -0.006280 7.65 
Lysine 0.9960 0.3 0.9-2000 1.122 * x + -0.024828 7.85 
Histidine 0.9987 3.0 12-2000 0.372 * x + -0.043117 8.06 
Hydroxylysine 0.9976 3.0 12-270 0.208 * x + 0.006536 8.26 
Tyrosine 0.9984 0.3 0.9-2000 2.449* x + -0.001631 8.35 
Proline-Hydroxyproline 0.9906 12.0 12-270 0.047 * x + -0.002474 8.61 
Tryptophan 0.9987 0.03 0.3-270 1.44 * x + -0.003679 8.69 
Cystathionine 0.9930 3.0 12-270 0.133 * x + 0.001518 9.20 
Cystine 0.9950 3.0 12-1000 0.186 * x + 0.012430 9.55 
a Coefficient of determination (square of the correlation coefficient r of the regression analysis)  
b Limit of Detection (S/N ≥ 3)   
c LOD and LOQ were calculated for a sample volume of 50 µL 
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The calibration ranges ranged from 0.3 µM to 2000 µM for most amino acids. 
Satisfactory linearity was obtained for the calibration curves with a R square-
value ≥ 0.99 for all amino acids except hydroxyproline (0.9758) and glycyl-
proline (0.984). However, for these amino acids no corresponding stable-
isotope had been available. 
5.3.5 Method validation 
A certified amino acid standard from NIST was analyzed to check the accuracy 
of the method. This Standard Reference Material (SRM) is an aqueous mixture 
of 17 amino acids in 0.1 M hydrochloric acid. We were able to quantify 16 out of 
17 amino acids. Arginine could not be determined because of the thermal 
instability of its propyl chloroformate derivative that carries a free guanidine 
group. The certified concentrations and estimated uncertainties for the 16 
amino acids are given in Table 6. These values are based on in-house analysis 
at NIST and a round-robin study that was conducted in cooperation with the 
Association of Biomolecular Research Facilities. The certified value is the 
equally weighted mean of the NIST average and the round robin average. 
Additionally gravimetric values given by NIST are shown in the Table 6. The 
gravimetric value is based on the weighed amount of each amino acid used to 
prepare the solution. For all amino acids, there is an excellent correspondence 
between the results obtained by GC-MS and the certified values obtained by 
means of conventional amino acid analyzers. In addition, a recovery based on 
the gravimetric values was calculated. It ranged from 94.3% up to 105.3% for 
methionine and lysine, respectively. Only the recovery for histidine is high 
(123.7%). But for this amino acid, the certified concentration measured by NIST 
is also higher than the gravimetric value. 
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Table 6: Arithmetic means and standard deviations of the concentrations [mM] of amino acids 
in a certified standard compared to the reference values given by NIST and compared to the 
gravimetric values in terms of recovery. 
Amino acid GC-MS ( n=6) NIST ravimetric 
lue 
Recovery (%)of 
the GC-MS data 
based on 
gravimetric 
values 
Alanine 2.506 ±0.027 2.51 ±0.09 2.5 100.2 
Glycine 2.604 ±0.026 2.45 ±0.08 2.51 103.7 
Valine 2.623 ±0.020 2.44 ±0.08 2.55 102.9 
Leucine 2.562 ±0.018 2.48 ±0.09 2.6 98.5 
Isoleucine 2.650 ±0.013 2.39 ±0.07 2.54 104.3 
Threonine 2.549 ±0.069 2.39 ±0.08 2.44 104.5 
Serine 2.584 ±0.082 2.43 ±0.09 2.47 104.6 
Proline 2.592 ±0.035 2.44 ±0.09 2.5 103.7 
Aspartic acid 2.576 ±0.020 2.5 ±0.09 2.55 101.0 
Methionine 2.386 ±0.144 2.43 ±0.09 2.53 94.3 
Glutamic acid 2.513 ±0.055 2.27 ±0.10 2.44 103.0 
Phenylalanine 2.566 ±0.025 2.44 ±0.08 2.58 99.5 
Lysine 2.642 ±0.032 2.47 ±0.10 2.51 105.3 
Histidine 3.080 ±0.052 2.83 ±0.11 2.49 123.7 
Tyrosine 2.609 ±0.047 2.47 ±0.09 2.49 104.8 
Cystine 1.157 ±0.071 1.16 ±0.06 1.2 96.4 
 
The applicability of the method to biological samples was demonstrated by 
analyzing amino acids in a certified biological matrix. We chose Clinchek 
plasma controls from RECIPE, which are used for internal quality assurance in 
clinical-chemical laboratories. The mean values and confidence intervals have 
been established by independent reference laboratories using conventional 
amino acid analyzers. To quantify the amino acid concentration in plasma, 
plasma was measured 10 times by GC-MS. We were able to determine 18 
amino acids in the plasma. All measured values were well inside the control 
range given by RECIPE (Table 7). The sole exception was asparagine, for 
which the GC-MS value was slightly too high. The control range for asparagine 
was 17.3 to 25.9 µM and the concentration measured by GC-MS was 29.7 µM. 
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Table 7: Amino acid concentrations in a plasma reference as determined by GC-MS in 
comparison to the reported control range (data given by the manufacturer). 
 
Amino acid Concentration by GC-MS 
[µM] 
Control range 
[µM] 
 Mean ± SD (n =10)  
Alanine 349.9 ± 3.51 327-491
Glycine 168.7 ± 2.84 148-222
α-Aminobutyric acid 9.8 ± 0.55 10.8-16.2
Valine 195.7 ± 1.60 178-266
Leucine 192.3 ± 1.82 157-235
Isoleucine 68.7 ± 0.86 56.7-85.1
Proline 191.7 ± 1.66 159-239
Asparagine 29.7 ± 0.88 17.3-25.9
Aspartic acid 19.0 ± 0.39 16.9-25.3
Methionine 38.8 ± 1.03 30.3-45.5
Glutamic acid 243.3 ± 2.84 236-354
Phenylalanine 80.6 ± 1.67 65.8-98.8
Ornithine 125.7 ± 3.34 112-168
Glutamine 205.1 ± 9.01 199-299
Lysine 154.6 ± 1.57 128-192
Histidine 71.4 ± 5.61 60.6-91
Tyrosine 64.1 ± 1.47 47.6-71.4
Tryptophan 50.7 ± 0.78 37.8-56.6
 
5.3.6 Precision of GC-MS analysis of amino acids in different 
biological matrices 
The method’s precision low determination of amino acid concentrations in 
different biological matrices was evaluated by analyzing human urine, mice 
urine, control plasma and cell culture medium. Ten or more replicates were 
analyzed for each sample and the RSDs obtained for different amino acids are 
listed in Table 8. For human urine, we determined not only the intra-day but 
also the inter-day precision. The reproducibility in all biological samples for all 
amino acids was excellent, with RSDs typically < 5%. Generally, the RSDs are 
higher in urine than in cell culture medium or plasma, but consistently < 9% in 
the intra-day experiments. For most amino acids, the precision for intra-day and 
inter-day measurements are comparable, except for aspartic acid, methionine 
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and cystine.  For the latter amino acids, the RSDs increased above 10% in the 
inter-day measurements with a maximum value of 14.1% for aspartic acid. 
 
Table 8: Reproducibility of GC-MS analysis of amino acids in different biological matrices using 
aliquots of 20 µL of sample, except for 50 µL of human urine. 
Relative standard deviation [%] 
 
Amino acida 
Human 
Urine 
(n=10) 
Intra-day 
Human Urine
(n=11) 
Inter-day 
Mice urine 
(n=10) 
Intra-day 
Plasma 
(n=11) 
Intra-day 
Media 
(n=10) 
Intra-day 
Alanine 2.0 1.5 1.3 1.0 2.6 
Sarcosine 5.6 5.7 4.6 n.d. n.d. 
Glycine 3.1 2.2 2.1 1.7 2.0 
α-Aminobutyric acid 7.9 4.2 3.9 5.6 3.5 
Valine 2.4 2.1 1.3 0.8 3.4 
ß-Aminoisobutyric acid 5.7 5.6 8.9 n.d. n.d. 
Leucine 3.0 2.8 2.4 0.9 3.0 
allo-Isoleucine 3.6 2.5 1.6 1.6 n.d. 
Isoleucine 2.5 2.7 2.3 1.3 2.6 
Proline 3.2 3.0 3.1 0.9 3.0 
Asparagine 3.5 2.2 5.4 3.0 4.0 
Aspartic acid 8.1 14.1 6.9 2.0 3.8 
Methionine 7.1 11.8 4.8 2.7 4.3 
Hippuric acid 8.7 16.7 7.5 n.d n.d 
Glutamic acid 3.1 3.3 2.5 1.2 3.0 
Phenylalanine 2.5 3.4 3.6 8.3 n.d. 
α-Aminoadipic acid 4.3 2.5 4.3 3.6 n.d. 
Ornithine 3.7 4.8 3.2 2.7 8.2 
Glutamine 8.7 4.2 9.1 4.4 3.9 
Lysine 2.4 3.9 2.0 1.0 3.6 
Histidine 4.9 2.2 7.5 7.8 5.4 
Tyrosine 4.0 2.5 5.8 2.3 3.7 
Tryptophan 2.9 2.8 3.3 1.5 3.9 
Cystathionine 8.8 2.5 n.d. n.d. n.d. 
Cystine 7.1 11.3 8.0 n.d. 14.3 
a Amino acids printed in bold were quantified with a corresponding stable isotope. 
n.d. - not detected above the LLOQ. 
 
5.3.7 Quantification in biological matrices 
Matrix spike experiments were performed in human urine to evaluate the 
impact of the biological matrix on the quantification. Amino acid standards in 
three different absolute amounts (1.5, 6.0 and 10.5 nmol) were added to three 
different urine samples and measured in triplicate. Linear regression analysis 
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was performed for the standard addition and the calculated slopes were 
compared with those obtained from the calibration with the aqueous standards. 
The correlation between the slopes for the amino acids found in human urine is 
shown in Figure 21. A slope of 1.08 and a correlation coefficient (RSQ) of 0.95 
indicate the absence of matrix effects for most amino acids and justify the use 
of aqueous standards for calibration. Only glycine, sarcosine, α-aminobutyric 
acid and tyrosine are slightly over- or underestimated. The average recovery for 
all amino acids calculated over all spike levels and all replicates were 93.6%, 
ranging from 70.9% for glutamine to 120% for glycine. However, glutamine and 
glycine have high levels in urine and the spike levels used are too low to 
evaluate these amino acids correctly. 
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Figure 21: Evaluation of matrix effects by comparison of the slopes of the calibration curve (x-
axis) with the slope of the standard addition curve in human urine (y-axis). 
 
5.3.8 Inborn errors of amino acid metabolism 
Analysis of blood and urinary amino acids are used routinely in the diagnosis 
and treatment of inherited metabolic disorders, such as phenylketonuria (PKU) 
and maple syrup urine disease (MSUD). The screening for inborn errors of 
metabolism is widely done using direct infusion LC-MS-MS methods,2, 50, 51 
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which allows the very fast analysis of large number of samples. However, 
isobaric amino acids, such as leucine, isoleucine and allo-isoleucine or alanine 
and sarcosine cannot be distinguished. In contrast, the GC-MS method takes 
longer, but separation of those isobars is achieved. 
To demonstrate the applicability of the GC-MS method to the determination of 
abnormal amino acid levels in inherited disorders of amino acid metabolism, 
serum and urine samples were ascertained from patients with various inborn 
errors of metabolism. Four different serum samples and four different urine 
samples were analyzed.  The serum samples originated from patients with 
maple syrup urine disease, phenylketonuria, propionic acidemia and 
tyrosinemia I, whereas the urine samples were from patients with 
argininosuccinic aciduria, propionic acidemia, maple syrup urine disease and 
aminoaciduria. All samples were measured in triplicate. The amino acid 
concentrations observed in these patients are listed in Table 9 and Table 10 in 
this chapter. Phenylketonuria (PKU) is caused by a deficiency of the enzyme 
phenylalanine hydroxylase or its cofactors,1 leading to the accumulation of 
phenylalanine (Figure 3, chapter 4.2).45 PKU can be diagnosed by an increased 
ratio of phenylalanine to tyrosine in serum.52 In the serum samples with this 
inborn error, there is a high concentration of phenylalanine, in comparison to 
the other samples. This is obvious from the dominant phenylalanine peak (q) in 
the GC-MS total ion current chromatograms shown in Figure 22a. Figure 22a 
and Figure 22b show chromatograms of the propyl chloroformate derivatives of 
amino acids from a PKU-positiv serum and MSUD-positv serum, respectively.  
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Figure 22: GC-MS total ion current chromatograms of propyl chloroformate derivatives of 
amino acids from a PKU-positive serum (a) and a MSUD-positive serum (b).  Labeled peaks 
are the derivatives of a) Ala, b) Gly, d) Val, f) Leu, h) Ile, i) Thr, j) Ser, k) Pro, l) Asn, m) Asp, n) 
Met, p) Glu, q) Phe, s) Gln, t) Orn, u)Lys, v) His, w) Tyr, and y) Trp.  
 
A high concentration of phenylalanine (296.8 µM) was detected in the PKU 
serum sample compared to the other samples analyzed that yielded an 
average phenylalanine concentration of 39.1 µM.  
Patients with maple syrup urine disease (MSUD) have a defect in branched-
chain α-keto acid decarboxylase, resulting in increased serum concentrations 
of keto acids and their corresponding amino acids. The pathways of the 
degradation of the branched chain amino acids are shown in Figure 23. The 
amino acid that accumulates the most is leucine. Further, increased 
concentrations of valine and isoleucine are often observed.2  
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Figure 23: Branched chain amino acid metabolism. MSUD is caused by a deficiency of the 
metabolic enzyme branched chain α-keto acid dehydrogenase (BCKDH). 
 
MSUD can be diagnosed by an increased ratio of leucine and isoleucine to 
phenylalanine.52 As shown in Table 9, leucine is the most abundant amino acid 
with serum concentration of 394 µM, while the average concentration was only 
58 µM in the three MSUD-negative serum samples. The concentrations of 
valine and isoleucine in the MSUD serum sample were also higher than in the 
other serum samples. In addition, allo-isoleucine was detected in the serum 
sample with a concentration of 32.1 µM. There were also pronounced 
differences in the urinary amino acid profiles between MSUD-positive and 
MSUD-negative samples. In comparison to argininosuccinic aciduria and 
propionic acidemia, the urinary concentrations for valine, leucine and isoleucine 
were increased 8-, 15- and 17-fold, respectively. Even allo-isoleucine could be 
detected and quantified with a concentration of 56 µM. In addition, high urinary 
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concentrations of threonine, serine, α-aminoadipic acid, lysine, histidine and 
proline-hydroxyproline were detected.  
Tyrosinemia I and II are characterized by an accumulation of tyrosine.2 The 
tyrosinemia type I is caused by a deficiency of fumarylacetoacetase. The 
tyrosinemia-positive urine sample has a ten times higher concentration of 
tyrosine compared to the other urine samples analyzed.  Propionic acidemia is 
categorized as a deficiency of propionyl-CoA-carboxylase. Methylcitrate and 
propionic acid are the key indicators for that disorder.53-55 Additionally, high 
concentrations of glycine can occur in urine and serum.56 Accordingly, high 
glycine concentrations were detected in the propionic acidemia positive serum 
and urine samples. Argininosuccinic aciduria is an inborn error with a urea 
cycle defect that causes ammonia to accumulate in the blood. It is caused by a 
deficiency of argininosuccinate lyase.9, 57 There were no characteristic 
concentration changes for any of the amino acids quantified by GC-MS in the 
argininosuccinic aciduria-positive urine. Aminoaciduria is a condition that can 
occur in several disorders, like Hartnup disease, Dent`s disease and Fanconi 
syndrome. The aminoaciduria is generally characterized by high urinary amino 
acid excretion.58 Levels of almost all amino acids were increased except for α-
aminobutyric acid, isoleucine, aspartic acid, and methionine. Interestingly, the 
concentration for α-aminoadipic acid decreased by a factor of four in 
comparison to the levels detected in the urine of patients with argininosuccinic 
aciduria or propionic acidemia. 
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Table 9: Plasma amino acid concentrations [µM] for patients with inborn errors of metabolism. 
Each sample was measured in triplicate.  
Amino acid Maple syrup 
urine disease 
Phenyl-
ketonuria 
Propionic 
acidemia 
Tyrosinemia I 
Alanine 69.56 ± 1.46  174.81 ± 0.95 86.51 ± 0.48 187.75 ± 1.29 
Glycine 81.67 ±2.05 151.57 ± 4.93 489.14 ± 2.93 187.45 ± 6.03 
α-Aminobutyric acid 3.81± 0.17 3.07 ± 0.12 2.97 ± 0.02 3.46 ± 0.08 
Valine 245.49 ± 5.16 126.69 ± 1.11 80.67 ± 0.31 70.55 ± 0.39 
ß-Aminoisobutyric acid n.d. n.d. 1.2 ± 0.07 1.06 ± 0.04 
Leucine 394.3 ± 7.95 55.15 ± 0.47 69.44 ± 0.68 49.7 ± 0.68 
allo-Isoleucine 32.11 ± 1.06 n.d. n.d. n.d. 
Isoleucine 123.37 ± 2.44 31.65 ± 0.21 29.11 ± 0.1 21.71 ± 0.35 
Threonine 39.91 ± 1.49 50.39 ± 0.40 39.02 ± 1.08 50.74 ± 0.84 
Serine 56.1 ± 0.55 79.86 ± 0.31 60.49 ± 1.89 77.21 ± 1.46 
Proline 47.4 ± 1.21 95.59 ± 1.76 65.21 ± 0.41 80.75 ± 0.54 
Asparagine 13.47 ± 0.29 n.d. 16.43 ± 0.62 17.33 ± 1.22 
Aspartic acid 14.17 ± 0.45 13.62 ± 0.3 8.27 ± 0.27 13.95 ± 0.26 
Methionine 8.58 ± 0.17 7.06 ± 0.43 8.12 ± 0.21 7.52 ± 0.45 
Hydroxyproline n.d. n.d. n.d. 9.26 ± 1.29 
Glutamic acid 36.35 ± 0.62 50.65 ± 0.22 21.3 ± 0.3 47.39 ± 0.46 
Phenylalanine 45.54 ± 0.65 296.75 ± 1.81 33.43 ± 0.65 38.4 ± 0.42 
α-Aminoadipidic acid n.d. n.d. 1.05 ± 0.05 n.d. 
Glutamine 120.63 ± 1.76 151.81 ± 3.58 103.23 ± 3.87 173.81 ± 3.27 
Ornithine 18.87 ± 1.25 51.45 ± 2.86 11.67 ± 0.15 32.83 ± 2.25 
Lysine 50.85 ± 1.07 67.61 ± 1.14 118.23 ± 1.08 70.65 ± 0.77 
Histidine 31.43 ± 1.15 32.05 ± 1.95 27.67 ± 0.58 39.8 ± 0.43 
Tyrosine 25.02 ± 0.56 34.97 ± 0.30 19.46 ± 0.25 277.05 ± 1.83 
Proline-hydroxyproline 66.07 ± 5.68 53.23 ± 21.84 53.99 ± 21.27 50.26 ± 17.09 
Tryptophan 13.92 ± 0.23 23.55 ± 0.09 15.21 ± 0.02 18.06 ± 0.07 
n.d. - not detected above the LLOQ. 
 
Table 10: Urinary amino acid concentrations [µM] for patients with inborn errors of metabolism. 
Each sample was measured in triplicate. 
Amino acid Argininosuccinic 
aciduria 
Propionic acidemia MaMaple 
syrup  
 D   urine 
disease 
Amino- 
aciduria 
Alanine 123.87 ± 1.64 180.57 ± 1.33 129.34 ± 1.70 2424.03 ± 38.64 
Sarcosine n.d. 1.06 ± 0.18 2.06 ± 0.07 40.02 ± 1.51 
Glycine 489.81 ±1.67 5524.1 ± 188.5 2034.0 ± 18.3 27090 ± 1259.7 
α-Aminobutyric acid 6.58 ± 0.18 4.73 ± 0.18 4.35 ± 0.14 5.3 ± 0.11 
Valine 32.27 ± 0.69 16.64 ± 0.21 194.71 ± 1.17 129.38 ± 1.92 
ß-Aminoisobutyric 
acid n.d. 25.35 ± 1.04 3.9 ± 0.02 262.69 ± 6.43 
Leucine 19.55 ± 0.15 23.03 ± 0.06 305.33 ± 2.26 80.88 ± 1.16 
allo-Isoleucine n.d. n.d. 56.12 ± 0.37 n.d. 
Isoleucine 6.31 ± 0.04 9.89 ± 0.16 134.8 ± 0.61 8.67 ± 0.22 
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Threonine 68.13 ± 3.27 57.41 ± 4.43 178.41 ± 10.72 2398.44 ± 20.06 
Serine 202.89 ± 4.52 294.62 ± 13.09 903.29 ± 7.70 1885.23 ± 40.18 
Proline 13.38 ± 0.18 11.09 ± 0.83 23.63 ± 0.08 4909.14 ± 96.19 
Asparagine 51.77 ± 0.74 86.95 ± 0.75 82.71 ± 1.54 1236.85 ± 13.46 
Thiaproline 1.43 ± 0.21 2.38 ± 0.18 1.46 ± 0.1 4.13 ± 0.2 
Aspartic acid 19.13 ±0.32 11.77 ± 0.73 12.94 ± 0.55 12.87 ± 0.14 
Methionine 54.57 ± 1.04 11.31 ± 0.22 21.68 ± 0.71 33.87 ± 1.14 
Hydroxyproline n.d. n.d. 41.29 ± 1.82 1083.45 ± 52.37 
Glutamic acid 11.99 ± 0.34 18.39 ± 1.31 60.49 ± 0.36 175.23 ± 8.95 
Phenylalanine 46.44  ± 0.71 48.93 ± 0.66 87.4 ± 1.87 596.53 ± 10.76 
α-Aminoadipic acid 26.68 ± 1.08 29.71 ± 0.45 136.79 ± 1.22 6.65 ± 0.2 
Glutamine 556.96 ±19.8 220.95 ± 6.94 447.29 ± 25.19 2899.77 ± 73.38 
Ornithine 11.1 ± 0.72 8.75 ± 0.20 15.43 ± 0.51 338.05 ± 8.88 
Glycyl-proline 24.93 ± 1.86 8.24 ± 1.49 119.95 ± 5.08 n.d. 
Lysine 46.78 ± 0.31 49.85 ± 0.87 173.27 ± 1.53 3565.4 ± 60.90 
Histidine 172.27 ± 0.99 182.45 ± 1.26 1416.05 ± 65.85 1806.71 ± 15.21 
Tyrosine 30.99 ± 1.09 141.63 ± 5.22 125.92 ± 3.95 754.26 ± 21.63 
Proline-
hydroxyproline 135.29 ± 9.95 167.34 ± 36.54 742.37 ± 70.66 87.01 ±8.72 
Tryptophan 22.63 ± 0.53 42.79 ± 0.41 72.45 ± 0.35 86.45 ± 1.25 
Cystathionine 34.6 ± 1.85 n.d. 5.25 ± 0.18 18.33 ±  1.40 
Cystine 44.73 ± 6.26 51.18 ± 0.93 84.28 ± 3.59 286.35 ± 22.9 
n.d. - not detected above the LLOQ 
5.3.9 Method limitations 
Arginine is an important amino acid that cannot be analyzed by GC-MS 
following alkyl chloroformate derivatization.38 This is due to the thermal 
instability of the derivative that carries a free guanidine group. We could not 
confirm the report by Namera et al.59 that threonine, serine, asparagine and 
glutamine cannot be derivatized and analyzed by GC-MS successfully. 
However, we did observe the complete, respectively partial elimination of water 
during the derivatization of asparagine and glutamine. As a result, the 
corresponding derivatives contain a nitrile function instead of the amide group 
as confirmed by NMR (see experimental section 5.6). The reaction is shown in 
Figure 24. 
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Figure 24: Reaction scheme for the loss of water in the propyl chloroformate derivate of 
asparagines. 
 
The quantitation of asparagine and glutamine proved robust in our hands, while 
this was not consistently the case for serine and threonine. Standards of serine 
and threonine could be detected readily after proper conditioning of the SILTEC 
liner as described above. For human adult urine samples, however, a rapid 
deterioration of the liner performance was observed, which resulted in 
increasingly broader peaks over very few injections. Reconditioning of the liner 
did not alleviate this problem. Interestingly, we were able to detect the threefold 
derivatized serine and threonine with the hydroxyl group being also acylated. In 
both cases the threefold derivatized product is the minor product.  In 
comparison to the major derivative the threefold derivative was observed in the 
urine samples in low quantity. This observation led to the assumption that the 
free hydroxyl group and the biological matrix can interact with the liner. 
5.4 Applications to different biological projects 
5.4.1 Metabolome analysis of E. coli 
A capillary electrophoresis – mass spectrometry (CE-MS) method was 
developed and validated for the quantitative analysis of negatively charged 
metabolites, using a time-of-flight (TOF) mass by Timischl et al.60 The method 
was used to elucidate metabolic changes in an Escherichia coli mutant, UdhA-
PntAB, a double kock out for the nicotinamide nucleotide transhydrogenase.  
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To validate the CE-MS method and to get a more comprehensive coverage of 
the E. coli metabolome, the E. coli samples were also subjected to the amino 
acid analysis by GC-MS with propyl chlorofromate. For the amino acids 
glutamic acid and aspartic acid, which were detected by both methods, a very 
good correlation was observed. Many of the other amino acids showed 
significant differences between the wild type and the mutant strain. The results 
of the amino acid analysis are also puplished by Timischl et al. 60 
5.4.2 Cross-validation with 2D NMR 
A two-dimensional (2D) nuclear magnetic resonance (NMR) spectroscopy 
method was developed by Gronwald et al. for the quantification of metabolites 
in biological fluids and tissue extracts. 46 The quantitative 2D NMR data of a 
selected set of the urinary metabolites were compared with data obtained by 
GC-MS amino acids analysis with and propyl chloroformates. To crossvalidate 
the NMR measurement with other analytical methods a blinded set of 50 
human urine samples originating from the INTERMAP study were analyzed by 
NMR, GC-MS and LC-MS. The set contained 6 triplicates (18 samples) 5 
duplicates (10 samples), 14 single samples, and 8 samples that were mixed at 
a ratio of 1:1 (Figure 25). 
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Figure 25: Study design of the blinded sample set. 
 
The RSDs (%) for the GC-MS analysis are shown in Figure 26 for the 
triplicates, duplicates, mixed samples and for the average over all. 
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Figure 26: Reproducibility as relative standard deviation of urinary GC-MS amino acids 
analysis of the 50 samples using 50 µL sample aliquots. 
 
The 2D NMR results of the 50 urine samples taken from the INTERMAP study 
for 7 compounds (alanine, glutamine, glycine, hippuric acid, histidine and 
lysine) were linearly regressed with the data obatianed by GC-MS and the R-
square values were calculated.  One important urinary metabolite amenable to 
both NMR and GC-MS is hippuric acid. Figure 27 shows the comparison of the 
corresponding NMR and GC-MS results for the 50 urine samples investigated. 
As indicated by the high R-square value of 0.99, both methods allowed the 
precise determination of hippuric acid and showed a linear correlation over the 
entire observed concentration range.46 
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Figure 27: Correlation between 2D NMR analysis and GC-MS analysis for hippuric acid. 
 
5.4.3 Other biological projects 
Due to the broad applicability of the method a lot of different samples were 
measured. Samples ranging from sera and plasma to urine, cell media, cell 
extracts and milk. Mice urine samples were measured for a working group of 
the biology department, cell media was measured for our in house working 
group examining the intake of glutamine, human urine samples were measured 
for the correlation of GC-MS and NMR for hipuric acid.61 Tryptophan analysis 
was performed for a project investigating mesenchymal stem cells (MSC) 
inhibiting the immune response in vitro.62 
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 6  A Comparison of iTRAQ®-LC-MS/MS, GC-MS and 
 Amino Acid Analyzer 
6.1 Introduction 
The goal of the present study was to compare sample preparation, amount of 
sample needed for analysis, runtime, number of analytes amenable to 
quantification, cost, lower limit of quantification (LLOQ), reproducibility, 
reliability, and validity of three methods for urinary amino acids analysis: A 
conventional amino acid analyzer, GC-MS of propyl chloroformate derivatives,47 
and iTRAQ®-LC-MS/MS.41 Use of iTRAQ®-LC-MS/MS for this purpose is 
described here for the first time. The iTRAQ® method is based on differential 
derivatization of standard and sample amino acids with isobaric tags that show 
identical chromatographic retention, but can be distinguished by tandem mass 
spectrometry upon collision-induced dissociation of reporter ions that differ by 
one mass unit. The advantage of iTRAQ®-LC-MS/MS over other existing 
methods is the availability of 42 internal standards of physiological amino acids 
and related amines that enable absolute quantification by isotope ratio analysis.  
For the comparison of the three methods blinded sets of 98 and 341 urine 
specimens, respectively, were analyzed. The urine specimens were aliquots 
from the timed 24-hour urine collections of the INTERMAP study 
(INTERnational collaborative of MAcronutrients and blood Pressure) on relation 
between diet and blood pressure among 4,680 men and women ages 40-59 
years in Japan, Peoples Republic of China (PRC), UK and USA.3, 63 This 
chapter will be published in the Journal of Chromatography B.64 
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6.2 Materials and Methods 
6.2.1 Urine specimens 
The urine specimens were aliquots taken from the timed 24-hour urine 
collection of the 17 population samples collected by the INTERMAP Study from 
1996 to 1999 in 4 countries. Boric acid had been added as a preservative to the 
urine samples upon collection. Before preparation of aliquots for this study, 
specimens had been stored at -20°C. Aliquots were shipped from London to 
Regensburg and Framingham, respectively, on dry ice and, thereafter, stored at 
-20°C until analysis. 
The first test set comprised 30 triplicates and 4 duplicates from 34 INTERMAP 
urine specimens randomly selected from five (of 17) population samples: 
Sapporo (Japan), Aito Town (Japan), Guangxi (PRC), Chicago (US), and 
Minneapolis (US), respectively. The second set comprised 341 aliquots from 
144 INTERMAP urine specimens that were different from those in batch I, but 
selected from the same five population samples. Of the 144 different urine 
specimens, 91 were represented as duplicates and 53 as triplicates. 
6.2.2 iTRAQ®-LC-MS/MS 
The analysis by LC-MS/MS was carried out by Applied Biosystems. 
Derivatization of urinary amino acids with iTRAQ® was performed semi-
automated using the Apricot Designs TPS-24 Total Pipetting Solution™ liquid 
handler with a 12-position pipetting head. Forty µL of urine were manually 
pipetted into 96-well plates. The plates were placed on the liquid handler and 
10 µL of 10% sulfosalicylic acid containing 4 nmol of norleucine were added to 
each well to precipitate the proteins. Norleucine served as internal standard to 
calculate extraction efficiency. The plates were removed from the liquid 
handler, mixed for 30 s, and then centrifuged in an Eppendorf Centrifuge 
5810R for 5 min at 2,000 RPM (700xg). The plates were returned to the liquid 
handler, 10 µL of supernatant were transferred to new wells and mixed with 40 
µL labeling buffer (0.45 M borate buffer, pH 8.5, containing 20 pmol/µL 
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norvaline as internal standard to calculate derivatization efficiency). Ten µL of 
the diluted supernatant were transferred to new wells and mixed with 5 µL of a 
diluted iTRAQ® reagent 115 solution (1 tube mixed with 70 µL of isopropanol) 
and incubated at room temperature for 30 min. Then 5 µL of 1.2% 
hydroxylamine solution were added to each well. The samples were allowed to 
evaporate overnight to dryness and were reconstituted the next day with 32 µL 
of iTRAQ® reagent 114-labeled standard mix (5 pmol of each amino acid/µL - 
with the exception of L-cystine, present at 2.5 pmole/µL - in 0.5% formic acid). 
Chromatographic separation of amino acids with an identical nominal mass was 
achieved at 50°C using an Agilent 1100 HPLC system. An Applied Biosystems 
C18-5 µm column (4.6 i.d. x 150 mm) was used. LC separation was carried out 
using a mobile phase consisting of 0.1% formic acid and 0.01% 
heptafluorobutyric acid in water (solvent A) and 0.1% formic acid and 0.01% 
heptafluorobutyric acid in acetonitrile (solvent B). The column was equilibrated 
in 98% A and the gradient was 98%-72% A over 10 min, 72%-0% A over 0.1 
min, hold at 100% B for 5.9 min. A flow rate of 800 µL min-1 was used and the 
injected sample volume was 2 µL. Tandem mass spectrometry was performed 
on an API 3200 mass spectrometer (Applied Biosystems) with turbo ion spray 
in positive mode using the following parameters: Ion spray voltage (IS) 1500 V; 
auxiliary gas temperature (TEM) 700ºC; curtain gas (CUR), nebulizer gas 
(GS1), and auxiliary gas (GS2) 20, 70, and 70 arbitrary units, respectively; 
collision gas medium. Entrance potential (EP) was set at 10 V, declustering 
potential (DP) at 20 V, collision energy (CE) at 30 V, and collision cell exit 
potential (CXP) at 5 V. Quantitative determination was performed in multiple 
reaction-monitoring (MRM) mode using one transition for the analyte and one 
for the internal standard, according to the manufacturer’s instructions. 
Processing of the chromatograms was performed using a beta version of the 
Cliquid® software (Appl. Biosys.) for automated tracking of mass traces and 
stable isotope ratio analysis. A chromatogram of a urinary sample, using MRM, 
is shown in Figure 28. 
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Figure 28: Separation of 44 amino acids in an urine sample on a C18 column with iTRAQ® 
(labeled with numbers) in MRM mode, divided into 4 different time windows. Labeled peaks are 
the derivatives of: 1) Pser, 2) PEtN, 3) Tau, 4) Asn, 5) Ser, 6) Hyp, 7) Gly, 8) Gln, 9) Asp, 10) 
EtN, 11) Cit, 12) Sar, 13) bAla, 14) Ala, 15) Thr, 16) Glu, 17) His, 18) M1His, 19) M3His, 20) 
Hcit, 21) GABA, 22) ßAib, 23) Abu, 24) Aad, 25) Ans, 26) Car, 27) Pro, 28) Arg, 29) Hly, 30) 
Orn, 31) Cth, 32) Cys-Cys, 33) Asa, 34) Lys, 35) Val, 36) Nva, 37) Met, 38) Tyr, 39) Hcys, 40) 
Ile, 41) Leu, 42) Nle, 43) Phe, 44) Trp. 
 
6.2.3 Amino acid analyzer 
The amino acid analyzer Biochrom 30 was used (Laborservice Onken, 
Gründau, Germany) for the analysis of the first batch of urine specimens. 
Sample preparation and analysis were performed using the manufacturer’s 
standard protocols, including protein precipitation with sulfosalicylic acid before 
chromatographic separation. The amino acids were eluted with lithium citrate 
buffer from a cation-exchange column using a step gradient, followed by post-
column ninhydrin derivatization and UV absorbance detection at 570 nm and 
440 nm, respectively. Data on urinary levels of 21 selected amino acids for the 
second batch of specimens had been measured previously at the INTERMAP 
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central laboratory in Leuven, Belgium, using a Biochrom 20 (Biochrom Ltd, 
Cambridge, UK) amino acid analyzer. 
6.2.4 Statistics 
Intra-specimen reliability of amino acid duplicate and triplicate measurements 
was tested separately on the 34 and 144 urine specimens of batches 1 and 2, 
respectively, by calculating the technical error (TE) of measurements, which is 
interpreted to be the typical magnitude of measurement error that one can 
expect to incur.65 It was computed as the square root of the sum of variance 
between corresponding measurements divided by the number of urine 
specimens analyzed. For calculation of percent TE (%TE), TE was divided by 
the mean of all split sample values and multiplied by 100. Pearson’s correlation 
analysis was implemented to calculate the association between the three 
techniques for each urinary amino acid. The Bland-Altman test66 was employed 
to determine the 95% limits of agreement between the techniques. The urinary 
amino acid concentrations measured are reported as micromolar (µmol/L) 
ranges both uncorrected and corrected for the molar concentration of urinary 
creatinine, which had been measured previously at the INTERMAP central 
laboratory in Leuven by the Jaffe method.63 The uncorrected values are given 
for direct comparison of urinary amino acid concentrations with the respective 
lower limits of quantitation (LLOQ) for GC-MS and iTRAQ®-LC-MS/MS. The 
LLOQ is defined as the lowest point of the calibration curve that can be 
determined with 80-120% accuracy, in agreement with the FDA Guide for 
Bioanalytical Method Validation.48 We abstained from reporting means and 
standard deviations for urinary amino acid concentrations because of the small 
number of ethnogeographically diverse specimens. Data were analyzed using 
SAS/STAT 9.1 software (SAS Institute Inc., Cary, NC) and descriptive statistical 
functions implemented in Excel® 2004 for Mac (version 11.4.1, Microsoft Corp., 
Redmond, WA). 
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6.3 Results and Discussion 
6.3.1 Reproducibility 
First a blinded set of 98 urine samples was analyzed by GC-MS, iTRAQ®-LC-
MS/MS and the amino acid analyzer. The set comprised 34 different urine 
specimens, from which 2 or 3 replicate aliquots had been prepared. All 34 urine 
specimens were analyzed by the amino acid analyzer, while only 33 and 31 
specimens were subjected to GC-MS and iTRAQ®-LC-MS/MS, respectively, 
due to specimen volume limitations. Not all amino acids and their derivatives 
were amenable to analysis by all three methods and the same applied to the 
availability of stable isotope labeled internal standards for GC-MS analysis 
(Table 11). 
  
Table 11: List of amino acids amenable to analysis by each of the three methods. 
Amino Acid Abbreviation iTRAQ GC-MS Biochrom30 
α-Aminoadipic Acid Aad Χ X Χ 
α -Aminobutyric acid Abu Χ Χ Χ 
Alanine Ala  Χ Χ Χ 
Anserine Ans Χ  Χ 
Arginine Arg Χ  Χ 
Argininosuccinic Acid Asa Χ   
Asparagine Asn Χ Χ Χ 
Aspartic Acid Asp Χ Χ Χ 
β-Alanine β-Ala X   
β-Aminoisobutyric acid βAib Χ Χ Χ 
Carnosine Car Χ  Χ 
Citrulline Cit Χ  Χ 
Cystathione Cth Χ Χ Χ 
Cystine Cys-Cys Χ Χ Χ 
Ethanolamine EtN Χ  Χ 
γ-Aminobutyric Acid GABA Χ  Χ 
Glutamine Gln Χ Χ Χ 
Glutamic acid Glu Χ Χ Χ 
Glycine Gly Χ Χ Χ 
Glycine-Proline Gpr  Χ  
Homocitrulline Hcit Χ   
Homocystine Hcys    
Hippuric acid Hip  Χ  
Histidine His Χ Χ Χ 
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Hydroxylysine Hyl Χ X Χ 
Hydroxyproline Hyp Χ X  
allo-Isoleucine allo-Ile  Χ  
Isoleucine Ile Χ Χ Χ 
Leucine Leu Χ Χ Χ 
Lysine Lys  Χ Χ Χ 
1-Methylhistidine M1His Χ  Χ 
3-Methylhistidine M3His Χ  Χ 
Methionine Met Χ Χ Χ 
Ornithine Orn Χ Χ X 
Phosphoethanolamine PEtN Χ  Χ 
Phenylalanine Phe Χ Χ X 
Proline Pro Χ Χ  
Phosphoserine Pser Χ  Χ 
Sarcosine Sar Χ Χ Χ 
Serine Ser Χ  Χ 
Taurine Tau Χ  Χ 
Threonine Thr Χ  Χ 
Tryptophan Trp Χ Χ Χ 
Tyrosine Tyr Χ Χ Χ 
Valine Val Χ Χ Χ 
Number of analytes covered by the different methods ranged from 26 analytes 
for GC-MS to 40 and 42 for the amino acid analyzer and iTRAQ®-LC-MS/MS, 
respectively. As described previously,47 urinary serine, threonine, 
hydroxylysine, and hydroxyproline, could not be measured reliably by the GC-
MS method because of secondary interactions of their underivatized hydroxyl 
group with the liner in the injector, resulting in increasingly broader peaks within 
only a few injections. In addition, anserine, arginine, argininosuccinic acid, 
carnosine, citrulline, ethanolamine, γ-aminobutyric acid, homocitrulline, 
phosphoethanolamine, phosphoserine, taurine, and the methylhistidines were 
not amenable to GC-MS because of either their thermal instability (e.g., 
arginine) or low vapor pressure and high polarity (e.g., phosphoethanolamine). 
Quantification of ß-alanine by iTRAQ® was impeded by coeluting matrix 
components, hence it was excluded. Urinary levels of some amino acids, such 
as phosphoserine, cystathionine and proline, were low and, consequently, not 
all urine specimens analyzed yielded concentration values above the lower 
limits of quantitation, which are listed together with the ranges of urinary amino 
acid levels observed for both batches of urine specimens in Table 12.  
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Table 12: Range of urinary amino acid concentrations [µmol/L] uncorrected and corrected for 
urinary creatinine [µmol/mmol creatinine] in batches 1 and 2 (434 and 433 urine aliquots, 
respectively), and LLOQs [µmol/L] for GC-MS and iTRAQ®-LC-MS/MS. 
Amino 
Acid 
 
GC-MS 
(N=434) 
µmol/L 
iTRAQ® 
(N=433) 
µmol/L 
GC-MS 
µmol/mmol 
creatinine* 
iTRAQ® 
µmol/mmol 
creatinine* 
GC-
MS 
LLOQ 
µmol/L 
iTRAQ® 
LLOQ 
µmol/L 
Aad <3.00 – 99.28 3.58 – 153.12 0.05 – 0.83 0.07 – 1.22 3 0.5 
Abu 0.38 – 35.80 <0.5 – 40.40 0.01 – 0.23 0.02 – 0.27 0.3 0.5 
Ala 19.56 – 1072.70 22.19 – 1376.46 0.4 – 7.82 0.39 – 10.9 0.3 1 
Ans UD <1.00 – 806.71 - 0.01 – 9.12 - 1 
Arg UD <5.00 – 128.58 - 0.06 – 1.73 - 5 
Asa UD <5 – 37.83 - 0.03 – 0.49  5 
Asn 10.62 – 550.48 17.31 – 713.97 0.22 – 5.0 0.36 – 6.39 12 5 
Asp <3.00 – 65.44 0.66 – 49.67 0.02 – 0.48 0.01 – 0.35 3 0.5 
βAib 6.50 – 2299.96 4.64 – 2523.59 0.09 – 27.3 0.06 – 23.05 0.9 0.5 
Car UD 1.43 – 260.80 - 0.02 – 5.87 - 1 
Cit UD <0.50 – 30.80 - 0.09 – 0.4 - 0.5 
Cys-Cys <12.00 – 355.24 <10 – 1491.36 0.15 – 2.43 0.21 – 15.62 12 10 
EtN UD 60.45 – 803.76 - 0.67 – 10.53 - 0.5 
GABA UD <1 – 23.96 - 0.01 – 0.49 - 1 
Gln 32.06 – 1753.00 37.15 – 1867.69 0.66 – 21.51 0.59 – 31.49 30 0.5 
Glu 1.60 – 38.76 2.18 – 36.19 0.06 – 0.72 0.05 – 0.65 3 0.5 
Gly 70.60 – 5175.28 124.50 – 6524.52 1.44 – 69.44 1.89 – 121.8 3 0.5 
Gpr <3.00 – 35.36 UD 0.02 – 0.45 - 3 - 
Hcit UD <5.00 – 163.69 - 0.07 – 1.13 - 5 
Hip 42.08 – 5148.88 UD 0.34 – 111.3 - 30 - 
His 54.58 – 2444.74 55.27 – 2865.53 1.16 – 19.25 0.95 – 34.4 12 0.5 
Hyl UD <1.00 – 76.31 - 0.02 – 0.94 12 1 
Hyp UD <0.5 – 65.15 - 0.003 – 0.41 3 0.5 
Allo-Ile <0.9 – 10.3 UD 0.004 – 0.06 - 0.9 - 
Ile 1.44 – 40.72 1.47 – 51.24 0.03 – 0.25 0.03 – 0.32 0.9 0.5 
Leu 3.42 – 96.56 3.63 – 103.33 0.07 – 0.63 0.07 – 2.45 0.3 0.5 
Lys 7.06 – 1862.82 8.6 – 2206.81 0.14 – 25.0 0.15 – 29.61 0.9 0.5 
Met <3.00 – 18.90 <0.5 – 18.81  0.01 – 0.13 0.004 – 0.24 3 0.5 
M1His UD 7.98 – 5614.71 - 0.1 – 63.44 - 1 
M3His UD 10.15 – 2966.78 - 0.14 – 40.04 - 0.5 
Orn 1.66 – 75.78 <5.00 – 110.66 0.03 – 1.02 0.04 – 1.49 0.9 5 
PEtN UD 2.40 – 106.43 - 0.05 – 0.9 - 0.5 
Phe 6.62 – 192.74 6.50 – 220.00 0.12 – 1.14 0.12 – 1.2 0.9 0.5 
Pro 0.94 – 24.60 <5 – 24.19 0.02 – 0.32 0.03 – 0.25 0.3 5 
Sar 0.92 – 7.94 0.6 – 11.01 0.01 – 0.14 0.01 – 0.14 0.9 0.5 
Ser UD 48.99 – 1092.64 - 0.72 – 9.77 - 0.5 
Tau UD 11.88 – 5238.65 - 0.27 – 71.84 - 1 
Thr UD 10.33 – 498.27 - 0.2 – 6.11 - 1 
Trp 5.88 – 242.08 7.17 – 269.72 0.12 – 1.3 0.1 – 1.45 0.3 0.5 
Tyr 8.76 – 350.36 8.8 – 363.43 0.18 – 2.03 0.14 – 2.4 0.9 1 
Val 4.98 – 136.10 4.21 – 146.67 0.1 - 0.82 0.1 – 0.92 0.3 1 
*Ranges are only given for amino acid concentrations above the LLOQ, UD, undeterminable. 
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 For amino acids, for which not all urine specimens could be included in 
computation of %TE due to limits of quantitation, the actual number of 
specimens is given in brackets next to the %TE value in Table 13. Average 
percent technical error (%TE) over all sample replicates was calculated for 
each amino acid in Table 13. 
 
Table 13: Percent technical errors computed from duplicate and triplicate measurements of 
urinary amino acids for batches #1 and #2 of urine specimens. Number of duplicates or 
triplicates used for computing percent technical error is given in brackets. Urine specimens with 
amino acid levels below the lower limit of quantitation were excluded. 
First batch Second batch Amino 
acid 
 
iTRAQ 
(N=31) 
GC-MS 
(N=33) 
Biochrom30 
(N=34) 
iTRAQ 
(N=143) 
GC-MS 
(N=144) 
Biochrom20 
(N=101) 
Aad 11.08 34.84 (30) 6.72 22.73 4.08 ND 
Abu 22.15 (30) 56.54 5.26 20.37 6.63 ND 
Ala 9.90 16.33 2.20 23.54 3.38 4.02 
β-Ala UD ND 5.65 (10) UD ND ND 
Ans 46.81 (22) UD 5.24 (18) 50.53 (132) UD ND 
Arg 17.67 (28) UD 7.45 22.25 (140) UD 15.60 (84) 
Asa <LLOQ UD <LLOQ 43.15 (94) UD ND 
Asn 13.40 16.21 5.00 18.86 4.16 5.86 
Asp 21.43 12.80 (16) 12.00 25.55 15.02 (138) ND 
β-Aib 64.26 33.49 10.95 (30) 63.99 11.02 ND 
Car 18.59 UD 9.36 (3) 29.32 UD 8.23 (100) 
Cit 22.45 UD 6.60 30.01 (141) UD ND 
Cth 8.72 (9) 13.18 (6) 17.62 (26) 25.81 (6) 9.98 (18) ND 
Cys-Cys 14.91 31.65 3.29 73.31* (142) 14.02 (139) 5.84 
EtN 7.30 UD 5.27 13.88 UD 7.53 
GABA 26.01 (22) UD 25.42 26.57 UD ND 
Gln 25.11 22.70 3.98 22.27 13.95 3.84 
Glu 11.99 19.92 19.03 (32) 22.03 3.93 ND 
Gly 13.91* (30) 19.22 2.98 40.64 4.47 2.66 
Gpr UD 36.25 (17) ND UD 28.69 (121) ND 
Hcit 21.50* (26) UD ND 30.24 (138) UD ND 
Hip UD ND UD UD 25.08 UD 
His 18.26 10.14 2.13 27.15 4.39 3.30 
Hyl 33.72 (28) UD 11.72 (24) 43.01 (133) UD ND 
Hyp 36.93 (31) UD <LLOQ 23.05 (37) UD ND 
allo-Ile UD <LLOQ ND UD 5.23 (30) ND 
Ile 6.60 15.24 16.05 (28) 18.32 5.22 16.86 (60) 
Leu 52.15 14.29 9.06 (30) 16.59 4.13 ND 
Lys 18.96 20.73 6.27 50.60 4.53 5.72 
Met 16.12 (27) 20.16 (8) <LLOQ 115.64 (102) 10.30 (79) 19.01 (95) 
M1His 14.89 UD 6.76 35.78 UD 3.30 
M3His 17.01 UD 2.92 21.17 UD 4.80 
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Orn 15.40 (25) 23.11 4.00 33.76 (121) 9.13 ND 
PEtN 6.90 UD 5.58* (33) 17.56 UD ND 
Phe 11.92 16.15 4.07 16.45 4.10 10.60 (99) 
Pro 7.51 (7) 18.76 <LLOQ 18.21 (89) 5.65 ND 
Pser 13.11 (2) UD <LLOQ 23.05 (37) UD ND 
Sar 22.20 ND 11.40 (32) 23.74 7.49 (104) ND 
Ser 19.28 UD 2.39 15.38 UD 3.56 (100) 
Tau 15.75 UD 4.53 20.84 UD 3.01 
Thr 13.33 UD 2.56 23.75 UD 4.18 
Trp 9.49 12.80 5.04 18.22 4.29 12.69 (82) 
Tyr 9.51 22.10 2.57 16.30 4.37 6.63 
Val 7.74 12.15 7.15 18.54 3.85 12.07 (98) 
*One outlier exceeding 8 SDs of the mean excluded;  
ND, not determined;  
UD, undeterminable. 
 
 For 20 urinary amino acids, quantitative data were available from all three 
methods; the following comparison of reproducibility is limited to those analytes. 
Mean ± SD of %TE (range) for the 20 amino acids was 7.27±5.22 (2.13-19.03), 
21.18±10.94 (10.14-56.54), and 18.34±14.67 (6.60-64.26), respectively, for 
amino acid analyzer, GC-MS, and iTRAQ®-LC-MS/MS. For α-aminoadipic acid 
(Aad), α-aminobutyric acid (Abu), ß-aminoisobutyric acid (β Aib), cystathionine 
(Cth), and cystine (Cys-Cys), no stable isotope labeled standards had been 
available for GC-MS analysis of the first batch of urine specimens. As a result, 
the concentrations of Aad, Abu, β-Aib, Cth, and Cys-Cys, had to be calculated 
using the nearest eluting stable isotope standard as a reference. However, this 
fails to account fully for any variation of ionization that may occur between 
analyses and, therefore, technical error is expected to be higher. This was 
confirmed by excluding Aad, Aba, βAib, and Cys-Cys, from computation of TE. 
For GC-MS, %TE improved from 21.60±11.07 (mean ± SD) to 16.93±4.15, 
range 10.14-23.11. For iTRAQ®-LC-MS/MS, the corresponding values also 
improved slightly from 18.85±14.89 to 16.38±11.19, range 6.60-52.15, due to 
omission of the high %TE associated with the measurement of βAib. 
Limiting the above comparison to amino acid analyzer and iTRAQ®-LC-MS/MS 
and the 34 amino acids that could be measured by both methods, mean ± SD 
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(range) of %TE was 7.43±5.43 (2.13-25.42) and 19.08±12.92 (6.60-64.26), 
respectively. 
GC-MS and iTRAQ®-LC-MS/MS were further evaluated with a second batch of 
341 split samples from 144 INTERMAP urine specimens randomly selected 
from the same five population samples used for the first batch. For 101 urine 
specimens from these population samples, urinary levels of 21 selected amino 
acids had been analyzed previously in duplicate at the INTERMAP central 
laboratory using a Biochrom 20 amino acid analyzer. For 13/21 amino acids 
with urinary levels determined successfully by amino acid analyzer, GC-MS, 
and iTRAQ®-LC-MS/MS, mean ± SD (range) of %TE was 8.39±5.35 (2.66-
19.01), 6.23±3.84 (3.38-14.02), and 35.37±29.42 (16.30-115.64), respectively. 
Excluding methionine, whose urinary levels were the least reproducible for 
amino acid analyzer and iTRAQ®-LC-MS/MS with %TEs of 19.01 and 115.64, 
respectively, reduced the corresponding average %TEs to 7.51±4.48, 
5.89±3.80, and 28.68±17.59. Expanding the comparison to all 21 amino acids 
amenable to both amino acid analyzer and iTRAQ®-LC-MS/MS yielded average 
%TEs of 7.59±4.96 and 30.90±23.88, respectively. 
Overall, including the %TEs of all amino acids whose urinary levels could be 
determined (Table 13), the amino acid analyzer yielded the most consistent 
results with average %TEs of 7.43±5.43 and 7.59±4.96 (mean ± SD) for 
batches 1 and 2, respectively, despite the fact that the measurements had been 
done on different instruments at different locations. GC-MS matched the 
reliability of the amino acid analyzer for the second batch of urine specimens 
only with an average %TE of 8.28±6.64, while the average %TE for the first 
smaller batch of urine specimen had been 21.69±10.67. There is no obvious 
reason for the improvement in precision for the second batch other than the 
gain in experience over time by the operator of GC-MS. Reproducibility of GC-
MS measurements depends to a significant extent on the availability of stable 
isotope labeled amino acid standards that allow to account for variation of 
electron impact ionization due to matrix effects. This is immediately obvious 
from comparing the average %TE of 5.87±3.59 for the 17 amino acids, for 
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which stable isotope labeled internal standards were available, with the 
average %TE of 13.03±8.31 for the 8 amino acids, whose concentrations were 
determined using the nearest eluting stable isotope labeled standard as 
reference. Hence, further improvements of GC-MS performance will depend on 
the successful synthesis of additional stable isotope labeled amino acids. This 
will not benefit the most significant drawback of GC-MS, namely, the 
comparatively small number of only 26 urinary amino acids and related amines 
amenable to successful analysis versus 34 and 40 for amino acid analyzer and 
iTRAQ®-LC-MS/MS, respectively. The latter method also carries the advantage 
of having stable isotope labeled internal standards available for 44 amino acids, 
including norleucine and norvaline that are added to biological samples to 
account for extraction and derivatization efficiency, respectively. As a 
consequence, one would expect iTRAQ®-LC-MS/MS to be highly reproducible. 
But for reasons discussed below, iTRAQ®-LC-MS/MS yielded the highest 
average %TE of 30.38±19.16 for the second batch of urine specimens and 
surpassed only slightly GC-MS with an average %TE of 19.08±12.58 for the 
first batch. 
6.3.2 Correlation between methods 
The second batch of urine samples had been analyzed previously on a 
Biochrom 20 amino acid analyzer at the INTERMAP central laboratory in 
Leuven, Belgium. These data and those obtained by GC-MS and iTRAQ®-LC-
MS/MS were correlated with each other; Pearson r-values are listed in Table 
14. The Pearson’s correlation coefficients for the 12 amino acids that could be 
measured by both GC-MS and the amino acid analyzer ranged from 0.800 
(Trp) to 0.980 (Gly). GC-MS and iTRAQ®-LC-MS/MS had 19 amino acids in 
common and showed generally good correlation (cystathionine was excluded, 
because its urinary levels were with few exceptions below the LLOQs of GC-
MS and iTRAQ®-LC-MS/MS). The single exception was the sulfur containing 
amino acid cystine (r=0.822). The correlation coefficients for the remaining 18 
analytes ranged between 0.934 (Glu) and 0.988 (Tyr). Urinary levels of 20 
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amino acids were available for the comparison of iTRAQ®-LC-MS/MS with the 
amino acid analyzer. Correlation coefficients for arginine (0.561), carnosine 
(0.801), cystine (0.811), isoleucine (0.802), taurine (0.885) tryptophan (0.764), 
and tyrosine (0.780) were poor. The correlation coefficients for the remaining 
13 amino acids varied from 0.899 (Phe, Val) to 0.951 (Lys). 
 
Table 14: Pearson correlation coefficients (R) and slopes computed from the mean 
concentrations of duplicate and triplicate measurements of 144 urine specimens using the 
amino acid analyzer Biochrom 20 , GC-MS and iTRAQ® -LC-MS/MS. 
Amino 
Acid 
GC-MS vs. 
Biochrom 20 
iTRAQ®-LC-MS/MS 
vs. GC-MS 
iTRAQ®-LC-MS/MS 
vs. Biochrom 20 
 R slope R slope R Slope 
Aad - - 0.968 1.258 - - 
Abu - - 0.953 0.974 - - 
βAib - - 0.967 0.722 - - 
Ala 0.970 0.928 0.979 1.175 0.944 0.823 
Arg - - - - 0.561 0.900 
Asn 0.953 0.719 0.986 1.050 0.940 1.170 
Asp - - 0.929 0.618 - - 
Car - - - - 0.801 1.462 
Cys 0.944 0.684 0.822 1.49 0.811 0.616 
EtN - - - - 0.917 0.873 
Glu - - 0.934 0.752 - - 
Gln 0.956 1.111 0.958 0.628 0.938 1.231 
Gly 0.980 0.968 0.937 1.198 0.921 0.730 
His 0.969 1.056 0.965 1.042 0.940 0.799 
Ile 0.812 0.812 0.976 1.059 0.802 0.737 
Leu - - 0.984 0.997 - - 
Lys 0.969 0.966 0.977 0.963 0.951 0.968 
M1His - - - - 0.934 0.799 
M3His - - - - 0.906 0.753 
Orn - - 0.963 1.310 - - 
Phe 0.909 0.778 0.986 1.018 0.899 1.015 
Ser - - - - 0.939 0.856 
Tau - - - - 0.885 0.694 
Thr - - - - 0.946 1.071 
Trp 0.800 0.782 0.981 0.907 0.760 0.841 
Tyr 0.844 0.525 0.988 0.974 0.807 1.318 
Val 0.912 0.995 0.983 0.952 0.899 0.851 
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 6.3.3 Bland-Altman plots 
Bland-Altman plots depict agreement between two different analytical methods: 
This graphical method plots the concentration difference between the two 
techniques for each specimen against the average of the two techniques. In 
addition, the mean difference (đ) and lower and upper limits of agreement are 
shown as horizontal lines. The limits of agreement are defined as the mean 
difference plus/minus 1.96 times the standard deviation (đ ± 1.96 SD). The 
mean difference, limits of agreement and the type of plot obtained are listed in 
Table 15.  
 
Table 15: Mean differences (⎯d) and limits of agreement (⎯d ± 1.96 SD) between methods in 
µM and types of Bland-Altman plots (TP*). 
AA Biochrom vs. GC-MS GC-MS vs. iTRAQ BIOCHROM vs. iTRAQ 
 ⎯ đ ±1.96 SD TP ⎯ đ ±1.96 SD TP đ ±1.96 SD TP 
Aad    -7.45 -24.95 – 10.04 E    
Abu    -0.89 -4.96 – 3.18 A    
bAib    98.96 -320.6 – 518.6 D    
Ala 23.2 -55.7 – 102.0 A -11.2 -134.1 – 111.7 F 11.9 -135.9 – 159.8 A 
Arg       -4.76 -42.1 – 32.5 C 
Asn 31.57 -39.2 – 102.4 D -7.96 -49.1 – 33.1 F 23.7 -54.0 – 101.4 F 
Asp    4.54 -2.1 – 11.1 D    
Car       70.8 1.1 – 140.5 D 
Cys 18.0 
-14.8 – 50.8 D 
-26.29 
-139.31 – 86.72 E 
-8.27
-117.83 – 
101.28 
E 
EtN       -15.1 -127.6 – 97.5 A 
Gln - 59.3 -219.9 – 101.3 C 141.7 -83.0 – 366.3 D 82.4 -84.7 – 249.4 D 
Glu    2.95 -3.3 – 9.2 B    
Gly 2.2 -292.1 – 296.5 A -44.9 -927.0 – 837.2 A -42.6 -954.8 – 869.6 A 
His - 44.0 -254.4 – 166.3 E -2.53 -340.7 – 335.7 F -46.6 -440.3 – 347.1 F 
Ile - 1.9 -6.2 – 2.4 C -0.75 -4.5 – 3.0 A -2.7 -8.5 – 3.1 C 
Leu    -0.12 -8.2 – 8.0 A    
Lys 68.5 -67.3 – 204.3 D 1.8 -192.6 – 196.1 F 70.4 -158.0 – 298.8 F 
M1Hi
s  
  
 
  
28.9 
-524.0 – 581.7 A 
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M3Hi
s  
  
 
  
-8.3 
-107.5 – 90.9 A 
Orn    -2.8 -14.3 – 8.7 E    
Phe 6.4 -16.6 – 29.3 B -2.7 -15.6 – 10.1 A 3.7 -22.0 – 29.3 A 
Ser       -3.0 -128.6 – 122.7 A 
Tau  
  
 
  -
121.
5 
-993.1 – 750.2 E 
Thr       23.2 -48.3 – 94.8 B 
Trp -9.03 -48.5 – 30.4 C 5.1 -11.0 – 21.3 A -4.7 -33.9 – 24.4 A 
Tyr 5.49 -82.2 – 93.2 A 2.7 -20.0 – 25.4 A 4.86 -38.5 – 48.2 A 
Val - 2.35 -16.3 – 11.6 F 1.4 -8.0 – 10.8 F -0.94 -17.0 – 15.1 F 
*A, methods are interchangeable; B, absolute mean difference between two methods has a 
positive value exceeding 15% of mean concentration for all measurements; C, absolute mean 
difference between two methods has a negative value exceeding 15% of mean concentration for 
all measurements; D, absolute mean difference becomes proportionatly more positive the higher 
the analyte concentration; E, absolute mean difference becomes proportionatly more negative the 
higher the analyte concentration; F, absolute mean difference increases with analyte 
concentration. 
 
Since it is not possible to display all plots, each Bland-Altman plot was 
categorized according to its graphical appearance and six major plot types 
were defined. 
Type A: Type A represents the ideal agreement between two methods. The 
mean difference is almost zero and the individual differences scatter randomly 
with no apparent systematic error. For type A plots, the mean of the difference 
is lower than 15 % of the mean concentration over all measurements obtained 
with two methods. A typical plot is shown in Figure 29 a for glycine (comparison 
of GC-MS to iTRAQ®-LC-MS/MS). Here the mean of the concentration over all 
measurements for both methods is 991.6 µmol/L and the mean of the 
difference is -44.9 µmol/L. 
Type B: If the mean difference has a negative value and is higher than 15 % of 
the mean concentration over all measurements, the Bland-Altman plot is 
labeled as type B. In this case an absolute systematic error is detected, 
because the first analytical method underquantifys compared to the second 
method as is exemplified in Figure 29 b for the analysis of arginine by Biochrom 
and iTRAQ®-LC-MS/MS. 
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Type C: Type C equals type B, but the mean difference has a positive value 
indicating that the first method overquantifys relative to the second method. An 
example is shown in Figure 29 c for glutamic acid and the comparison of GC-
MS with iTRAQ®-LC-MS/MS. 
Type D: Type D plots represent a proportional error in the agreement between 
the methods. In this case the first method underquantitates the more the higher 
the concentration of the analyte. An example for type D is the comparison 
between Biochrom and GC-MS for lysine (Figure 29 d). 
Type E: In case of type E plots the first method overquantitys the more the 
higher the concentration of the analyte. This is exemplified for the comparison 
between GC-MS and iTRAQ®-LC-MS/MS for cystine (Figure 29 e).  
Type F: Type F indicates that variation of at least one method depends strongly 
on the magnitude of measurements as shown in Figure 29 f for valine 
(Biochrom vs. iTRAQ®-LC-MS/MS).  
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Figure 29: Different types of Bland-Altman plots: (a) type A with glycine shown as an example; 
(b) type B with arginine as an example; (c) type C with glutamic acid as an example; (d) type D 
with lysine as an example; (e) type E with cystine as and example; and (f) type F with valine as 
an example. 
 
Overall, only 19 out of 51 (37.3%) Bland-Altman plots revealed an excellent 
type A agreement between any of two methods compared. Glycine and tyrosine 
were the only amino acids with quantitative data that agreed well across all 
three methods, i.e. for these amino acids the three methods are 
interchangeable. For phenylalanine and tryptophan, type A agreements were 
observed between GC-MS and iTRAQ®-LC-MS/MS as well as BIOCHROM and 
iTRAQ®-LC-MS/MS, while absolute systematic errors were found between 
BIOCHROM and GC-MS, with the former method either slightly under- (Trp) or 
overquantifying (Phe) in comparison to GC-MS. In case of isoleucine, 
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BIOCHROM underquantitated relative to both GC-MS and iTRAQ®-LC-MS/MS, 
while the latter two methods showed type A agreement. Overall, absolute 
systematic errors were observed in 8 (15.7%) instances; proportional errors, i.e. 
mean difference rises (type D) or falls (type E) with increasing urinary amino 
acid concentrations, in 8 (15.7%) and 6 (11.8%) cases, respectively; in 10 
(19.6%) cases, variation of at least one method depended strongly on 
magnitude of measurements (type F), i.e. error proportional to concentration of 
the quantity being measured. 
Especially, since only 7 out of 19 (36.8%) comparisons between GC-MS and 
iTRAQ® showed excellent agreement over the urinary amino acid 
concentrations measured, and 5 other comparisons revealed a multiplicative 
error (type F), we validated the accuracy of these methods using a NIST 
certified amino acid standard. 
6.3.4 Validation with a certified standard 
The certified NIST standard, comprising a total of 17 amino acids, was 
analyzed to validate GC-MS and iTRAQ®-LC-MS/MS. We quantitated 16 
amino acids with the GC-MS method. Arginine could not be determined due to 
the thermal instability of its propyl chloroformate derivative. An excellent 
correspondence with the NIST certified values was obtained for all amino acids 
measured by GC-MS and iTRAQ®-LC-MS/MS (Figure 30). The recoveries for 
GC-MS varied from 98-111% and for iTRAQ®-LC-MS/MS from 91-106%. 
Overall, GC-MS tended to overestimate the NIST certified values by 
5.33±3.70% (mean ± standard deviation), whereas iTRAQ®-LC-MS/MS, on 
average, matched the certified values well with -0.04±4.18%. The 
reproducibility of the GC-MS data was excellent with relative standard 
deviations (RSDs) of about 1% (based on 6 replicate measurements) for most 
amino acids. The iTRAQ®-LC-MS/MS data showed RSDs of about 3-6% based 
on 40 replicate measurements. 
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Figure 30: Arithmetic means and standard deviations of amino acid concentrations [mM] in a 
NIST-certified standard that was analyzed by GC-MS (n=6) and LC-MS/MS (n=40). 
 
Both GC-MS and iTRAQ®-LC-MS/MS quantitated accurately the concentration 
of cystine in the acidified NIST standard, which does not contain any free 
cysteine. In urine, however, iTRAQ®-LC-MS/MS consistently overquantitated 
cystine with the difference from GC-MS and the amino acid analyzer becoming 
greater with higher urinary cystine levels (Table 14, Figure 29 e). Cysteine may 
oxidize under non-acidic conditions to cystine; the rapid disappearance of small 
amounts of urinary cysteine has been reported in non-acidified urine in contact 
with air.67 Although the urine specimens were alkalized with borate buffer to pH 
8.5 for the labeling of amino acids with the iTRAQ® reagent, followed by the 
addition of a 1.2% hydroxylamine solution after completion of the labeling 
reaction to reverse partial labeling of the phenolic hydroxyl group of tyrosine 
and to stabilize cysteine to prevent its oxidation to cystine, the excess in urinary 
cystine by iTRAQ®-LC-MS/MS far exceeded the reported levels of urinary 
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cysteine, which is typically present at about 10% of cystine.67 Therefore, 
reasons other than the potential oxidation of cysteine to cystine have to account 
for the apparent overquantitation of urinary cystine. 
6.3.5 Comparison of methods 
Both, amino acid analyzer and iTRAQ®-LC-MS/MS require protein precipitation. 
GC-MS allows the direct derivatization of amino acids with propyl chloroformate 
in native urine and, therefore, automation of the entire analytical procedure. 
The urine volumes needed for GC-MS and iTRAQ®-LC-MS/MS analysis are 40-
50 µL, while 200 µL are required for the amino acid analyzer. Given that urine 
is typically available in large quantities, these differences in sample volume are 
negligible. 
A drawback of the amino acid analyzer is the typical runtime of 130 min. In 
contrast, total runtimes for GC-MS and iTRAQ®-LC-MS/MS are 20 and 25 min, 
respectively. The LLOQs for the amino acid analyzer (2-3 µmol/L) are also on 
average higher than those for GC-MS (0.3-30 µmol/L) and iTRAQ®-LC-MS/MS 
(0.5-10 µmol/L). 
A disadvantage of GC-MS is the smaller number of amino acids amenable to 
analysis. In principle, 33 urinary amino acids can be detected by GC-MS, but 
only 22 amino acids were measurable above the LLOQ in ≥ 80% of the 144 
urine specimens of the second batch. In contrast, it was possible to quantify 34 
analytes in at least 80% of the urine specimens by iTRAQ®-LC-MS/MS. 
The higher TEs of iTRAQ®-LC-MS/MS appear to be mainly due to excess of 
multiple reaction-monitoring transitions acquired in the third of the four 
predefined time windows. In the first, second, and fourth period, 3 (PSer, PEtN, 
Tau), 7 (Asn, Ser, Hyp, Gly, Gln, EtN, Asp), and 10 (Val, Nva, Met, Tyr, Hcy, 
Ile, Leu, Nle, Phe, Trp) amino acids are monitored, respectively. In contrast, in 
the third period 24 amino acids (Cit, Sar, bAla, Ala, Thr, Glu, His, 3MHis, 
1MHis, Hcit, Asa, GABA, bAib, Abu, Aad, Ans, Car, Pro, Arg, Hyl, Orn, Cth, 
Cys, Lys) are monitored, with only half as many data points recorded. This has 
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a significant influence on the reproducibility of peak areas. For the second 
batch of urine specimens, mean ± SD of %TE (range) was 33.09±14.60 (18.21-
73.31) for period 3, while it was (excluding methionine) 21.16±7.39 (13.88-
40.64) for periods 1, 2, and 4. This shortcoming may be alleviated by recent 
implementation of scheduled sMRM that allow definition of as many 
overlapping periods as there are amino acids, with each amino acid monitored 
only for the time period of its expected elution from the column. For maximum 
precision, chromatographic resolution of amino acids will have to be improved 
to limit number of overlapping periods. 
In conclusion, GC-MS and LC-MS/MS are attractive alternatives to the amino 
acid analyzer. The advantages of GC-MS are its complete automation, short 
runtime, and higher precision; its one limitation is the smaller number of amino 
acids amenable to analysis. In comparison, iTRAQ®-LC-MS/MS excels in 
greater number of amino acids amenable to analysis and current availability of 
42 stable isotope labeled standards. Incorporation of scheduled MRM, 
improved chromatographic resolution, and an advanced integration algorithm 
may improve reproducibility of the iTRAQ® method. 
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7 Combined amino and fatty acid analysis by GC-MS 
7.1 Introduction 
An important sub-compartment of the metabolome are lipids and their 
comprehensive analysis is the subject of lipidomics.68, 69 Lipids can be 
categorized into several classes, including for example non-esterified fatty 
acids (NEFAs), triglycerides and phospholipids. Essentially all NEFAs in serum 
are bound to albumin.70 Fatty acids are compound with a carboxyl group and an 
alkyl chain which is either saturated or unsaturated and differ in length. Most of 
the natural fatty acids have an even number of carbon atoms, usually 14, 16, 
18 or 20 because their biosynthesis involves acetyl-CoA, a coenzyme carrying 
a two-carbon-atom group. The double bond can occur in a cis or trans 
configuration. In general, the fatty acids in biological systems contain only cis 
double bonds. The most common fatty acids in mammals are shown in Table 1. 
Fatty acids, in particular stearic acid, oleic acid, linolenic acid and palmitic acid, 
are precursors for the synthesis of cholesterol and steroid hormones that 
regulate a wide range of functions, including blood pressure, blood clotting, 
blood lipid levels, immune and inflammatory responses to injury and infection.71, 
72 Several analytical methods have been developed for lipid analysis. Lipid 
extraction is commonly performed by Folch73 or Bligh & Dyer extraction.74 
Another approach is the determination of the fatty acid composition by GC-FID 
or GC-MS after conversion into fatty acid methyl esters (FAMEs). Esterification 
is achieved using acidic methanol75, iodomethane  or BF3/methanol. To avoid 
lengthy sample preparation steps Lepage & Roy developed a method for the 
direct transesterification of all classes of lipids in plasma using an acetyl 
chloride/methanol mixture.76 This method was further simplified by Masood et 
al. by introducing a one-step stock solution method, without the requirement for 
subsequent neutralization or centrifugation to separate phases.77 
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Table16: Common natural fatty acids (saturated and unsaturated) 
Common name 
of acid 
Abbreviation Chemical structur 
Saturated fatty acids 
Myristic acid C14:0 
HO
O
 
Palmitic acid C16:0 
HO
O
 
Stearic acid C18:0 
HO
O
 
Unsaturated acid 
Palmitoleic 
acid 
C16:1 
O
HO  
Oleic acid C18:1 
O
HO  
Linoleic acid C18:2 
O
HO
Arachidonic acid C20:4 
O
HO  
Docosahexanoic
acid 
C22:6 
O
HO
 
Husek et al. reported the applicapility of alkyl chloroformate derivatization to 
fatty acids.37 Mateo-Castro et al. used ethyl chloroformate derivatization in 
aqueous medium to analyze amino, fatty and bile acids by GC-FID in binders 
used in artistic paintings after the samples were hydrolyzed by HCl.78 Our aim 
was to integrate fatty acids in the fully automated quantitative method by GC-
MS using propyl chloroformate derivatization to analyze amino acids and fatty 
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acids in the same analysis. The analysis of the fatty acids should allow either 
the analysis of free fatty acids, or the total fatty acids from all lipid classes. Due 
to the behavior of propyl chloroformate in base as a good esterifying reagent, 
the fatty acids that are attached to other molecules should react with the 
reagent immediately. 
7.2 Materials and methods 
7.2.1 Chemicals 
The fatty acids C10:0, C12:0, C14:0, C16:1, C16:0, C18:1 cis, C18:0, C18:1 
trans, C18: 2, C18:3, C20:0, C20:4, C22:1, C22:0, C22:6, C24:1, and C24:0 
were purchased from Sigma. The [U-13C] fatty acid mix was from Medical 
Isotopes Inc. (Pelham, USA).  
7.2.2 Biological samples 
The applicability of the method was tested using human, mice and bovine 
serum. Human serum was collected from healthy volunteers. Bovine serum 
was provided by collaborators from the clinic for ruminants in the veterinary 
faculty of the Ludwig-Maximilians-University Munich (LMU). Mice serum was 
obtained from collaborators at the University of Regensburg. Due to low sample 
volume available from the latter, several samples were pooled to perform 
reproducibility studies. Twenty microliters of serum were always used.  
7.2.3 GC-MS analysis 
To that end, the method was adapted to allow the combined analysis of fatty 
acids and free amino acids in a single gas chromatographic run. The retention 
times and specific ion traces for the SIM analysis of the fatty acids C10:0, 
C12:0, C14:0, C16:1, C16:0, C18:1 cis, C18:0, C18:1 trans, C18:2, C18:3, 
C20:0, C20:4, C22:1, C22:0, C22:6, C24:1, and C24:0, as well as 25 
endogenous amino acids were determined and listed in Table 17. A 
temperature program was used starting at a temperature of 70°C and a heating 
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rate of 5°C/min to 300°C, and then held for 3 min. Column gas flow was set to 
1.1 mL He/min and a sample volume of 2.5 µL was injected with a split ratio of 
1:5. A stable isotope labeled fatty acid mix, containing uniformly 13C labeled 
C14:0, C16:0, C16:1, C18:0, C18:1 cis, C18:2 and C18:3 was integrated as 
internal standard for the fatty acids. The column and GC-MS is identical as 
discribed in chapter 5.2.3 
 
Table 17: Retention times and ion traces selected for the SIM analysis of endogenous amino 
acids plus norvaline and 17 fatty acids. Analytes printed in bold were quantified using the 
internal standard quantification trace of the corresponding stable-isotope labeled compound as 
reference. 
Analyte Retention 
time (min) 
Quantification 
trace 
Secondary 
ion trace 
Internal 
standard trace 
C10:0 10.78 173 214  
Alanine 12.45 130 88 133 
Sarcosine 12.9 130 217  
Glycine 13.19 102  105 
α-Aminobutyric acid 13.96 144 102  
Valine 14.64 158 116 163 
C12:0 14.92 183 242  
ß-Aminoisobutyric acid 13.19 116   
Norvaline 15.52 158 72  
Leucine 16.1 172 130 178 
allo-Isoleucine 16.24 172 130  
Isoleucine 16.46 172  178 
Proline 18.37 156  161 
C14:0 18.79 270 211 284 
Asparagine 19.04 155 69 160 
C16:1n7 22.39 296 237 312 
C16:0 22.36 298 239 314 
Aspartic acid 22.53 216 130 220 
Methionine 22.61 203 277 206 
Hippuric acid  134 105 139 
Glutamic acid 24.74 230  235 
Phenylalanine 24.73 190 206 199 
C18:1n9cis 25.59 324 265 342 
C18:0 25.68 326 267 344 
C18:1n9trans 25.71 324 265  
C18:2n6cis 25.85 322 263 340 
C18:3n3 26.28 320 261 338 
α-Aminoadipic acid 26.6 244  247 
Glutamine 28.41 84 187 89 
C20:0 28.7 354 354  
C20:4n6 28.73 346 287  
Ornithine 30.95 156 70  
C22:1n9 31.52 321 380  
C22:0 31.54 323 382  
C22:6n3 32.07 91 105  
Lysine 32.52 170 128 176 
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Histidine 33.59 282 168 290 
C24:1 34.2 349 408  
C24:0 34.19 410 351  
Tyrosine 35.28 107 206 114 
Tryptophan 36.8 130  140 
Cystathionine 37.51 203 272  
Cystine 41.3 248 216 252 
 
7.2.4 Derivatization 
Twenty microliters of serum were transferred together with 20 µL of a 
stabilization reagent containing 10% iso-propanol, 0.1% phenol and 2% 
thiodiglycol to a 2-mL autosampler vial. Then 10 µL of the stable isotope 
labeled fatty acid mix, containing uniformly 13C labeled C14:0, C16:0, C16:1, 
C18:0, C18:1 cis, C18:2 and C18:3 in n-propanol was added to the vial, 
followed by the addition of 10 µL of stable isotope labeled amino acid mix 
(descriped in chapter 5.2.4). Addition of the stable isotope labeled fatty acid mix 
was performed manually because addition of the n-propanol solution by the 
autosampler proved to be not reproducible (data not shown). The vial was then 
closed with a magnetic crimp cap to allow automated handling by the robot. 
The first step performed by the robot is the dilution of the sample with 135 µL 
water, followed by addition of 50 µL of n-propanol. Addition of n-propanol was 
performed, because for calibration purposes 50 µL of fatty acid standard in n-
propanol were used and the percentage of n-propanol in the reaction mixture 
should be kept constant. The next steps were identical to those described in 
chapter 5.2.4. 
7.2.5 Quantification 
Absolute quantification of 25 amino acids (alanine, sarcosine, glycine, α-
aminobutyric acid, valine, ß-aminoisobutyric acid, leucine, allo-isoleucine, 
isoleucine, proline, asparagine, aspartic acid, methionine, hippuric acid, 
glutamic acid, phenylalanine, α-aminoadipic acid, glutamine, ornithine, lysine, 
histidine, tyrosine, tryptophan, cystathionine and cystine) and 17 fatty acids 
(C10:0, C12:0, C14:0, C16:1, C16:0, C18:1 cis, C18:0, C18:1 trans, C18:2, 
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C18:3, C20:0, C20:4, C22:1, C22:0, C22:6, C24:1, and C24:0) was performed 
by analyzing standard solutions. Single stock solutions of the fatty acids were 
prepared in n-propanol at concentrations of 100 mM (C10:0, C12:0, C14:0, 
C16:0, and C18:1 trans, C18:3), 81mM (C16:1), 65.9mM (C22:0), 50mM 
(C18:2, C18:1 cis, C18:0, and C20:0), 39 mM (C24:0), 14 mM (C20:4), and 5 
mM (C22:6, C22:1, and C24:1). Using the single stock solutions a master mix 
of all fatty acids was prepared in n-propanol at a concentration of 1 mM for 
each analyte. A serial dilution containing 13 points of the master mix in n-
propanol was prepared resulting in a concentration range of 0.24 µM- 1000 µM, 
keeping the volume of propanol constant at 50 µL. 
7.3 Results and discussion 
7.3.1 Method development 
In comparison to the original protocol described in chapter 5 for the analysis of 
amino acids the number of amino acids quantified in the present method was 
modified. Threonine and serine were excluded because the quantification of 
these analytes proved to be not reproducible as already described in chapter 
5.3.9. Moreover, thiaproline, hydroxyproline, hydroxylysine, glycyl-proline, α-
aminopimelic acid and proline-hydroxyproline were not quantified because 
these analytes were not detected in the biological samples, specifically serum, 
analyzed so far in our laboratory. Another modification made to the original 
protocol is a longer temperature program. Using a temperature program with a 
start temperature of 70°C and a heating rate of 5°C/min provided sufficient 
separation of oleic (C18:1 n9 cis) and elaidic acid (C18:1 n9 trans). These two 
monounsaturated C18-acids yielded the same fragments after ionization by 
electron impact (EI) making baseline chromatographic separation crucial for 
their analysis. Stearic acid (C18:0) and elaidic acid were not baseline 
separated, but could be distinguished based on characteristic mass fragments. 
The ion traces for C18:0 and 18:1 isomers are shown in Figure 31. 
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Therefore, the molecular ion, although not being very intense, is used for 
quantification because this allows the differentiation between fatty acids with 
the same carbon number but different degrees of unsaturation, such as C18:0 
and C18:1 or C16:0 and 16:1. Figure 32 presents a typical chromatogram of the 
amino acids including norvaline and the 17 fatty acids. The analysis time was 
50 min.  
 
Figure 31: Separation of oleic acid (C18:1n9 cis), elaidic acid (C18:1 1n9 trans)and stearic acid 
(C18:0). 
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Figure 32: GC-MS analysis of fatty acids and amino acids standards after derivatization with propyl chloroformate.Analytes with their 
corresponding stable-isotope labeled are marked red.
 7.3.2 Method characterization  
A calibration was carried out using 13 calibration points. Figures of merit and 
calibration curve parameters are presented in Table 18. The R square-value or 
coefficient of determination was calculated as the square of the correlation 
coeffiient R of the regression analysis over the quantification range. The 
quantification range is determined by the lower (LLOQ) and the upper limit of 
quantification (ULOQ), which are defined as the lowest, respectively highest point 
of the calibration curve with an accuracy between 80-120%. The limit of detection 
(LOD) is defined as the concentration producing a signal to noise (S/N) ratio of at 
least 3:1. For some analytes it was observed that the stable isotope labeled 
internal standards contain minute amounts of the unlabeled analytes. In that case 
the LOD was defined as background analyte level plus three times the standard 
deviation of the background signal.  
 
Table 18: Figures of merit and calibration curve parameters. 
Analyte LODa,b 
(μM) 
LOQb 
(μM) 
ULOQb 
(μM) 
Regression line R2c 
C10:0 0.08 1.11 4375 45.687 * x + 1.302893 0.9994 
Alanine 0.15 1.50 4375 1.370* x + 0.016749 0.9997 
Sarcosine 0.30 1.50 525 1.207 * x + -0.008837 0.9996 
Glycine 0.15 4.50 4375 1.455 * x + 0.461975 0.9993 
α-Aminobutyric acid 0.15 4.50 4375 2.336 * x + -0.067501 0.9966 
Valine 0.15 0.53 4375 1.306* x + 0.004960 0.9999 
C12:0 0.31 2.44 2500 35.456 * x + 0.885587 0.9996 
ß-Aminoisobutyric acid 1.50 4.50 525 0.767 * x + -0.027075 0.9976 
Leucine 0.15 0.53 4375 1.257 * x + 0.005071 0.9998 
allo-Isoleucine 0.30 0.53 4375 1.402 * x + 0.000658 0.9996 
Isoleucine 0.15 0.53 4375 1.286 * x + 0.007381 0.9999 
Proline 0.15 52.50 4375 0.817 * x + -0.337205 0.9972 
C14:0 1.11 9.78 2500 6.481 * x + 0.305019 0.9996 
Asparagine 1.50 4.50 525 1.325 * x + -0.013764 0.9980 
C16:1n7 2.44 19.58 2500 14.855 * x + -1.077235 0.9990 
C16:0 4.88 19.58 2500 0.425 * x + 0.306325 0.9999 
Aspartic acid 1.50 7.50 4375 1.218 * x + -0.279939 0.9980 
Methionine 0.30 30.00 4375 1.069 * x + 0.190182 0.9992 
Hippuric acid 0.53 4.50 4375 0.093 * x + 0.073425 0.9999 
Glutamic acid 4.50 30.00 1250 1.030 * x + 0.317407 0.9934 
Phenylalanine 1.50 4.50 4375 1.369 * x + 0.011706 0.9993 
C18:1n9cis 9.78 19.58 2500 0.681 * x + 0.240229 0.9999 
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C18:0 0.61 4.88 2500 9.410 * x + 1.560254 0.9986 
C18:1n9trans 19.58 39.08 2500 0.401 * x + -0.084591 0.9969 
C18:2n6cis 0.31 19.58 2500 2.951 * x + 1.154595 0.9992 
C18:3n3 4.88 19.58 2500 5.302 * x + 2.658921 0.9995 
α-Aminoadipic acid 0.53 30.00 525 5.426 * x + -1.15785 0.9934 
Glutamine 7.50 30.00 525 1.564 * x + 0.073241 0.9995 
C20:0 9.78 19.58 2500 6.720 * x + -1.453153 0.9966 
C20:4n6 39.08 78.13 2500 0.704 * x + -0.416711 0.9986 
Ornithine 0.30 1.50 525 1.219 * x + -0.013352 0.9992 
C22:1n9 19.58 78.13 2500 0.214 * x + -0.157461 0.9981 
C22:0 4.88 39.08 2500 4.983 * x + -2.349723 0.9962 
C22:6n3 19.58 39.08 2500 143.757 * x + -89.363077 0.9967 
Lysine 0.15 0.30 4375 1.348 * x + 0.006601 0.9997 
Histidine 1.50 4.50 4375 1.764 * x + -0.017558 0.9996 
C24:1 39.08 78.13 2500 0.132 * x + -0.123526 0.9976 
C24:0 9.78 39.08 1250 4.097 * x + -1.994844 0.9945 
Tyrosine 0.15 1.50 4375 1.207 * x + 0.009607 0.9998 
Tryptophan 0.15 1.50 4375 1.327 * x + 0.002861 0.9999 
Cystathionine 1.50 7.50 525 3.588 * x + -0.158190 0.9895 
Cystine 0.53 7.50 1250 3.937 * x + 0.092151 0.9958 
a Limit of detection (S/N≥3 or method blank plus 3 times standard deviation of method blank) 
b LOD, LLOQ and ULOQ were calculated for a sample volume of 20 µL 
c Coefficient of determination (square of the correlation coefficient r of the regression analysis) 
Analytes printed in bold were quantified with a corresponding stable isotope labeled standard. 
 
Concentrations reported in Table 18 were calculated for the analysis of 20-µL 
sample aliquots. LODs for the fatty acids ranged from 0.08 µM up to 39 µM. The 
lowest LOD (0.08 µM) was observed for C10:0, corresponding to an absolute 
injection amount of 16 fmol. However, C10:0 is also a fatty acid for which no 
stable isotope labeled internal standard was available and which is consequently 
not disturbed by a background signal. C12:0, C18:0 and C18:2n6 cis had also 
LODs below 1 µM, while for the remaining fatty acids higher values were 
determined. The highest LOD (39 µM) was found for C20:4, which is caused by 
the high degree of fragmentation observed during EI ionization. Therefore no 
intense fragment ion was available for quantification resulting in the high LOD. 
LODs for the amino acids ranged from 0.15 µM to 7.5 µM. The lowest LOD (0.15 
µM) was observed for alanine, glycine, leucine, isoleucine, lysine, proline, 
tryptophan, tyrosine, valine and α-aminoadipic acid, while the highest value was 
determined for glutamine (7.5 µM). The range of LODs is similar to those 
described in chapter 5.3.4 Overall, lower detection limits were determined for the 
amino acids. Analysis of a standard solution (absolute amount in solution 
derivatized: fatty acids 6.25 nmol, amino acids 10.5 nmol) in six replicates yielded 
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an accuracy ranging from 83.9 to 105.6% for the fatty acids and from 90.4 to 
115.3% for the amino acids, respectively (datas not shown). Relative standard 
deviations (RSDs) were between 1.6 and 10.5% for the fatty acids with C24:0 
showing the highest RSD. For the amino acids RSDs were below 4% with the 
exception of α-aminoadipic acid (12.1%). Inter-day reproducibility of replicate 
standard analyses was in the same range as observed for intra-day 
reproducibility (Table 19). In addition to a standard, the method precision was 
tested for the analysis of human serum, bovine serum and mice serum. Human 
and bovine sera were analyzed in six replicates while for mice serum only 4 
replicates were measured due to the limited sample volume. The RSDs obtained 
for the fatty acids and amino acids analyzed in the different matrices are listed in 
Table 19. The reproducibility in all biological samples for all analytes was good, 
with RSDs ranging from 0.7 to 11%. The average reproducibility across all 
biological samples was excellent, but with 2.8% somewhat lower for the amino 
acids compared to the fatty acids with 5.5%. An influence of the serum type on 
the reproducibility was not observed. A number of analytes, such as C20:0, 
C22:1n9, C22:0, C24:1, C24:0, ß-aminoisobutyric acid, allo-Isoleucine, α-
aminoadipic acid, and cystathionine were not detected above the LLOQ in the 
serum samples, while detection of some analytes above the LLOQ depended on 
the serum type, for example C10:0 and C12:0 were only detected in human 
serum and hippuric acid was only found bovine serum.  
 
Table 19: Reproducibility of GC-MS analysis of fatty acids and amino acids solved in n-propanol 
and water, respectively and in different biological matrices using 20 µL sample aliquots. 
Reproducibility is given as relative standard deviation [%]. Concentration of standard in absolute 
amount: fatty acids 6.25 nmol, amino acids 10.5 nmol. 
Analyte 
 
Human 
serum 
(n=6) 
Bovine 
serum 
(n=6) 
Mice 
serum 
(n=4) 
Standard 
Intra-day 
(n=6) 
Standard 
Inter-day 
(n=3) 
C10:0 9.29 n.d. n.d. 4.21 5.36 
Alanine 0.67 2.97 1.30 0.45 0.24 
Sarcosine n.d. n.d. 4.62 3.20 5.05 
Glycine 3.04 3.23 1.08 0.45 0.45 
α-Aminobutyric acid 4.16 11.03 2.02 1.74 3.46 
Valine 1.17 1.18 1.35 0.61 0.40 
C12:0 6.54 n.d. n.d. 3.49 6.03 
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ß-Aminoisobutyric acid n.d. n.d. n.d. 2.55 2.17 
Leucine 2.46 2.17 1.17 0.46 0.29 
allo-Isoleucine n.d. n.d. n.d. 1.09 0.73 
Isoleucine 1.55 0.96 1.32 0.92 0.19 
Proline 0.86 1.81 0.87 0.45 0.89 
C14:0 8.75 10.30 n.d. 3.55 4.18 
Asparagine 3.55 4.76 4.07 2.89 0.51 
C16:1n7 5.46 6.58 10.72 8.90 2.88 
C16:0 4.50 3.14 3.92 2.61 1.99 
Aspartic acid 5.56 10.70 0.95 1.30 1.11 
Methionine n.d. n.d. 2.19 1.80 1.82 
Hippuric acid n.d. 2.17 n.d. 0.41 0.49 
Glutamic acid 5.33 n.d. 1.85 3.35 2.57 
Phenylalanine 0.84 2.46 4.96 3.63 0.66 
C18:1n9cis 3.73 2.75 6.12 2.27 3.71 
C18:0 1.56 2.83 3.62 5.36 5.07 
C18:1n9trans 8.69 n.d. 10.30 3.76 7.15 
C18:2n6cis 2.74 3.24 4.99 1.86 1.15 
C18:3n3 n.d. 2.83 n.d. 1.63 2.80 
α-Aminoadipic acid n.d. n.d. n.d. 12.06 12.52 
Glutamine 4.12 2.35 3.78 3.24 2.79 
C20:0 n.d. n.d. n.d. 6.80 0.30 
C20:4n6 6.15 6.28 5.11 4.01 4.69 
Ornithine 5.67 2.62 5.12 1.90 1.69 
C22:1n9 n.d. n.d. n.d. 6.08 2.63 
C22:0 n.d. n.d. n.d. 8.72 4.49 
C22:6n3 3.87 n.d. 5.40 3.39 8.76 
Lysine 1.56 1.95 1.82 0.40 0.05 
Histidine 4.18 3.24 2.21 3.84 0.03 
C24:1 n.d. n.d. n.d. 7.85 4.23 
C24:0 n.d. n.d. n.d. 10.50 6.36 
Tyrosine 1.68 1.81 1.57 0.64 0.93 
Tryptophan 1.21 1.91 3.14 0.44 0.61 
Cystathionine n.d. n.d. n.d. 2.65 5.93 
Cystine 0.87 n.d. n.d. 1.03 4.84 
n.d.: not detected above the LLOQ. 
Analytes printed in bold were quantified with a corresponding stable isotope labeled standard. 
 
Matrix spike experiments were performed using human and bovine serum to 
further validate the accuracy of the method. Twenty-µL aliquots of serum were 
spiked with 0, 1.56, 6.25 and 12.5 nmol absolute of the fatty acid standard and 0, 
1.5, 6 and 9.3 nmol absolute of the amino acid standard. Each spike level was 
prepared and analyzed in triplicate. The zero spike level was used to subtract the 
endogenous analyte concentration in order to calculate a recovery for the three 
spike levels. The average recovery of the analytes at the three different levels in 
the human and bovine serum matrix in both matrices was 103.6%, ranging from 
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91% for C24:0 in bovine serum to 125.4% for C18:0 in bovine serum as well. The 
average recovery for the amino acids was 102.8%, ranging from 88.2% for α-
aminobutyric acid up to 128.5% for glutamic acid, both in bovine serum. For 
some analytes in bovine serum, such as C18:0, glycine and proline, higher 
deviations from the spiked amount were observed at the first spike level. 
However, these analytes have higher endogenous levels in serum and the spike 
levels might be too low to evaluate these analytes correctly.  
 
Table20: Recovery rates for amino and fatty acids in human and bovine serum at three different 
spike levels. 
Analyte Spike level 1 Spike level 2 Spike level 3 
 Human Bovine Human Bovine Human Bovine 
C10:0 106.8±5.1 108.4±9.2 107.2±6.1 106.3±7.8 106.5±3.5 108.7±4.5 
Alanine 108.8±5.2 121.3±4.1 104.4±2.1 105±1 103±0.4 102.1±0.8 
Sarcosine 106.9±8.4 111.7±10.2 115±2.7 112.8±10.2 114.4±7.9 103.8±8.9 
Glycine 120.1±10.2 148.7±13.2 100.6±5.2 97.3±1.7 96.4±0.2 94.5±1.3 
α-Aminobutyric acid 87.1±1.3 79.2±10.1 93.2±1.3 90.6±5.2 93.6±1.6 94.8±4.9 
Valine 99.6±4.1 101.6±4.4 99.3±1.1 101.3±0.8 98.2±0.2 97.8±0.4 
C12:0 101.4±2.2 101.9±6.9 103.9±5.3 104.4±3.1 104.6±3.6 106.7±5.9 
ß-Aminoiso-butyric 
acid 
92.3±2.4 87.1±5.8 95.7±1.1 93.3±2.3 93.6±0.3 95.2±1.8 
Leucine 99.2±3.3 105.5±2.8 97.7±1 97.6±0.6 96.3±0.2 95.4±0.1 
allo-Isoleucine 101.8±0.9 98.3±1.8 106.3±0.6 103.1±1 107.2±0.6 102.9±1 
Isoleucine 102.8±1.1 103.5±2.7 102.5±0.9 103.5±0.4 101.9±0.2 100.9±0.2 
Proline 116.9±6.1 182.9±0.5 85.4±1.1 86±2.1 85.1±0.2 84.3±0.2 
C14:0 105.5±2.2 98.5±5.3 106.2±6.2 103.7±2.3 106.8±2.8 106.3±6 
Asparagine 89.2±1.5 99.3±5.6 91.2±0.5 94.6±5.3 99.2±1.1 97.8±5.6 
C16:1n7 97.3±2.6 84.7±2.1 103.6±6.3 89.6±4.8 105.2±2.5 100±6.2 
C16:0 117.1±43.4 94.6±17 118.8±4.9 110.5±17.4 112.2±7.8 113±9.3 
Aspartic acid 107.9±4.8 78.3±4.5 106.1±2.6 103.4±3.8 105.1±1.4 110.8±1.6 
Methionine 110.5±1.9 107.7±5 110.5±1.2 102.7±2.2 110.7±1 105.6±4 
Hippuric acid 99.4±2.2 106.3±0.7 98.7±0.7 98.5±1.6 97.8±0.2 96.3±0.7 
Glutamic acid 121.6±6.9 118.7±6.7 120.5±0.9 140.2±3.5 114.7±6 126.7±3.7 
Phenylalanine 101.4±1.5 101.7±0.9 99.6±0.8 99.4±0.3 98.5±0 97.8±0.7 
C18:1n9cis 111.3±9 101.4±34.7 104.5±3.8 99.9+5.6 103.7±2.4 109.9±5.1 
C18:0 115.1±29.1 141.5±32.2 111.1±14.5 115.3±4 108.7±6.2 119.3±2 
C18:1n9trans 98.4±1.6 114.3±3.4 94.6±1.2 102.9±3.3 98.8±5.1 107.4±4.9 
C18:2n6cis 118.5±14.8 111.6±28.5 118.1±4.2 112.8±2.6 108.3±2.8 115±7.6 
C18:3n3 93.9±6.2 115.6±13.7 95.3±1.2 108.2±4.5 99.2±1.1 113.4±4.8 
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α-Aminoadipic 
acid 
107.8±7.8 105.8±4.1 108.6±3.7 106.6±3.8 105.9±1.9 105.8±5.1 
Glutamine 118.2±29.7 121.3±17.7 88.3±11 111.4±11.4 108.3±11.3 104.6±8.1 
C20:0 99.5±3.1 103.7±10.2 98.7±4.5 97.4±1.5 101.2±3 100.7±4 
C20:4n6 80.5±2 98.3±14.3 103.2±8.1 117.3±3.2 106.8±3.4 119.1±3.8 
Ornithine 104.9±5.6 113±5.7 104.9±3.9 102.9±1 103.3±1.5 96±1.6 
C22:1n9 117.9±6.3 101.7±3.1 94.2±3.1 89.4±5.7 99.6±1.2 97.7±6.3 
C22:0 100.3±4.3 93.6±0.7 96.6±4.7 89±2.9 101.2±2.4 98.5±5.2 
C22:6n3 96.8±2.8 105.7±6.7 91.1±6.6 93±1.7 99.2±1.5 102.9±7.5 
Lysine 102.1±3.2 114.9±1.4 101±0.9 101.4±0.4 100.5±0.6 100.4±0.7 
Histidine 98.3±1.3 95.8±2.4 97.4±1.2 99.1±2.9 97.2±1 97.7±0.2 
C24:1 112±12.2 114.4±6.2 91.3±5.7 89.3±3.1 98.1±2.7 97.9±7.2 
C24:0 88±3.5 81.5±2 96±6.3 88.8±3.8 106.1±2.3 102.7±6.6 
Tyrosine 104.8±1.1 111.9±2.3 103.6±0.9 103.6±1 101.7±0.4 100.2±0.7 
Tryptophan 98.6±1.8 103.6±1.1 97.7±0.3 99.2±0.5 97.2±0.2 97.8±0.2 
Cystathionine 95.1±4 103.2±3 87.9±2.7 95.5±8.1 83.5±3.5 98.2±9.7 
Cystine 104.6±0.8 105.7±1.9 103.4±0.6 103.1±0.6 102.1±0.4 101±0.03 
Analytes printed in bold were quantified with a corresponding stable isotope labeled standard. 
 
7.3.3 Saponification of triglycerides 
Derivatization with propyl chloroformate, as described in 5.2.4, is performed 
under alkaline conditions and might also result in transesterfication of fatty acids 
bound in triglycerides. To investigate whether triglycerides actually are esterified 
with the propyl chloroformate, the triglyceride trimyristic (C14:0/ C14:0/ C14:0) 
was dissolved in propanol, derivatized and the amount of free myristic acid was 
analyzed. The experiment was performed in triplicates with a 0.2 mM and 0.02 
mM solution in propanol using 50 µmol each. The recoveries for the free fatty 
acid ranged from 95 % to 130 %. Due to the unpolar character of triglycerides it 
was not possible to examine higher triglycerides, which are not soluble in n-
propanol. Using high glyceride solutions in chloroform did not result in high 
glyceride saponification, because the ester in the organic phase is not amenable 
to the NaOH. 
7.3.4 Outlook for the analysis of NEFAs 
One major aim in lipidomics is the exclusive analysis of nonesterified fatty acids 
(NEFA) only without a labour intensive TLC separation prior to the analysis. This 
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might be achieved by modifying the derivatization procedure. Omission of the 
base should prevent saponitfication or reesterfication. Preliminary experiments 
were performed on the triglyceride of C10:0.  As shown in Figure 33, upon 
omission of the base no free fatty acid was detected. Further, the yield of the 
internal standard C14:0 was comparable in both analyses, i.e. with and without 
the base. Hence, it may be feasible to analyse NEFA by omitting the base. 
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Figure 33: Analysis of the triglyceride tricaprin under two different conditions: with and without 
base. The ion traces for C10:0 and the internal standard 13C14:0 are shown for the two different 
derivatization conditions. 
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8 Quantitative analysis of amino acids and related 
compounds by LC-MS/MS 
8.1 Introduction 
Some important amino acids are thermally instable and cannot be quantified by 
GC-MS, such as arginine, citruline, as well as 1- and 3- methylhistidines. Amino 
acids are highly polar analytes and, therefore, not suited for conventional 
reversed-phase high-performance liquid chromatography (RP-HPLC). Therefore, 
a derivatization is needed. The potential of derivatization with propyl 
chloroformate, followed by LC-MS/MS analysis for amino acid determination was 
investiged in this work. The method was expanded to tryptophan metabolites and 
polyamines, which are of great biomedical interest. Due to their amino or carboxy 
function they can be derivatized with propyl chloroformate and analyzed by LC-
MS/MS. First experiments for this project were performed by Stephan Fagerer. 
The most important polyamines are spermine, spermidine and putrescine. They 
can be detected in the cells of all living organisms often in high concentrations.79 
Moreover, they are important factors for cell growth, protect DNA and proteins 
from damage by active oxygen species,80, 81 and were suggested as tumor 
markers. 82-84 Therefore, polyamine analysis is an important extension to the 
method. Similarly, tryptophan metabolites were implemented in the method. 
Various articles report that the tumor escape mechanism of cancer cells involves 
depletion of tryptophan and accumulation of its (toxic) metabolites. 85, 86 The 
kynurenine pathway is the main pathway of tryptophan metabolism and is 
activated during inflammatory processes such as immune activation and 
neurodegenerative disorders. Activation of the pathway decreases the level of 
tryptophan and increases the concentration of downstream metabolites, including 
kynurenine, 3-hydroxykynurenine and 3-hydroxyanthranilic acid.87-89 Parts of the 
tryptophan pathway are shown in Figure 34. 
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Yamada et al. described the simultaneous measurement of tryptophan and 
related compounds by liquid chromatography-electrospray ionization tandem 
mass spectrometry without derivatization by using trifluoroacetic acid as ion pair 
reagent. 90 The separation was carried on a C18 column. A tandem mass 
spectrometer operated in MRM with ESI in positive mode was used for detection. 
Quantification was demonstrated to be reliable for compounds with a dedicated 
isotope-labeled standard. In contrast, compounds that are not normalized against 
an isotope-labeled standard, such as polyamines, ornithine and citrulline yield 
poor linearity and, consequently, are not quantified reliably. Therefore, 
introduction of isotope-labeled standards for as many analytes as possible should 
be pursued. Our experiments have already established the importance of internal 
standards. However, isotope-labeled standards are not available commercially 
for all metabolites of interest. Instead of synthesizing individual standards for 
each metabolite, we exploited the derivatization of amino and carboxy functions 
with propyl chloroformate employing d3 labeled propanol. Propyl chloroformate 
(PCF) reacts with carboxylic acids and amines. At room temperature the 
carboxylic acids are esterified and amines are converted to carbamoyl derivatives 
and esters, respectively.  
8.2 Material and Methods 
8.2.1 Chemicals 
An amino acid standard (Sigma) containing 27 compounds, mostly amino acids 
at a concentration of 2.5 mM each (except cystine 1.25 mM), formic acid (puriss 
p.a.) heptafluorobutyric acid (puriss. p.a.), iso-octane (GC-MS grade) and n-
propanol (GC-MS grade), glutamine, arginine, histidine, hydroxylysine, lysine, 
ornithine, γ-aminobutyric acid, hippuric acid, tryptophan, 3-hydroxy-kynurenine, 
kynurenine, kynurenic acid, anthranilic acid, agmatine, putrescine, U-13C 
putrescine, spermine, spermidine, ethanolamine, taurine, norleucine, citrulline, 1- 
and 3-methyl-histidine, [2H3] 3-methyl-histidine were purchased from Sigma-
Aldrich (Taufkirchen, Germany). The [U-13C, U-15N] cell free amino acid mix 
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was from Euriso-Top (Saint-Aubin Cedex, France). [2, 5, 5-2H3] α-aminoadipic 
acid and [2,3,4,5,6-2H5] hippuric acid were purchased from C/D/N Isotopes 
(Quebec, Canada). Methanol (LC-MS grade) and chloroform (HPLC grade) were 
purchase from Fisher (Fisher Scientific GmbH, Ulm, Germany). The EZ:faastTM 
C18 RP column (250 mm x 2.0 mm, 4 µm) for LC-MS was from Phenomenex . 
8.2.2 Instrumentation 
An Agilent 1200 series binary SL system with autosampler was used for liquid 
chromatography. The column was kept at a constant temperature of 50 °C in a 
column oven . Five µL of sample were injected each run. For separation a binary 
gradient was used with mobile phase A: water with 1 % (v/v) formic acid and 0.1 
% heptafluorobutyric acid and mobile phase B: methanol with 1 % (v/v) formic 
acid and 0.1 % heptafluorobutyric acid. A C18 RP column (4.6 mm x 150 mm, 5 
µm) equipped with a guard cartridge system from Phenomenex® was used for 
separation to avoid column contamination. The LC-separation was evaluated by 
Stephan Fagerer. The gradient is shown in Table 21.  
 
Table 21: Gradient for LC separation. 
Total time 
[min] 
% Mobile 
Phase A 
% Mobile 
Phase B 
0.0 38 62 
12.0 21 79 
12.01 2 98 
15.0 2 98 
15.01 38 62 
23.0 38 98 
 
An ABI 4000 QTRAQ mass spectrometer was used for detection. Experiments 
were performed using the Analyst Software 1.5. The Turbo Ionspray, declustering 
potential, exit potential and collision energy parameters as well as all precursor 
and product ion masses for the analytes and internal standards are listed in 
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Table 22. ESI in positive mode and scheduled MRM were used. The transitions 
were recorded for one minute at the scheduled retention time. The transitions 
were adopted from Stephan Fagerer for except 3-methylhistidine IS, hippuric acid 
IS, putrescine IS, hydroxylysine, agmatine and α-aminoadipic acid IS that were 
added later to the method.   
  
Table 22: List of derivatized compounds after propyl chloroformate derivatization and their 
optimized MRM parameters. The numbers in the left column indicate the labeling in the 
chromatogram in Figure 35. 
Compound 
(number ) 
Mass 
[Q1] 
Mass 
[Q3] 
RT 
[min] 
DP 
[V] 
CE 
[V] 
CXP 
[V] 
Ethanolamine (1) 148.1 62 2.3 29 14 9
Taurine (2) 212.05 126 2.4 53 17 10
Glutamine (2) 275.15 172.1 3.2 61 19 10
Glutamine IS 282.1 178.1 3.2 61 19 10
3-Methylhistidine (4) 298.2 256.1 3.2 60 18 10
3-Methylhistidine IS 301.2 259.1 3.2 60 18 10
Citrulline (5) 304.2 156.1 3.3 46 24 11
1-Methylhistidine (4) 298.2 210.1 3.6 60 26 12
Hippuric acid (6) 222.1 162.1 3.7 30 13 10
Hippuric acid IS 227.1 167.1 3.7 30 13 10
Serine (7) 234.13 174.08 3.7 50 14 10
Serine IS 238.1 178.1 3.7 50 14 10
Arginine (8) 303.2 70 4.2 88 55 11
Arginine IS 313.2 70 4.2 88 55 11
Asparagine (9) 243.13 157.1 3.9 66 14 11
Asparagine IS 249.13 163.1 3.9 66 14 11
Glycine (10) 204.12 144.07 4.5 56 12 12
Glycine IS 207.1 147.1 4.5 56 12 12
Threonine (11) 248.14 160.1 4.6 53 16 8
Threonine IS 253.14 164.1 4.6 53 16 8
Kynurenic acid (12) 232.1 190.1 4.7 32 21 10
Putrescine (13) 261.2 201.2 5.4 31 13 10
Putrescine IS 265.2 205.2 5.4 31 13 10
ß-Alanine (14) 218.13 158.1 5.6 42 14 10
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Agmatine (15) 217.2 158.1 5.8 48 17 9
Alanine (16) 218.13 130.09 5.9 59 17 10
Alanine IS 222.13 133.09 5.9 59 17 10
γ-Aminbutyric acid (17) 232.2 172.1 6.5 30 13 9
Sarcosine (18) 377 317 6.9 60 17 10
Hydroxylysine (19) 377 125 7 30 14 8
ß-Aminoisobutyric acid (20) 232.2 172.2 7.2 44 14 9
Anthranilic acid (21) 266.1 206.1 7.5 48 11 10
α-Aminobutyric acid (22) 232.3 172.3 7.9 30 13 9
Proline (23) 244.15 184.1 8.5 50 12 10
Proline IS 250.15 190.1 8.5 50 12 10
Ornithine (24) 347.21 287.16 8.6 67 14 8
Methionine (25) 278.13 190.09 8.6 55 15 10
Methionine IS 284.13 195.09 8.6 55 15 10
Aspartic acid (26) 304.17 216.12 9.7 61 18 11
Aspartic acid IS 309.17 220.12 9.7 61 18 11
Histidine (27) 370.19 196.1 9.8 60 31 9
Histidine IS 379.19 204.1 9.8 60 31 9
Valine (28) 246.16 158.12 10 58 16 13
Valine IS 252.16 163.12 10 58 16 13
Lysine (29) 361.23 301.18 10.2 71 14 8
Lysine IS 369.23 309.18 10.2 71 14 8
3-OH-Kynurenine (30) 439.2 336.1 10.2 38 15 9
Glutamic acid (31) 318.18 230.14 10.4 64 18 12
Glutamic acid IS 324.18 235.14 10.4 64 18 12
Tryptophan (32) 333.17 245.13 10.8 68 22 10
Tryptophan IS 346.17 257.13 10.8 68 22 10
Spermidine (33) 404.3 284.3 11 76 23 7
α-Aminoadipic acid (34) 332.3 244.2 11.7 50 18 10
α-Aminoadipic acid IS 335.3 247.2 11.7 50 18 10
Leucine (35) 260.18 172.13 12 58 17 10
Leucine IS 267.18 178.13 12 58 17 10
Phenylalanine (36) 294.16 206.12 12.2 60 16 11
Phenylalanine IS 304.16 215.12 12.2 60 16 11
Isoleucine (37) 260.18 130.08 12.4 53 25 10
Isoleucine IS 267.18 136.08 12.4 53 25 10
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Cystine (38) 497.19 248.1 14.5 89 23 6
Cystine IS 505.19 252.1 14.5 89 23 6
Tyrosine (39) 396.19 308.15 14.9 84 19 9
Tyrosine IS 406.19 317.15 14.9 84 19 9
Spermine (40) 547.36 427.26 15.5 95 28 12
Kynurenine (41) 423.21 320.1 16.2 74 14 9
 
8.3 Sample preparation 
8.3.1 General procedure 
The sample preparation was carried out as described in section 5.4. This protocol 
was performed by the MPS-2 Prepsation or manually. In contrast to this protocol 
120 µL from the upper organic phase were transferred to a new autosampler vial. 
The sample was concentrated in an infrared vortexing concentrator and 
redissolved in 100 µL of mobil phase.  
8.3.2 Preparation of the internal standard using d3-propanol 
Two hundred µL of standard mix A and B (mixed equimolar) were added in a 2 
mL glass vial followed by the addition of 120 µL of 0.33 M NaOH solution. In the 
next step 50 µL of a picoline/ d3-propanol solution were added. The ratio of 
picoline to d3-propanol was 23:77. Fifty µL of propyl chloroformate in 
chloroform/isooctane mix were added to the sample, the solution was mixed for 
12 seconds, equilibrated for 1 min and once again mixed for 12 seconds. To 
extract the derivatized analytes, 250 µL of issooctane were added and the vial 
was vortexed for 12 seconds. From the upper layer 200 µL were transferred to a 
new vial. The created internal standard was diluted 1:50 and 10 µL of the solution 
were added to the samples after transferring of the 120 µL organic phase to a 
new vial and before the evaporation step. The ratio of propanol to propyl 
chloroformate is 7:1 in the standard protocol. To reduce the percentage of non-
labeled d3-derivatives the ratio of picoline/ d3-propanol/propyl chloroformate was 
varied. The ratio of d3-propanol to propyl chloroformate of 2.5:1 and 14:1 was 
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also tried. In one experiment the content of the catalyst picoline was increased, 
so the ratio of d3-propanol and picoline was 1:1.  
8.3.3 Different extraction procedures 
Furthermore, the extraction of the derivatives was investigated to increase the 
yield. Ectraction with isooctane, chloroform, ethyl acetate and isooctane plus 
addition of a saturated NaCl solution to use the salt out effect was tested. An 
overview of all tested protocols is shown in Table 23. 
 
Table 23: Different Derivatization protocols. 
General  procedure: 
isooctan extration 
Expanded 
reaction time 
Isooctane + 
salt out (sat. 
NaCl solution)  
Chloroform 
extraction 
Ethyl 
acetate 
extraction 
1. Pipette 50 µL standard 
mixture  
2. Complement volume 
with H2O to a total of 200 
µL 
3. Add 120 µL 0.33 M 
NaOH 
4. Add 80 µL 3-methyl-
pyridine (23% in n-
propanol)  
5. Add 50 µL propyl 
chloroformate in 
chloroform/isooctane 
(17.4:71.6:11.0) 
6. Mix (12 sec), wait 1 
min, mix (12 sec) agan 
7. Add 250 µL isooctane  
8. Transfer 120 µL 
(organic layer) to a new vial  
9. Evaporate solvent (100 
mbar, 45 min) 
10. Redissolve in 100 µL 
mobile Phase  
Step 1-5 equal 
to the general 
procedure 
 
 
 
 
 
 
 
 
6. Mix (12 
sec), wait 2 
min, mix (12 
sec) again 
  
Step 7-10 of 
the general 
procedure 
Step 1-7 equal to 
the general 
procedure 
 
 
 
 
 
 
 
 
 
 
 
8. Add 50 µL 
brine 
Step 7-10 of the 
general 
procedure 
Step 1-6 
equal to the 
general 
procedure 
 
 
 
 
 
 
 
 
 
 
7. Add   250 
µL 
chloroform 
Step 8-10 of 
the general 
procedure 
Step 1-6 
equal to the 
general 
procedure 
 
 
 
 
 
 
 
 
 
 
7. Add   250 
µL ethyl 
acetate 
Step 8-10 of 
the general 
procedure 
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8.4 Quantification 
Absolute quantification of compounds was performed by analyzing standard 
solutions containing equimolar amounts of all amino acids. Three different 
solutions were used and listed in Table 28. The first solution consisted of 22 
compounds in 0.1 M HCl, the second mixture contained 12 compounds, including 
amino acids not stable in acidic solution, complementary amino acids and 
tryptophan metabolites, while the third mixture included polyamines, aromatic 
amino acids and ethanolamine. The first and the second mixture was 2.5 mM, 
while the third one was 5 mM. For calibration, the three different solutions were 
mixed at the following ratio: 2:2:1 resulting in a final concentration of 1 mM. For 
calibratio,n this standard mix was employed in a range of 2.5 pmol to 10 nmol 
absolute in 16 serial dilutions corresponding to a concentration range of 125 nM 
to 0.5 mM using 20 µL of biological sample. The calibration and first 
quantification experiments were performed by using the same standard mix of 20 
uniformly 13C and 15N-labeled amino acids as described in 5.4, including arginine 
and cystine. Arginine was concentrated too low for use as internal standard. 
During the course of experiments compounds were added to expand the 
spectrum of internal standards: [2,5,5-2H3] α-aminoadipic acid and [2,3,4,5,6-2H5] 
hippuric acid, [2H3] 3-methylhistidine, and U-13C labeled putrescine. 
8.5 Results and Discussion 
8.5.1 LC-MS/MS  
The LC-MS/MS method used was adopted from Stephan Fagerer. Previously the 
tandem mass spectrometer was operated in MRM mode with positive ESI and 
the separation time was divided into four periods. Now the scheduled MRM 
modus was used for the analysis. A chromatogram of a standard solution is 
shown in Figure 35. The separation of the analytes was completed in less than 
17 min.  
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Figure 35: Full chromatogram of the propyl chloroformates obtained by LC-MS/MS. Fourty-one 
peaks were identified and labeled with numbers. The corresponding compounds are given in 
Table 22. 
 
8.5.2 Calibration 
Quantification was carried out as described in 7.2.5 and figures of merit are 
shown for 38 compounds in table Table 24.The calibration range defined as the 
LLOQ and ULOQ and the R-square from the calibration are listed. The calibration 
was linear from 25 pmol to 10,000 pmol for most analytes. R-square-values ≥ 
0.99 were obtained for all compounds except kynurenic acid (0.9882), 
hydroxylysine (0.9877), anthranilic acid and spermidine (0.9862). However, for 
these amino acids no corresponding stable-isotope had been available. No linear 
relation between analyte signal and amount was observed for ethanolamine, 
taurine and agmatine and therefore excluded from Table 24.  
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Table 24: Calibration parameters of the analytes. LLOQ and ULOQ are given in pmol absolute. 
Analytes printed in bold were quantified using the internal standard transition of the 
corresponding stable-isotope labeled amino acid as reference. The internal standard used for the 
other compounds is given in brackets.  
Compound LLOQ [pmol] ULOQ 
[pmol]
R-square 
Glutamine 25 10000 0.9997 
Methyl-histidine 25 10000 0.9992 
Citrulline (Glutamine IS) 25 7500 0.998 
Arginine (Glutamine IS) 1000 7500 0.994 
Hippuric acid 50 10000 0.9997 
Serine 25 10000 0.9998 
Asparagine 50 10000 0.9998 
Glycine 50 10000 0.9996 
Kynurenic acid (Hippuric acid IS) 70 10000 0.9882 
Threonine 25 10000 0.9999 
Putrescine 25 2500 0.9928 
ß-Alanine (Alanine IS) 25 10000 0.9947 
Alanine 50 10000 0.9996 
γ-Aminobutyric acid (Alanine IS) 100 10000 0.993 
Sarcosine (Proline IS) 150 7500 0.991 
Hydroxylysine (Threonine IS ) 250 10000 0.9877 
α-Aminobutyric acid (Aminoadipic acid IS) 25 7500 0.9972 
ß-Aminoisobutyric acid (Alanine IS) 100 7500 0.9952 
Anthranilic acid (Hippuric acid IS) 500 7500 0.9854 
Proline 25 10000 0.9999 
Ornithine (Lysine IS) 150 2500 0.9918 
Methionine 25 10000 0.9992 
Aspartic acid 50 2500 0.9984 
Valine 50 10000 0.9997 
Histidine 100 2500 0.9967 
Lysine 150 2500 0.9927 
3-OH-Kynurenine (Hippuric acid IS) 100 7500 0.9965 
Glutamic acid 500 10000 0.9985 
Tryptophan 100 2500 0.9968 
Spermidine (Putrescine IS) 50 2500 0.9862 
α-Aminoadipic acid 25 2000 0.9998 
Leucine 50 10000 0.9992 
Phenylalanine 100 5000 0.9974 
Isoleucine 50 10000 0.9997 
Cystine 100 2500 0.9943 
Tyrosine 100 2500 0.9955 
Spermine (Putrescine IS) 100 2500 0.9915 
Kynurenine (Hippuric acid IS) 25 5000 0.9965 
To prove the reproducibility of the method a standard solution was derivatized 
and analyzed in triplicates in three different concentrations. An absolute amount 
of 100 pmol, 250 pmol and 2500 pmol were analyzed and the RSDs are shown in 
Table 25. The RSDs for the analytes corrected by their own internal standard 
were between 1 and 5 % except for glycine, hippuric acid, putrescine, alanine, 
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aspartic acid, valine and tyrosine, which yielded higher RSDs at the low 
concentration level. RSDs higher than 10 % were observed for kynurenic acid, ß-
alanine, γ-aminobutyric acid, sarcosine, hydroxylysine, α-aminobutyric acid, ß-
aminoisobutyric acid, and anthranilic acid. But these compounds did not have a 
corresponding internal standard. 
 
Table 25: Reproducibility of LC-MS/MS analysis of propyl chloroformate for independent 
derivatizations.  
Analyte Relative standard deviation [%]; n=3 
 100pmol 250 pmol 2500 pmol   
Glutamine 0.61 2.31 0.62 
Methyl-histidine 1.05 2.99 2.42 
Citruline 15.25 6.53 5.56 
Arginine n.d. 3.93 30.65 
Hippuric acid 12.56 5.46 1.08 
Serine 10.03 3.62 0.41 
Asparagine 2.57 2.25 2.52 
Glycine 6.46 0.48 2.70 
Kynurenic acid 7.45 7.27 41.77 
Threonine 1.48 1.61 0.70 
Putrescine 7.45 1.34 2.90 
Alanine 17.59 1.99 1.41 
ß-Alanine 21.96 7.19 25.55 
γ-Aminobutyric acid 13.19 9.85 29.31 
Sarcosine 21.74 13.07 12.20 
Hydroxylysine 7.61 19.53 17.63 
α-Aminobutyric acid 15.93 20.24 10.39 
ß-Aminoisobutyric acid 18.06 5.60 25.00 
Anthranilic acid 1.52 5.35 33.75 
Proline 3.50 0.71 1.07 
Ornithine n.d. 6.85 4.80 
Methionine 0.62 0.77 1.73 
Aspartic acid 7.27 2.79 2.84 
Valine 7.00 1.24 0.71 
Histidine 2.65 1.14 3.41 
Lysine n.d. 2.67 4.72 
3-OH-Kynurenine 9.44 7.05 4.89 
Glutamic acid 3.89 0.82 1.82 
Tryptophan 5.86 0.96 1.37 
Spermidine n.d. 1.76 12.15 
α-Aminoadipic acid 1.13 1.39 1.71 
Leucine 1.07 0.68 0.45 
Phenylalanine 3.25 1.76 0.23 
Isoleucine 2.09 2.79 1.03 
Cystine 1.78 0.98 9.70 
Tyrosine 7.27 1.35 0.43 
Spermine 8.86 1.91 27.29 
Kynurenine 36.95 9.08 7.39 
a Analytes printed in bold were quantified with a corresponding stable isotope. 
n.d. - not detected above the LLOQ. 
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 8.5.3 Biological samples 
For a set of mice serum samples the tryptophan analysis by LC-MS/MS was 
compared to GC-MS analysis as described in chapter 5. The results are shown in 
Table 29. Another aim was to detect changes of the tryptophan metabolites 
kynurenine, kynurenic acid or hydroxykynurenine. In mouse serum the 
concentrations of kynurenine varied between the LLOQ and two times the 
concentation of the LLOQ. Kynurenic acid and hydroxykynurenine were not 
detected above the LLOQ. For some amino acids, e.g. lysine, the measured 
concentrations were almost outside the calibration range. Therefore, increasing 
the sample volume or injection volume would exclude some amino acids from the 
quantification. Up to this point, it proved impossible to quantify the tryptophan 
metabolites simultaneously with the amino acids. 
8.5.4 Synthesis of internal standards using d3-propanol 
Quantification is more reliable for compounds with a dedicated isotope-labeled 
standard. For some compounds, no standards are available or very expensive. 
An elegant way to create an isotope-labeld standard for a large group of 
compounds in a single reaction would be to derivatize a standard mix with propyl 
chloroformate in isotope-labeled propanol. The alkoxy group found in the 
esterfied carboxylic acid corresponds to the alcohol in the reaction medium and 
not to the alkoxy group of the chloroformate. That was demonstrated by Zampolli 
and Wang et al.39, 91 Propyl chloroformate (PCF) reacts with carboxylic acids and 
amines. At room temperature the carboxylic acids are esterified and amines are 
converted to carbamoyl derivatives and esters, respectively. Using this approach 
our aim was to use labeled propanol to produce stabil-isotope labeled derivatives 
that could be then added to the derivatized samples. A rearrangement of the 
ester should take place and the obtained product is shown in Figure 36 . 
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Figure 36: Reaction of the amino acids with d-3 propanol. 
 
Mastermix A and B (compounds listed in Table 28) were mixed equally and 200 
µL were subjected to the derivatization procedure as described in chapter 8.3. 
The rearrangement took place for all compounds but for some compounds also 
non-labeled derivatives were obtained. This would cause a background signal for 
the analyte and result in higher LLOQs. Different ratios of propanol to propyl 
chloroformate were investigated to decrease the content of non-labeled 
compound. Furthermore, a higher content of the catalyst picoline was tested. The 
percentage of non-labeled derivative relative to the labeled analyte is shown in 
Table 26. The amount of non-labeled analyte decreases with increasing d3-
propanol ratio. For glutamine the ratio decreased from 14.4 to 2.8 %. But the 
yield of the reaction decreased too (data not shown). Therefore, the following 
experiments were carried out with a ratio of d3-propanol to propyl chloroformate 
of 7:1. Here the ratios varied between 1 and 10 %, except for citrulline, sarcosine 
and glycine.  
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Table 26: The content of non-labeled analyte relative to the labeled analyte in percent for the 
different experiments. 
Percentage of the non-
labeled analyte [%] 
Analyte 
Ratio of d3-propanol to 
propylchloroformate 
     2.5:1        7:1              14:1 
Propanol: 
Picoline=1:1 
Arginine 4.0 0.4 3.0 0.6 
Glutamine 14.4 4.8 2.8 10.6 
Citrulline 137.8 37.4 35.1 83.0 
Serine 32.5 9.8 5.8 26.3 
Asparagine 16.8 5.1 3.1 18.9 
Sarcosine 61.8 23.6 10.7 36.9 
Kynurenic acid 17.8 5.9 3.4 16.4 
Glycine 100.5 32.2 17.7 92.5 
Threonine 16.2 4.8 3.1 14.0 
Alanine 16.0 4.3 2.2 9.8 
β-Alanine 16.2 5.4 2.7 10.8 
γ-Aminobutyric acid 31.6 9.1 4.6 18.4 
Hydroxylysine 3.6 1.7 0.6 4.0 
ß-Aminoisobutyric acid 15.1 4.3 2.1 8.9 
α-Aminobutyric acid 16.3 5.1 2.2 10.4 
Proline 31.0 9.4 4.9 26.3 
Ornithine 30.1 10.6 3.6 12.6 
Methionine 18.8 5.9 2.8 13.8 
Aspartic acid 3.1 0.3 0.0 1.2 
Valine 20.6 6.2 2.9 17.0 
Histidine 19.1 7.7 3.3 13.1 
Lysine 26.7 9.3 3.6 13.0 
3-OH-kynurenine 14.4 5.4 2.5 10.8 
Glutamic acid 5.3 0.6 0.2 2.7 
Tryptophan 22.9 7.8 3.9 12.9 
α-Aminoadipic acid 9.4 2.8 1.7 8.2 
Leucine 19.9 6.5 3.2 14.9 
Phenylalanine 15.8 5.3 2.6 11.0 
Isoleucine 18.0 6.6 2.9 14.8 
Cystine 15.6 5.1 3.1 14.2 
Tyrosine 16.9 6.5 3.7 12.0 
Kynurenine 20.8 5.5 3.3 15.6 
 
Experiments were carried out by using diluted self-made internal standard as 
described in section 7.3 The internal standard corrected well for injection as 
investigated for kynurenine. The RSD for a ten-fold injection was 10 % without 
using an internal standard and below 1 % using the corresponding d3-labeled 
internal standard (data not shown). But applying the d3-labeled internal standard 
decreased the accuracies during calibration compared to using the 13C and 15N-
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labeled amino acids of the algae mix for corrections. In both cases the ratio of 
analyte and internal standard were applied for the Quantification. A calibration 
range from 41 -6250 pmol was compared. For threonine the accuracies ranged 
applying the d3 standard from 100 to 235 % for the different calibration levels 
compared to 100 to 119 % using 13C and 15N-labeled threonine. In conlusion, the 
self-made internal standard could correct for injection and ion suppression, but 
not for the differences in extraction efficiency. Therefore, this approach was 
discarded.   
8.5.5 Method limitations 
There are a few drawbacks of the method. First, the methyl histidines cannot be 
separated as described by Stephan Fagerer and therefore the method 
parameters are for the sum of 1-methyl-histidine and 3-methyl-histidine. No linear 
range was observed for ethanolamine, taurine and agmatine and a high LOQ 
was observed for arginine compared to the other analytes. Human serum was 
analyzed and no kynurenine or kynurenine derivatives were deteced. The 
method is not useful to quantify tryptophan metabolites because the biological 
concentration is lower than the LLOQ for those analytes. 
8.5.6 Extraction experiment 
The aim was to test different extraction solvent to increase sensitivity for polar 
compounds e.g. ethanolamine, citrulline or methylhistidine and to get better 
yields for all analytes and, consequently, better LLOQs. Changing the extraction 
medium to more a polar solvent (EtOAc, HCCl3) was tested. Additionally, the 
expansion of the reaction time as well as an additional step with brine solution 
was evaluated. The different conditions of the protocol are shown in 8.3, Table 
23. The analytes are divided into 6 different groups, which are discussed: neutral 
amino acids, polar amino acids, tryptophan metabolites and aromatic amino 
acids, basic compounds as polyamines and basic amino acids and ethanolamine 
and taurine. The areas of the neutral amino acids are shown in Figure 37.  
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Figure 37: Area obtained by different extraction protocols for derivatives of neutral amino acids. 
 
The areas for the polar amino acids are compared in Figure 38. All those amino 
acids contain a functional group e.g. threonine and serine have a hydroxyl group, 
aspartic acid and glutamic acid a second carboxy function, glutamine and 
asparagine an amide function, and cystine and methionine contain sulfur. Apart 
from methionine the higher extraction yields were obtained with ethyl acetate and 
chloroform compared to isooctane, with chloroform showing the best 
performance.  
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Figure 38: Area obtained by different extraction protocols for derivatives of polar amino acids. 
 
Ethyl acetate is the best solvent for the extraction of polyamines, lysine and 
ethanolamines (data not shown). For methylhistidine the yield was almost 5 or 9 
times higher using ethylacetate and chloroform, respectively. For arginine the 
yield was 30 or 25 times higher using ethylacetate and chloroform, respectively. 
Both are shown in Figure 39 
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Figure 39: Area obtained by different extraction protocols for arginine and methylhistidine 
 
The same trend was observed for aromatic amino acids and tryptophan 
metabolites (data not shown). In conclusion, using either ethyl acetate or resulted 
in higher yield and improved LLOQs. In particular, for the analysis of the 
tryptophan derivates improved LLOQs are needed. 
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 9 Conclusion and Outlook 
9.1 GC-MS method 
A robust and accurate GC-MS method was developed for the automated 
quantitative analysis of amino acids as their propyl chloroformate derivatives in 
various biological matrices. At present, 31 amino acids and dipeptides can be 
reliably quantified by using 19 stable-isotope labeled amino acids as internal 
standards. The advantage of the method in comparison to other available 
methods is the complete automation and a very robust quantification. By limiting 
manual sample preparation steps, the sample throughput is increased, which is 
of high importance in metabolomics studies. For the analysis of blood or urine a 
sample amount of 20 - 50 µL is necessary. The introduction of stable-isotope 
labeled amino acids as internal standards immensely improved the method 
reproducibility over using only norvaline as internal standard, which allowed the 
accurate and robust quantification of amino acids in large sample batches. The 
method was validated for the analysis of amino acids using certified amino acid 
standard and reference plasma, and its applicability was shown by matrix spike 
experiments. The application for metabolomic studies with large sample numbers 
was demonstrated by anaylyzing 2 blinded sets. The method was adapted to 
allow the combined analysis to the total fatty acid content of 17 fatty acids and 25 
free amino acids in a single gas chromatographic run. The chromatographic run 
time increased from 12 min to 50 min. Modification of the derivatization protocol 
may allow the analysis of free fatty acids as a subset of the lipidome. There is 
also the possibility to expand the method for the analysis of additional 
compounds e.g. polyamines or other dipeptides. 
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9.2 LC-MS/MS method 
Limitations of the GC-MS method are firstly that serine and threonine, depending 
on the biological matrix, may not always be measured reliably and, secondly, that 
certain amino acids, such as arginine, cysteine, citrulline, taurine, and the 1- and 
3-methylhistidines are not amenable to GC-MS analysis due to their thermal 
instability. Therefore, the potential of derivatization with propyl chloroformates, 
followed by LC-MS/MS analysis for amino acid determination was investigated. 
The method was expanded to tryptophan metabolites and polyamines. In total 41 
analytes were investigated. Due to their amino function they can be derivatized 
with propyl chloroformate and analyzed by LC-MS/MS. The main focus was the 
evaluation of a novel strategy to generate a stable-isotope labeled standard by 
using d3-labeled propanol. Experiments showed that the created standard was 
not suitable for quantification purposes. Therefore, isotope-labeled analogs have 
to act as internal standards. In total 23 stable-isotope labeled amino acids were 
used as internal standards but for many analytes no stable-isotope labeled 
standard was available. e.g. kynurenine. Means of synthesizing labeled 
compounds include chemical synthesis or the use of enzymes. Matin et al. 
demonstrated the enzymatic conversion of tryptophan to kynurenine using 
indoleamine 2,3-dioxygenase (IDO).92 Changing tryptophan to labeled tryptophan 
would lead to labeled kynurenine. It was not possible to detect all analytes e.g. 
tryptophan metabolites above the LLOQ in biological samples. Therfore the 
sensitivity of the method has to be increased. The sample preparation contain a 
extraction with isooctane. Experiments with different solvents showed that there 
is a way to increase the yield of extraction using chloroform or ethyl acetate. Due 
to the better handling applying the ethyl acetate approach would be the best way 
for the future. 
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 11 Appendix 
 
Table 27: [U-13C, U-15N] labeled cell free amino acid mix extracted from algae. Molar % and 
weight % as provided from the manufacturer (determined by HPLC). The standard was dissolved 
in 10 mL water (resulting concentrations given in the table). 
AA Molar % Weight % M [g/mol] m [mg] 
conc 
[µmol/10 
ml] 
conc 
[nmol/µl] 
       
Aspartic acid 7.84 8.25 138.1 2.327 16.846 1.6846 
Glutamic acid 10.04 11.67 153.13 3.291 21.491 2.1491 
Asparagine 4.34 4.56 138.12 1.286 9.310 0.9310 
Serine 4.26 3.53 109.09 0.995 9.125 0.9125 
Glutamine 4.43 5.15 153.15 1.452 9.483 0.9483 
Histidine 0.41 0.51 164.16 0.144 0.876 0.0876 
Glycin 9.33 5.53 78.07 1.559 19.975 1.9975 
Threonine 4.77 4.48 124.15 1.263 10.176 1.0176 
Alanine 13.29 9.35 93.09 2.637 28.324 2.8324 
Arginine 4.9 6.78 174.2 1.912 10.98 1.098 
Tyrosine 2.13 3.04 191.19 0.857 4.484 0.4484 
Valine 6.53 6.04 123.15 1.703 13.831 1.3831 
Methionine 1.63 1.92 155.21 0.541 3.488 0.3488 
Tryptophan 1.81 2.92 217.23 0.823 3.791 0.3791 
Phenylalanine 2.41 3.15 175.19 0.888 5.070 0.5070 
Isoleucine 4.71 4.88 138.18 1.376 9.959 0.9959 
Leucine 8.66 8.97 138.18 2.530 18.306 1.8306 
Lysine 3.98 4.6 154.19 1.297 8.413 0.8413 
Proline 3.9 3.55 221.13 1.001 4.527 0.4527 
Cysteine  not det.     
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Table 28: The three differt Mastermixsolutions for the analysis by LC-MS/MS as propyl 
chloroformates 
 
Mastermix A 
Conc: 2.5 µM  
Mastermix B 
Conc: 2.5 µM 
Mastermix C 
Conc: 5 µM 
ß-alanine Glutamin hippuric acid 
Alanine Arginine 3-methyl-histidine 
Α-aminoadipic acid γ-aminobutyric acid Anthranilic acid 
α-aminobutyric acid Histidine Spermine 
ß-aminoisobutyric acid Hydroxylysine Spermidine 
Asparagine Kynurenine Putrescine 
Aspartic acid Kynurenic acid Agmatine 
Citrulline Hydroxykynurenine Ethanolamine 
Cystine (1.25 µM) Lysine  
Glutamic acid 1-methyl-histidine  
Glycine Ornithine  
Isoleucine Tryptophan  
Leucine   
Methionine   
Phenylalanine   
Proline   
Sarcosine   
Serine   
Taurine   
Threonine   
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Tyrosine   
Valine   
 
 
 
Table 29: Comparison of tryptophan values analyzes as propyl chloroformates by GC-MS and 
LC-MS/MS 
µM GC-MS  LC-MS/MS 
 C1      78.45 74.5
 C2      101.8 97.5
 C3      135.25 124.5
 C4      93.35 88.5
 C5      143.9 130.5
 C6      132.55 120.5
 N1      158.75 142
 N3      126.35 112.5
 N4      182.65 145
 N5      129.4 120.5
 M1      190.95 168
 M2      120.9 113
 M3      132 122
 M4      129.95 121
 M5      124.3 114.5
 M6      145.45 133.5
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 14 Summary 
Amino acids are intermediates in cellular metabolism and their quantitative 
analysis plays an important role in disease diagnostics. A gas chromatography-
mass spectrometry (GC-MS) based method was developed for the quantitative 
analysis of free amino acids as their propyl chloroformate derivatives in biological 
fluids. Derivatization with propyl chloroformate could be carried out directly in the 
biological samples without prior protein precipitation or solid-phase extraction of 
the amino acids, thereby allowing for automation of the entire procedure, 
including addition of reagents, extraction and injection into the GC-MS. The total 
analysis time was 30 minutes, including sample preparation and 31 amino acids 
could be reliably quantified using 19 stable isotope-labeled amino acids as 
internal standards. Limits of detection (LOD) and lower limits of quantification 
(LLOQ) were in the range of 0.03 - 12 μM and 0.3 - 30 μM, respectively. The 
method was validated using certified amino acid standard and reference plasma, 
and its applicability to different biological fluids was shown. Intraday precision for 
the analysis of human urine, blood plasma, and cell culture medium was 2.0 - 
8.8%, 0.9 - 8.3%, and 2.0% - 14.3%, respectively, while the inter-day precision 
for human urine was 1.5 - 14.1%.  
Using two blinded sets of urine specimens containing replicates, the GC-MS 
method was further validated and the results were compared with those obtained 
for iTRAQ® derivatization HPLC-tandem mass spectrometry and ion exchange 
chromatography with postcolumn ninhydrin detection of amino acids. The 
technical error (TE), as determined by repeated aliquot measurements of various 
urine specimens was calculated to prove that the method was suitable for the 
quantitative analysis of amino acids in large clinical and epidemiological studies. 
The quantitative results obtained by the three methods were compared by 
regression analysis and Bland-Altman plotting.  
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The method was further expanded to fatty acids. Due to the carboxy function 
fatty acids can be derivatized with propyl chloroformate and included in the 
develpoped GC-MS method. To resolve isobaric fatty acids the GC program had 
to be expanded and the analysis time increased to 50 min for one GC run.  LODs 
for the fatty acids ranged from 0.08 µM to 39 µM. To that end, the method was 
adapted to allow the combined analysis of the total fatty acid content of 17 fatty 
acids and 25 free amino acids in a single gas chromatographic run. 
The number of amino acids amenable to GC analysis is limited and therefore, the 
potential of derivatization with propyl chloroformates, followed by LC-MS/MS 
analysis for amino acid determination was investigated. The method was 
expanded to tryptophan metabolites and polyamines that are of great interest in 
several biological projects. The intention to use an in-house synthesized internal 
standard for each analyte failed as experiments showed that the created 
standard is not suitable for quantification purposes. Therefore, isotopes labeled 
analytes have to act as internal standards. Using 23 stable-isotope labeled 
compounds as internal standards, the method aims the quantification of 41 
analytes comprising amino acids, tryptophan metabolites and polyamines. It was 
not possible to detect tryptophan metabolites above the LLOQ in biological 
samples. Preliminary experiments were performed to improve the method by 
evaluating choice of the extraction solvent. 
 138
 15 Zusammenfassung 
Aminosäuren sind Zwischenprodukte im zellulären Stoffwechsel und ihre quanti-
tative Analyse ist speziell bei der Diagnose von Krankheiten von enormer Be-
deutung. Zur Bestimmung von Aminosäuren in unterschiedlichen biologischen 
Proben wurde eine gaschromatographische mit Massspektrometer gekoppelte 
Methode entwickelt, welche auf der Derivatisierung von Aminosäuren mit 
Chlorameisensäurepropylester beruht. Diese Art der Derivatisierung kann ohne 
vorgeschaltete Proteinfällung oder Festphasenextraktion direkt in biologischen 
Proben durchgeführt werden, wodurch eine Automatisierung des gesamten 
Prozesses - Zugabe der Reagenzien, Extraktion und Injektion ins GC-MS - 
ermöglicht wird. Die Gesamtanalysenzeit inklusive Probenvorbereitung beträgt 
30 min, wobei durch die Verwendung von 19 stabile isotopenmarkierten 
Aminosäuren als interner Standard 31 Aminosäuren und Dipeptide quantifiziert 
werden konnten. Die Nachweisgrenzen (LOD) lagen zwischen 0,03 und 12 µM 
und die unterste Quantifizierungsgrenze (LLOQ) zwischen 0,3 und 30 µM. Die 
Methode wurde durch die Analyse eines zerifizierten Standards und 
Referenzplasma validiert und die Anwendbarkeit für verschiedene biologische 
Proben getestet. Die relative Standardabweichung für eine Zehnfachbestimmung 
am selben Tag lag zwischen 2,0 und 8,8% für menschlichen Harn, zwischen 0,9 
und 8,3% für menschliches Plasma und zwischen 1,3 und 9,1% für Mäuseharn, 
während die Standardabweichung für eine Zehnfachbestimmung für 
menschlichen Harn über mehrere Tage verteilt zwischen 1,5 und 14,1% lag.  
Die GC-MS Methode wurde weiterhin durch die Analyse von zwei verdeckten 
Probensets validiert, welche Splitproben enthielten. Dieselben Proben wurden 
zusätzlich mit der iTRAQ® Derivatisierung gefolgt von HPLC -Tandemmassen-
spektometrie und einer Nachsäulenderivatisierung mit Ninhydrin mittels eines 
Aminosäurenanalysator gemessen. Um die Eignung der Methode für einen 
hohen Probendurchsatz zu zeigen, wurde der technische Fehler für die 
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Splitproben berechnet. Die quantitativen Ergnisse aller drei Methoden wurden 
durch Regressionsanalyse und Bland-Altman Auftragungen miteinander 
verglichen. 
Die Methode wurde zusätzlich für die Analyse von Fettsäuren erweitert, welche 
aufgrund ihrer Carboxylgruppe mit Chlorameisensäurepropylester derivatisiert 
werden können. Um isobare Fettsäuren trennen zu können mußte die GC-
trennung auf von 11 auf 50 min erweitert werden. Der Bereich der 
Nachweisgrenzen (LOD) lag zwischen 0.08 und 39 µM. Mit der erweiterten 
Methode ist es möglich eine vereinte Analyse von Aminosäurenkonzentration 
und totalen Fettsäurenkonzentration für 17 Fettsäuren und  25 Aminosäuren 
durchzuführen.  
Da die Anzahl der Aminosäuren die mittels GC bestimmt werden können limitiert 
ist, wurde zusätzlich die Möglichkeit zur Aminosäurenanlytik mittels LC-MS/MS  
Chlorameisensäurepropylesterderivate getestet. Tryptophanmetabolite und 
Polyamine sind in mehreren biologischen Projekten von großem Interesse und 
wurden deshalb in die Methode integriert. Da der eigens synthetisierte Standard 
nicht zu Quantifizierungszwecken eingesetzt werden konnte wurden erneut 
isotopenmarkierten Aminosäuren als interner Standard verwendet. Insgesamt 
wurden 23 isotopenmarkierte Verbindungen für die Quantifizierung 41 Analyten 
(Aminosäuren, Tryptophanderivate und Polyamine) verwendet. Mit dieser 
Methode war es nicht möglich Konzentrationen für  Tryptophanmetabolite 
oberhalb der unteren Quantifizierungsgrenze in biologischen Proben zu 
bestimmen. Zur Verbesserung der Nachweisgrenzen wurden erste Experimente 
durchgeführt, die eine bessere Extraktion der Analyten ermöglichen. 
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